<SEC-DOCUMENT>0001193125-15-162309.txt : 20150430
<SEC-HEADER>0001193125-15-162309.hdr.sgml : 20150430
<ACCEPTANCE-DATETIME>20150430164640
ACCESSION NUMBER:		0001193125-15-162309
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150430
DATE AS OF CHANGE:		20150430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		15819576

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>d917300d10ka.htm
<DESCRIPTION>10-K/A
<TEXT>
<HTML><HEAD>
<TITLE>10-K/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, DC 20549 </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 10-K/A
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Amendment No.&nbsp;1 </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>For the fiscal year ended December&nbsp;31, 2014 </B></FONT></P>
 <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>or </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Commission File Number: 0-24006 </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>NEKTAR THERAPEUTICS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-3134940</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>455 Mission Bay Boulevard South </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>San Francisco, California 94158 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices and zip code) </B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>415-482-5300
</B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Each Class</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:156pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Each Exchange on Which Registered</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock, $0.0001 par value</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Select Market</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: </B></FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>None </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by
check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is not required to file reports pursuant
to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days)&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K (&#167; 229.405) is not contained
herein, and will not be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check
one): </FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule
12b-2)&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the
registrant&#146;s common stock on the last business day of the registrant&#146;s most recently completed second fiscal quarter, June&nbsp;30, 2014, as reported on the NASDAQ Global Select Market, was approximately $1,625,943,780. This calculation
excludes approximately 457,759 shares held by directors and executive officers of the registrant. Exclusion of these shares does not constitute a determination that each such person is an affiliate of the registrant. </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;23, 2015, the number of outstanding shares of the registrant&#146;s common stock was 131,526,201. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Portions of registrant&#146;s
definitive Proxy Statement to be filed for its 2015 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the
fiscal year covered by this Annual Report on Form 10-K. </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXPLANATORY NOTE </B></FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nektar Therapeutics (the &#147;Company&#148;) is filing this Amendment No.&nbsp;1 to its Annual Report on Form 10-K (this
&#147;Amendment&#148;) for the year ended December&nbsp;31, 2014, which was originally filed on February&nbsp;26, 2015 (&#147;Original Filing&#148;), to amend and restate in its entirety the Item&nbsp;5 of Part II of the Original Filing. The
Original Filing inadvertently included a graph depicting the five-year comparison of cumulative return for the period of 2008 to 2013 rather than 2009 to 2014. The only change in this Amendment is to replace that comparison graph with the updated
comparison graph from 2009 to 2014. </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended
(&#147;Exchange Act&#148;), this Amendment amends and restates in its entirety Item&nbsp;5 of Part II of the Original Filing and contains new certifications pursuant to Rule 13a-14 promulgated under the Exchange Act. This Amendment contains only the
sections and exhibits to the Original Filing that are being amended and restated, and those unaffected parts or exhibits are not included herein. This Amendment continues to speak as of the date of the Original Filing, and the Company has not
updated the disclosure contained therein to reflect events that have occurred since the filing of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company&#146;s other filings, if any,
made with the United States Securities and Exchange Commission subsequent to the filing of the Original Filing, including the amendments to those filings, if any. </FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART&nbsp;II </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock trades on The NASDAQ Global Select Market under the symbol &#147;NKTR.&#148; The table below sets forth the high and low
closing sales prices for our common stock as reported on The NASDAQ Global Select Market during the periods indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Year Ended December&nbsp;31, 2013:</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1st Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2nd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3rd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4th&nbsp;Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2014:</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1st Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2nd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3rd Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4th&nbsp;Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Holders of Record </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of February&nbsp;20, 2015, there were approximately 212 holders of record of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividend Policy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the
foreseeable future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no sales of unregistered securities and there were no common stock repurchases made during the
year ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities Authorized for Issuance Under Equity Compensation Plans </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Information regarding our equity compensation plans as of December&nbsp;31, 2014 is disclosed in Item&nbsp;12 &#147;Security Ownership of
Certain Beneficial Owners and Management and Related Stockholder Matters&#148; of this Annual Report on Form&nbsp;10-K and is incorporated herein by reference from our proxy statement for our 2015 annual meeting of stockholders to be filed with the
SEC pursuant to Regulation&nbsp;14A not later than 120&nbsp;days after the end of the fiscal year covered by this Annual Report on Form&nbsp;10-K. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Performance Measurement Comparison </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The material in this section is being furnished and shall not be deemed &#147;filed&#148; with the SEC for purposes of Section&nbsp;18 of
the Exchange Act or otherwise subject to the liability of that section, nor shall the material in this section be deemed to be incorporated by reference in any registration statement or other document filed with the SEC under the Securities Act or
the Exchange Act, except as otherwise expressly stated in such filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following graph compares, for the five-year period
ended December&nbsp;31, 2014, the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i)&nbsp;the NASDAQ Composite Index, (ii)&nbsp;the NASDAQ Pharmaceutical Index, (iii)&nbsp;the RGD
SmallCap Pharmaceutical Index, (iv)&nbsp;the NASDAQ Biotechnology Index and (v)&nbsp;the RDG SmallCap Biotechnology Index. Measurement points are the last trading day of each of our fiscal years ended December&nbsp;31, 2010, December&nbsp;31, 2011,
December&nbsp;31, 2012, December&nbsp;31, 2013 and December&nbsp;31, 2014. The graph assumes that $100 was invested on December&nbsp;31, 2009 in the common stock of the Company, the NASDAQ Composite Index, the Nasdaq Pharmaceutical Index, the RGD
SmallCap Pharmaceutical Index, the NASDAQ Biotechnology Index and the RDG SmallCap Biotechnology Index and assumes reinvestment of any dividends. The stock price performance in the graph is not intended to forecast or indicate future stock price
performance. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g917300g52u37.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or
incorporated by reference into, this Amendment No.&nbsp;1 to the Annual Report on Form 10-K. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;2.1(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset Purchase Agreement, dated October&nbsp;20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary
of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.3(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.4(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.5(6)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Bylaws of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reference is made to Exhibits&nbsp;3.1, 3.2, 3.3, 3.4, and 3.5.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen Common Stock certificate.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indenture dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association, including the form of 12.0% Senior Secured Note due
2017.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1(9)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee Stock Purchase Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Non-Officer Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2008 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5(11)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forms of Equity Award Agreements under the 2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Compensation Plan for Non-Employee Directors.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8(12)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">401(k) Retirement Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discretionary Incentive Compensation Policy.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Change of Control Severance Benefit Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Severance Letter for executive officers of the company.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with Howard W. Robin.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with John Nicholson.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement, executed effective on December&nbsp;10, 2009, with Stephen K. Doberstein,&nbsp;Ph.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Transition and General Release Agreement dated as of February 11, 2014, by and between Nektar Therapeutics and Rinko
Ghosh.++</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement dated as of May 14, 2014, by and between Nektar Therapeutics and Ivan Gergel, M.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Built-to-Suite&nbsp;Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August&nbsp;17, 2004, as amended on January&nbsp;11, 2005 and
July&nbsp;19, 2007.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease, dated as of September&nbsp;30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19(15)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement Agreement and General Release, dated June&nbsp;30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville,
Nektar Therapeutics AL Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Development, License and Co-Promotion Agreement, dated August&nbsp;1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC, as
amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated
September&nbsp;26, 2005, as amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive License Agreement, dated December&nbsp;31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October&nbsp;29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing,
Limited.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.24(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September&nbsp;20, 2009.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.25(7)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12% Senior Secured Notes due 2017 Purchase Agreement dated July 3, 2012, by and among Nektar Therapeutics and the purchasers named therein.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.26(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pledge and Security Agreement dated July 11, 2012 as amended by the Amendment to Pledge and Security Agreement dated as of February&nbsp;28, 2013, by and between Nektar Therapeutics
and Wells Fargo Bank, National Association.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.27(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Escrow and Deposit Account Control Agreement dated July 11, 2012 among Nektar Therapeutics, Wells Fargo Bank, National Association, as collateral agent, and Wells Fargo Bank,
National Association, as escrow agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.28(17)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.29(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to License Agreement dated as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.30(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Term Loan and Security Agreement dated as of October 7, 2013, by and between Nektar Therapeutics, as borrower, and AstraZeneca AB, as lender and as agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (reference is made to the signature page).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.1(21)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal executive officer required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.2(21)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal financial officer required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">32.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1350 Certifications.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following materials from Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, formatted in XBRL (Extensible Business Reporting
Language): (i)&nbsp;Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders&#146; Equity, (v) Consolidated Statements of Cash Flows,
and (vi) Notes to Consolidated Financial Statements.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management contract or compensatory plan or arrangement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;32.1 is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange
Act, except as otherwise stated in such filing. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL information is filed with Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2014. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2008.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 1998.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2000.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on January&nbsp;23, 2003.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on April&nbsp;11, 2011. </FONT></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;10, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;11, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Registration Statement on Form&nbsp;S-8 (No.&nbsp;333-98321), filed on August&nbsp;19,
2002. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2011.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;3, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2004.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2007.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2010.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2006.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2012.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2014.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City and County of
San&nbsp;Francisco, State of California on April&nbsp;30, 2015. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>John Nicholson</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Senior Vice President and Chief Financial Officer</I></B></FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>ILLIAN</SMALL> B.
T<SMALL>HOMSEN</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jillian B. Thomsen</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Senior Vice President, Finance and Chief Accounting Officer</I></B></FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below
constitutes and appoints John Nicholson and Jillian B. Thomsen and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead,
in any and all capacities, to sign any and all amendments to this Annual Report on Form&nbsp;10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could
do in person, hereby ratify and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in
the capacities and on the dates indicated: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;H<SMALL>OWARD</SMALL> W.
R<SMALL>OBIN</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Howard W. Robin</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief&nbsp;Executive&nbsp;Officer,&nbsp;President and Director (Principal Executive Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>OHN</SMALL>
N<SMALL>ICHOLSON</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>John Nicholson</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Financial Officer (Principal Financial Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>ILLIAN</SMALL> B.
T<SMALL>HOMSEN</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jillian B. Thomsen</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Robert B. Chess</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>R. Scott Greer</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Joseph J. Krivulka</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Christopher A. Kuebler</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Lutz Lingnau</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Susan Wang</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Roy A. Whitfield</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Dennis L. Winger</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;30, 2015</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>ILLIAN</SMALL> B. T<SMALL>HOMSEN</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jillian B. Thomsen</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Senior Vice President, Finance and Chief Accounting Officer</I></B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or
incorporated by reference into, this Amendment No.&nbsp;1 to the Annual Report on Form 10-K. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:88pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Documents</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;2.1(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset Purchase Agreement, dated October&nbsp;20, 2008, by and between Nektar Therapeutics, a Delaware corporation, AeroGen, Inc., a Delaware corporation and wholly-owned subsidiary
of Nektar Therapeutics, Novartis Pharmaceuticals Corporation, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.3(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.4(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.5(6)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Bylaws of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reference is made to Exhibits&nbsp;3.1, 3.2, 3.3, 3.4, and 3.5.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen Common Stock certificate.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indenture dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association, including the form of 12.0% Senior Secured Note due
2017.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1(9)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee Stock Purchase Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Non-Officer Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2000 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2008 Equity Incentive Plan, as amended and restated.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5(11)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forms of Equity Award Agreements under the 2012 Performance Incentive Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Compensation Plan for Non-Employee Directors.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8(12)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">401(k) Retirement Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discretionary Incentive Compensation Policy.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10(10)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Change of Control Severance Benefit Plan.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Severance Letter for executive officers of the company.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with Howard W. Robin.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Letter Agreement, executed effective on December&nbsp;1, 2008, with John Nicholson.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement, executed effective on December&nbsp;10, 2009, with Stephen K. Doberstein,&nbsp;Ph.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Transition and General Release Agreement dated as of February 11, 2014, by and between Nektar Therapeutics and Rinko Ghosh.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement dated as of May 14, 2014, by and between Nektar Therapeutics and Ivan Gergel, M.D.++</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17(13)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Built-to-Suite&nbsp;Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August&nbsp;17, 2004, as amended on January&nbsp;11, 2005 and
July&nbsp;19, 2007.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease, dated as of September&nbsp;30, 2009, by and between Pfizer Inc. and Nektar Therapeutics.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19(15)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement Agreement and General Release, dated June&nbsp;30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville,
Nektar Therapeutics AL Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Development, License and Co-Promotion Agreement, dated August&nbsp;1, 2007, between Nektar Therapeutics (and its subsidiaries) and Bayer Healthcare LLC, as
amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated
September&nbsp;26, 2005, as amended.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive License Agreement, dated December&nbsp;31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23(14)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October&nbsp;29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing,
Limited.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.24(16)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September&nbsp;20, 2009.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.25(7)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12% Senior Secured Notes due 2017 Purchase Agreement dated July 3, 2012, by and among Nektar Therapeutics and the purchasers named therein.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.26(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pledge and Security Agreement dated July 11, 2012 as amended by the Amendment to Pledge and Security Agreement dated as of February&nbsp;28, 2013, by and between Nektar Therapeutics
and Wells Fargo Bank, National Association.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.27(8)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Escrow and Deposit Account Control Agreement dated July 11, 2012 among Nektar Therapeutics, Wells Fargo Bank, National Association, as collateral agent, and Wells Fargo Bank,
National Association, as escrow agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.28(17)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.29(18)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to License Agreement dated as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.30(19)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Term Loan and Security Agreement dated as of October 7, 2013, by and between Nektar Therapeutics, as borrower, and AstraZeneca AB, as lender and as agent.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of Nektar Therapeutics.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1(20)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (reference is made to the signature page).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.1(21)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal executive officer required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.2(21)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Nektar Therapeutics&#146; principal financial officer required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">32.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1350 Certifications.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following materials from Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, formatted in XBRL (Extensible Business Reporting
Language): (i)&nbsp;Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders&#146; Equity, (v) Consolidated Statements of Cash Flows,
and (vi) Notes to Consolidated Financial Statements.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment with respect to specific portions of this Exhibit has been requested, and such portions are omitted and have been filed separately with the SEC.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management contract or compensatory plan or arrangement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;32.1 is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange
Act, except as otherwise stated in such filing. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL information is filed with Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2014. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2008.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 1998.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2000.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on January&nbsp;23, 2003.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on April&nbsp;11, 2011. </FONT></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;10, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;11, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Registration Statement on Form&nbsp;S-8 (No.&nbsp;333-98321), filed on August&nbsp;19,
2002. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2011.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form&nbsp;8-K, filed on July&nbsp;3, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2004.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2007.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2010.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2006.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2012.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Annual Report on Form 10-K for the year ended December&nbsp;31, 2014.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d917300dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Howard W. Robin,
certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Amendment No.&nbsp;1 to the Annual Report on Form 10-K of Nektar Therapeutics for the year ended
December&nbsp;31, 2014; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;30, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ H<SMALL>OWARD</SMALL> W. R<SMALL>OBIN</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Howard W. Robin</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Chief Executive Officer, President and Director</B></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d917300dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, John Nicholson,
certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Amendment No.&nbsp;1 to the Annual Report on Form 10-K of Nektar Therapeutics for the year ended
December&nbsp;31, 2014; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;30, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>John Nicholson</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Senior Vice President and Chief Financial Officer</B></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d917300dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1350 CERTIFICATIONS* </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and
Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#147;Company&#148;), and John Nicholson, Senior Vice
President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Amendment
No.&nbsp;1 to the Company&#146;s Annual Report on Form 10-K, for the year ended December&nbsp;31, 2014, to which this Certification is attached as Exhibit 32.1 (the &#147;Annual Report&#148;), fully complies with the requirements of
Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The information contained in the Annual Report
fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;30, 2015 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ H<SMALL>OWARD</SMALL> W. R<SMALL>OBIN</SMALL></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Howard W. Robin</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><B>John Nicholson</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Chief&nbsp;Executive&nbsp;Officer,&nbsp;President&nbsp;and&nbsp;Director</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><B>Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">This certification accompanies the Annual Report on Form 10-K/A, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the
Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
</TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g917300g52u37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g917300g52u37.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X6B\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@("`@/'AM
M<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]X;7`Z0W)E871O<E1O;VP^"B`@("`@("`@(#QX;7`Z36]D:69Y1&%T93XR
M,#$U+3`T+3,P5#$T.C`X.C`Y*S`U.C,P/"]X;7`Z36]D:69Y1&%T93X*("`@
M("`@("`@/'AM<#I#<F5A=&5$871E/C(P,34M,#0M,S!4,30Z,#@Z,#DK,#4Z
M,S`\+WAM<#I#<F5A=&5$871E/@H@("`@("`@("`\>&UP.DUE=&%D871A1&%T
M93XR,#$U+3`T+3,P5#$T.C`X.C`Y*S`U.C,P/"]X;7`Z365T861A=&%$871E
M/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR9&8Z
M06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM9SIH
M96EG:'0^,C`X/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@("`@
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@("`@("`@
M("`@("`@("`@("`\>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
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M8FY*,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
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M<GI+=R]+4%@T=&)T<CEB4%)T3&=397IL:&ES2DQH;3`Q8E,T.6%F)B-X03LV
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M8B]S1&)&5E,W+TM0>EIC959T3#`R-75R0RLQ1S)'<G)04$LP<V-53GAQ9#1B
M;4A5)B-X03MR64I'>F978F1A.%9.04-X06-D5U94<E1F>7-M<SE#.#5W9E=)
M,C%8>E9*<5!'-%9)27EK5C-,3S!1861,9$IY4VMW-3AY-%5J-$M$)B-X03MQ
M<7`R=C566$1A4#52=&)W5VEZ-DI/>39O;'973T=E=TQV3VQT4T]+1EIA6$5D
M=3=C;S!6:7).>$9E3TMS5G-F>5$X-E(K4S=B>7I()B-X03MD-F)P5'AZ4C-6
M,7%.=%-:-7!B5TEI,RM'1WHP,39,35)*>6QL;%E%1&1H5E-Q>5`X=CA!.'-0
M34]G96%R<GI&<61X6G9C-F]U;TYF)B-X03M,6B]#67!R>3A&=VA35#!);G56
M-#=F=C8K;5(X1WI%67%K82]K,35V:',R:'1O=$=I;6PP<3DP4S=U56UU,6MU
M=G(P56-C=7!80DU,)B-X03MQ,#5-6$EX.&1Y9#54=%)603(S-41E9&].9G8Y
M5F)63$M:2G`U8G$Q=&UK;591+S969S%#3DMI1FEG:U<S;S=F1GA9-T)S5EI$
M<%`U)B-X03ME9FU(<$YV<FM6;$QP<7IE64Q2;UIB,#-.=TAS<'!,=2MU4S!5
M9C%9:69I3E%!57,P938Q<#)X5D%,*U)E<"]O:$Q#-$]L6&1X6398)B-X03MR
M3VQA9G%$4D]K<DQE<$5.4$PX:VUD4'$S-S50-WAY<6M52DQ.4E92.#`O:V(U
M:S%,5S!U-V$U<W)J5$Q7.$8U6F%F8W-&0W1D5S58)B-X03M53UAR5VPO065D
M>$A&26Y/1BMR9$141E=696%V>71'=#-6:&57.%9L<#DW8C9,9F%A,31K84Y.
M1F-Z>'=P85-23W-59%9T*T5V1FAW)B-X03M+:'9G07%A2V]$5'9Y9G)*<&LY
M.7`R:U%#>C%V.4IF;S)"5$YB,C%M3$$R-70W6C5955DK<&-H3&AL2W%V3&8W
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M;&DP;6942G1/5%%R.5IR9FDX<E!A=E`V1C-)<W$K;E!'+W<X0G=!<%95>%9!
M87(U)B-X03M&.&QM3W=T:BM9=&XV5'!,6C)C1C!98G$S;'1P<FU7-S1Z56Y2
M;F8Q;UEU36AK0W-994I6:7A'2W%R95102U5.,V(S869M1G`Q;7-C)B-X03LV
M,U-3869&8G="-7!(;FY35S=K5V0P4$\R=7`T;&(T2S%8:C`T<W%N5VXK6'9,
M1G1:,T9Q=FUB43=L=$IV2DPV-G,W4WIJ94\R45%P)B-X03M'>DQ:>#--:E(S
M2T=";D4R-41&:G=*<FEQ6'9P54U$=G@O3F-4,U1A9F-X=U%V97I*8D)X-FQV
M.5EK:T8S2U9+>EA#+V%A=DIA2E-G)B-X03M#<7$Y-S5A1G%M;659.5(O37E3
M6%%B5F]X3G=E-&MT<G%3,VHU='I+,VMS9&%1<U)X5V]O0V54,5IL5DLQ,%A2
M=$PX<TI,<5`U;4YQ)B-X03M/;G<V;$8V1V]7-W4S;U9T,FHK<'A35SEX3$I&
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M=T1"3TQP4D9Z4$UU)B-X03MO,UEQ;%1S059683`X=C9"9&56;3!N>F(U.&@Q
M=7I7.6EM;#%!=#8X1%),1F-X;W)Z6&(S8T5B>4Q%-T]6;T5+8E5F-'EQ;U!O
M3VMP)B-X03MQ0C`V,"].>C9J8E=6=$A"2G!Y6&)*>&-S1S5,3#EC5V@U>$XX
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M:3%'2$E+:V$X2R]966-L;S(K2W)B<CAP=DED,C`W5#)--W1D8W9R)B-X03M"
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M:7%R-64X=#9N<&QJ<4]S<G`Q.7%L.7%E;R]O;3=J=F1-=6]#=6Q447!*2D9:
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M4TM7-D%F-C`W3T]B)B-X03MF=E0X5WDK;T951G%0;39W,"MW,'4R,6XX=D,Q
M+V5X<F\V0U<T=7)A95,Q,#EL9$DT6'594DDQ5UE0>#E4:34T:C%(8EI653DQ
M<E$W)B-X03M0>71Q5C!D3#AH>39L2&5A:DAC>EA%3GAQ5'%K,&--3$IC1E5J
M=7I);VQU<%$S0D8R5#=,16)+;TAY9C5:,$16,T=G87(K6$XY<$YL)B-X03MQ
M1GA0*VLW;6$U,49B95(T65DU16U+;79W=395:41V4DXK3&-M24MR,&5$.'!V
M261U>DYB5TTX0F58,3(Y2RMV;WAZ-'-N4EIH4F5,)B-X03MS3U`R844W8FY!
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M8W5R)B-X03M3>EAL=F%V8G<X*U-2>GE"2&U00DI44D)V,"MN1E='*U9V>E`X
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M9#8R:3-$5U=N=VTO=C`R:VE1.%EO<2\W+VUO5FHO,60S<'5&3TMP6F0O57IC
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M<7=,4690;S@Q451"-5)B>$-2;S1T3S`U,FMV8FQ/4D-Y330T+U8T,E@S0D@W
M5'`P=W%Y97DP;2]K=&MG9FIP1VYR6&AP,6E12D-#)B-X03MA+W9,:&%C4S%A
M:U)!14@Y='-#<'1:5T9N6E$K:&%1<$)&57-6455Q>#9S>#9S>#=K-VY&5F9&
M6%EQ-T9867$W1EA9<6MN;3=Z9'`S)B-X03ML8E1R92]V-'!:66)I-V=S:U=%
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M3WA7=W0U4'-61WAN;$):=7EL0W1#<6HK6%`U5BM7=GDO=#<V1%)*3&U69%%A
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M<'IV1DI*2'`Q,#-!9TMH14M-.6$Q-&E34E!S.2M64&%U2W!86659)B-X03LY
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M2'-Q9VLT<7AB-C5R=FUW1DQ.5S`S46UQ1W5(+T%,>5E6-V-4.%-K9&Q02&]3
M>F9&)B-X03M(:%9K;6MA2G`K;%%E;&%*.%1"4DQ-,41)+T556&M10G-O,E92
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M,S`T<7AR5&1%+T]M3%5W.3DU:3`K-#`T86I"2G=7)B-X03LS0WE(5&MA-3EE
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M2W`S.&8R831P67@K64]M959*=C!5;7)E6$Q794\R5S1M<S1,;#0T4UA6-%4K
M<C)Y4E!X86%98U=5)B-X03M(<W1/=&%+<R]A-&U$.%)A>6MC>6Y)1T]L079,
M;G4Y94YF:#AA.7%B-$95,S%#4T]0,4IB4U=.045,1C)G05AM845%*W!4-$]R
M9FA8)B-X03M&571F>F9P<D%I,F5/-&QO+T=+3V%/5GEY;6E$:&)M9#90-#AD
M=D-U,DMR=C`O<4UJ9U=M:UA&>$9Z;S!L1$%65&I7=D,W1G-395<Q)B-X03M"
M=#-R,GA6:C-N;4QZ+V9E5611:'1:.4\P:6531TPP8G5E6F]Y:W%Y07-R9W),
M1GAL,E%+6$DS,S56<&A643AT5S)O,G9L;E0W3%@O)B-X03M!1&=K,39,9&QB
M.4='35-31FU.5FI0-S$U3T)(0E1(1W`R,GA63E)P5FYC=C9K9&AQ5V]Y;'DV
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M-F)L8U93=69Y3G`P65IT2&YN,&PR2EIO<F5A9&):)B-X03LR4&531T]33#4Q
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M,'5R4EI&:&PO95--2W`V>C=D2S<P<4)25FMU:WAX)B-X03MX,V5R3$=O4F9R
M86YI;T%&5&%W13E-5E1(1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&)B-X03M867$W1EA9<3=&6%EQ-T9867$W
M1EA9<7A(5714+TUI4'I4.5<P-U-R5V914')69VI88W)H2$9P2DA/8C919G9A
M;#1N4T5)3TAF;V$X)B-X03ML5E0R,6<Q3T,T=EI04V=:8FU94W`K.6-%05%X
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M87%N=%1&5F)&6%EQ-T9867%K4&Y7>3@S6&UH=$8U578T=%`Q8U-X37,P-%AG
M,%%B.39N2C1B;TE3;&5,96LR+V)&5T<O;T0X+WHU)B-X03MJ,&EC*UI.35A1
M645S0G$Q<4DQ37-Z4DI(.65+:S)G+W9816Y$:3950D@R8U9E;UEQ-T9867%P
M6&%816QR3DAB4RMJ8U!'>7=Z14)G)B-X03MJ:T5+,T4W1V@S<&ER>G)3=$,O
M4%=/,71&,41Z1G`W,TM094<W8TEK:75S;&Y';&U!1G1,8F%/-T5K:DQS94I!
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M5G1R:&Y754Y$4VI+9&I1<BLR<6ET0C`S.'=R9GI%)B-X03M:9%DQ4T,X,$U7
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M<U9E92MC=GI3+TYF4E!-5W`R3VUE4G)J5CE-:D12-EIE=W<S1&9V1V=G9$=K
M.5`Q)B-X03M1-E)Y4$E'-#AE5W=$07$Q5E5F;R]W0V%N;C(W,60Y4'5V26PS
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M45!S:FM65W`Y>FEQ4V$S<BMQ,D]J=F0R;6E85GIE8WA(1F%$,&U/.5!J9C!N
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M:T=R1R\X=$Y(3%IE;TQD1C!M.59I<5A6=$5S;T@Q;5=/-%IO6G`S.4='6"]D
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M,4M44F1E,#8T.'AP4$YR63`U;79*3$)8<$Y95'1/,&MS5'I-:R]Q1BM.1S9)
M1E4X9W5+<5@O04-O<GI01%IX5W1H)B-X03LU*W9R2T\S:VYK='94:&-#4#$Q
M;5=I9UA#.&5!;C):84XQ-44O=2]45E9R8CAK9DUY6'HS,7@U.3%/839M;'1X
M8U1O8FU'4U<P:&QM)B-X03ML93)9<&0X5C5M64)7:E9E05@T5G%Z17%O85`X
M:V903G(V.35B+VU&9E,V;SA-15-3=4QH3U@Q6&UY:'!8=6)L-D\X:F-U465-
M8VU))B-X03MJ*WAW5EI,*U9V:S-Z=#5F3B],-7$Q<#E5;'5/2#%A1F)U-G5O
M66%L;6LT9E=V:D$S4D9Q>D=I.'$Q9&AI<E!S5E=Y;WIX=6EU63)9)B-X03M%
M0U)A1FQ*2#)H>41,564T>%9H+VYR>58U;C$W451985(U<W9T2G9$2VMG=3`Y
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M,#<V;F1X,TTO;W)B9G9O:W)Y:5!#2U`W6"M6>5AX5G-64E=U*U9R=E9T0S%0
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M;5<U9VEG=')23&-Z>E),8C(O1FY19G,Y1EAF:T95:C!4+T%*>#`Q9E-92F)E
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M4')R)B-X03M20S-0<65.051I<6$V<"MB2&PS5$Q',79R=3)U,&=U;W)385`T
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M4CAP5DUJ<6]O>7)5+W=#>$))5E%D,2]Z:U`U3'1B0T<K;G-T4E-'94Y:;S%:
M8E53)B-X03M'2C(T3$HV6G5!+TAM<DM45%ER=C%8:W$Y4&EL:6QJ5U=*,6MI
M8T)K9%-'5F=E:$)(6$96,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6
M,DMO8E4U3#905')Q5%0T,6UV,&AK83!H8S!6-6=P36%S87)S5V]$=4U696%Z
M-G`K9D9J<45L=EHK5SE);',R:4TP;#5B8U%R,V),)B-X03MY66-*8GE"-DTK
M>&-I=F5H-EEQ<C9P-6LO3RM04F1$87<X=3)$-B]D9E=7,6EY;$Q'1TI95U%2
M0DIK;CE*9E56:CEQ46YW6%IQ2W%K)B-X03M/=69N;69,<EA5=FPW5'AR679&
M:2]2-&M13#E516)S,#1F-C)66FUF9V]5<W1.*W9:5EI,<FXU-G@V:DEN-D,P
M,E14-$=4+U-"<UI9)B-X03MX55--:7)E4T]P86=)0FI*6'`X6GA6,'9M6#@U
M-VI29$UV9$LX=C(P;#%C=T-3-V=U-"]Q<DDU;6M5:&MK=D$X5&5K<V)C4&HS
M2D)9)B-X03M5,U9A9E=V>C=K,6Q,94Q1=$UG,'-L960W3'AD;#-!96MA6'=:
M:%)Q<3)X4$AD45=O1E56;U=R9FY64'(Y<F)A=F\R;C(R:6Q63C5F)B-X03MP
M45-":%%U<5%R950W2&1687`W17(K>FEQ9"M4-VIZ=54Y4'I(8D1I4DE9-78S
M06U"*W,S0553:4=6-#9F5C%G231,,6)F=E)6:RM+)B-X03MU>%9O26=C=49(
M3F=&6G%B:T-P04HY<6Y&5SA654IT4'-*-W$S=DIR84M7-W1/9C%3-&1&85-,
M,5)X:SE.>4]38S$R86Y81E9F1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$O=T0O,E$]/3PO>&UP1TEM9SII;6%G93X*("`@
M("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.D%L=#X*
M("`@("`@("`@/"]X;7`Z5&AU;6)N86EL<SX*("`@("`@/"]R9&8Z1&5S8W)I
M<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@
M("`@("`@("`@('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(^"B`@("`@("`@(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A
M<GD@,3`N,#$\+W!D9CI0<F]D=6-E<CX*("`@("`@/"]R9&8Z1&5S8W)I<'1I
M;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@
M("`@("`@('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(^"B`@("`@("`@(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C
M<FEP=#PO9&,Z9F]R;6%T/@H@("`@("`@("`\9&,Z=&ET;&4^"B`@("`@("`@
M("`@(#QR9&8Z06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI('AM;#IL86YG
M/2)X+61E9F%U;'0B/G-T,CPO<F1F.FQI/@H@("`@("`@("`@("`\+W)D9CI!
M;'0^"B`@("`@("`@(#PO9&,Z=&ET;&4^"B`@("`@("`@(#QD8SIC<F5A=&]R
M/@H@("`@("`@("`@("`\<F1F.E-E<3X*("`@("`@("`@("`@("`@/')D9CIL
M:3YR<C$P-S`R,3PO<F1F.FQI/@H@("`@("`@("`@("`\+W)D9CI397$^"B`@
M("`@("`@(#PO9&,Z8W)E871O<CX*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^
M"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@
M("`@('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+W0O<&<O(@H@("`@("`@("`@("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@("`@("`@("`@
M("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4
M>7!E+T9O;G0C(@H@("`@("`@("`@("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O9R\B/@H@("`@("`@("`\>&UP5%!G.DY086=E
M<SXQ/"]X;7!44&<Z3E!A9V5S/@H@("`@("`@("`\>&UP5%!G.DAA<U9I<VEB
M;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/@H@("`@("`@("`\>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^
M5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B`@("`@("`@(#QX
M;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M("`@("`@("`@("`\<W1$:6TZ=SXX+C4P,#`P,#PO<W1$:6TZ=SX*("`@("`@
M("`@("`@/'-T1&EM.F@^,3$N,#`P,#`P/"]S=$1I;3IH/@H@("`@("`@("`@
M("`\<W1$:6TZ=6YI=#Y);F-H97,\+W-T1&EM.G5N:70^"B`@("`@("`@(#PO
M>&UP5%!G.DUA>%!A9V53:7IE/@H@("`@("`@("`\>&UP5%!G.D9O;G1S/@H@
M("`@("`@("`@("`\<F1F.D)A9SX*("`@("`@("`@("`@("`@/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS
M=$9N=#IF;VYT3F%M93Y!<FEA;$U4+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@
M("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;"!-5#PO
M<W1&;G0Z9F]N=$9A;6EL>3X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O
M;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@("`@("`@("`@("`@("`@
M("`\<W1&;G0Z9F]N=%1Y<&4^5'EP92`Q/"]S=$9N=#IF;VYT5'EP93X*("`@
M("`@("`@("`@("`@("`@/'-T1FYT.G9E<G-I;VY3=')I;F<^,#`Q+C`P,SPO
M<W1&;G0Z=F5R<VEO;E-T<FEN9SX*("`@("`@("`@("`@("`@("`@/'-T1FYT
M.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@("`@("`@("`@
M("`@("`@("`\<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%B7U]?+E!&0CL@87)I
M86)?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1.
M86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@("`@("`@("`@("`@("`@
M("`\<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*
M("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T
M1FYT.F9O;G1&86-E/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=%1Y
M<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*("`@("`@("`@("`@("`@
M("`@/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B`U+C$P/"]S=$9N=#IV
M97)S:6]N4W1R:6YG/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z8V]M<&]S
M:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B`@("`@("`@("`@("`@("`@
M(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86PN='1F/"]S=$9N=#IF;VYT1FEL
M94YA;64^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`\
M+W)D9CI"86<^"B`@("`@("`@(#PO>&UP5%!G.D9O;G1S/@H@("`@("`@("`\
M>&UP5%!G.E!L871E3F%M97,^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@
M("`@("`@("`@("`\<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B`@("`@("`@("`@
M(#PO<F1F.E-E<3X*("`@("`@("`@/"]X;7!44&<Z4&QA=&5.86UE<SX*("`@
M("`@("`@/'AM<%109SI3=V%T8VA'<F]U<',^"B`@("`@("`@("`@(#QR9&8Z
M4V5Q/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$<Z9W)O=7!.86UE/D1E
M9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*("`@("`@("`@
M("`@("`@("`@/'AM<$<Z9W)O=7!4>7!E/C`\+WAM<$<Z9W)O=7!4>7!E/@H@
M("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q
M/@H@("`@("`@("`\+WAM<%109SI3=V%T8VA'<F]U<',^"B`@("`@(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@("`@("`@("`@("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+VUM+R(*("`@("`@("`@("`@>&UL;G,Z<W12968](FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M"B`@("`@("`@("`@('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@("`@("`@("`\>&UP
M34TZ1&]C=6UE;G1)1#YX;7`N9&ED.C-$-T%$-#-!1CE%144T,3$Y0C4V03DY
M044S,#`V0T,V/"]X;7!-33I$;V-U;65N=$E$/@H@("`@("`@("`\>&UP34TZ
M26YS=&%N8V5)1#YX;7`N:6ED.C-$-T%$-#-!1CE%144T,3$Y0C4V03DY044S
M,#`V0T,V/"]X;7!-33I);G-T86YC94E$/@H@("`@("`@("`\>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,CE#-C,Q-3`W,S8Q13$Q,4%&,T%%
M0C!&,#`U,#DW.40\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*("`@("`@
M("`@/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I
M=&EO;D-L87-S/@H@("`@("`@("`\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`\<W12968Z:6YS=&%N
M8V5)1#YU=6ED.F-C,S8Y8F8V+61D,SDM-&9C."UA-F,W+64T8S=F,3$R-6(T
M8SPO<W12968Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@/'-T4F5F.F1O8W5M
M96YT240^>&UP+F1I9#HP,C<X,T8P13$T149%-#$Q.3$T1CE%,3=$1CDR0D5!
M,3PO<W12968Z9&]C=6UE;G1)1#X*("`@("`@("`@("`@/'-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#YX;7`N9&ED.C(Y0S8S,34P-S,V,44Q,3%!1C-!14(P
M1C`P-3`Y-SE$/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B`@("`@("`@
M("`@(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD
M:71I;VY#;&%S<SX*("`@("`@("`@/"]X;7!-33I$97)I=F5D1G)O;3X*("`@
M("`@("`@/'AM<$U-.DAI<W1O<GD^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@
M("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z:6YS=&%N8V5)
M1#YX;7`N:6ED.C(Y0S8S,34P-S,V,44Q,3%!1C-!14(P1C`P-3`Y-SE$/"]S
M=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z=VAE
M;CXR,#$R+3`R+3(W5#$R.C$X.C4R+3`W.C`P/"]S=$5V=#IW:&5N/@H@("`@
M("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S4\+W-T179T.G-O9G1W87)E06=E;G0^"B`@("`@("`@("`@
M("`@("`@(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B`@("`@
M("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@
M("`@("`\<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.C-$-T%$-#-!1CE%144T
M,3$Y0C4V03DY044S,#`V0T,V/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@
M("`@("`@("`@("`\<W1%=G0Z=VAE;CXR,#$U+3`T+3,P5#$T.C`X.C`Y*S`U
M.C,P/"]S=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q/@H@("`@("`@("`\+WAM<$U-
M.DAI<W1O<GD^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`\+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A
M8VME="!E;F0](G<B/S[_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_VP!#`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_P``1"`'&`C,#`1$``A$!`Q$!_\0`'P`!``(#
M`0$!`0$!``````````<(!08)!`,*`@$+_\0`3!```00#`0`!`@0"!P4#"@$-
M!0,$!@<``@@!"1$5$A,4%A<A(B,Q05:7UPH8-G>W&20E,C,T45AAE9C4UB8U
M0D12-T-466)Q=('8_\0`&`$!`0$!`0````````````````$"`P3_Q``X$0`"
M`0,#`@4"!0,$`@,!`0```1$"(3$205%A<8&1H;'P(L$#,E+1X4*2\1-B<H*R
MTB.BPD-3_]H`#`,!``(1`Q$`/P#]_&`,`8`P!@#`&`,`8`P#EC\I75%V4+&>
M9*:YH)QJ*7[VATO".<839<Q`(RJ/5&(.-WQ28V9M%72B3"5&8Z,9H)`HX3V^
MVOW;_9P\T<IL?T+L;HI3EN8I4N,OA$-FI/\`(?\`'+7/6]Z=*](P'N+FZK.:
MC]HUZ8DE=1ZE+Y'7D#V6U9U\\!59&$8$8J<_Y^4N1E9$LG+0KI^Q9"Q+EB-?
M+/`6FITI)TMM)WE1S>\KQGT*469<_P`L?)W$,#^56RNSH7=0#[-3%N73Q3_N
M\5I#:X8U5<QZ(#U(=6EJ!?/+*;S"#,IP-_3GCI@DU*NVKUP_U,H,6[$V-)45
M5:$HRE5+;E8E8OT7CN?[[\KM^UG\S=^UG:EH(.?CTC\6$`X[&7D)@0G:O)J7
MXHC?60(TO-6<98SLDYD[6$6J/9BI!+"(Y-V9_2Z,]4V8CT6&A/\`#I:7U.7,
MO"JC'25=(H)`?EO^3%_\>W<UY63T(RB%KU_<_"RM7R9*HJ3W:574W4[(5/'P
MOT(YKC0-)4TX'*PFFQ"8#S)IO^DV5;DFSE59?<;T4:DDI452I=W2VN>5L=/_
M`([.\[LL'Y`)ESDAW;$/DIYB&\PO+BEW082AX-2:%#6(PF:`4;"BTAK@<*A$
MB:2(!^J+;IN_5R7GX]5FFP]O&3WW(<ZJ4J9TZ',1+<J.L^\&#^/3Y1NG[K[J
M9)7P48)\4]](]%//C@1WB\:!$!'O,$_=1\D**%V$>$R$H[L6!,R,U6_=IV1*
M)$FPME&?&C!_NFH+512J;?FIC7X_L[>)1NUOE(Z287#\B\>+?+2MSU85#=27
MU5G*W)C3B.J[G<VX(A:GOM9Q!I+AM8.91^ME<D4UKU%P0+OS391),X_=.?%-
MMMYX^GSIY7*J5%/T3*EO4URGTM9X.D4([C^0@WU!1]72",,`]A3/X3)1UF=Y
M?(Q4`$9$>R1\U5!QUH2+D6&MA1)N5<ZL@!"$+S)L.CWC]=J3;>FAZQ'RF8IA
MO9?B0G_MA_MP5;^.SY"NHK/Z=YXKBV_D''.[@F.QMIU1P9U[R>CRU+HD3V".
M5T6'*\WB%:[(S8Y%CK=VU81^<35B_F$<&J%'XMB7=K-A0U52H;5-EBI5:I_Y
M)N5X*Q,E*6Q\I'R%47=G>]#=J1?FFOQ,VN=GS%R^WYXK&P8K+8=3!<N%9[75
M8DR0<SIL<L4B!?"RRT9<-&D5\_\`'P;7\+E,.S$>BEJETS92Y::E398M)6ZQ
M/G3Z:8F_C"Z<C,;V7YIM7F6;W3V]348BH`TN,!PFV$:0LRRH88("WEB-V%9R
M)RO,0P,5(]&SV/#M4Y3XX8IE#+9\^WS]BZ%%2GZE4J:7>^\<77J=F_CMZNL'
MIJ]_D8&F[&&V)4M2=!0`!STZ#B8HU%#ZOE].QF<,_1IR.!Q[V5,#+DOZ99&9
M"_-O]VSM/1N^U9^)(ZC%2A46AM.<[-K?H5-AUB_(3\CG07<'O.O9@WB2B^.N
MAI9R?`@(#G^LKHDMH6S6#!EO/YE992S4G*K"+I&B+5L$!1/4:F0"O=='6Z1,
M,H3-"_32J9IU.I:G+:A7Q'O<YZVQ\P_54@Y^X0+R7I(7Q7+S75G4/*?9MOU]
M1D4O4!][Y_%!O6<OB%>2^%SHLHR-*$Q#MP.C;5JJB2,D]=/_``A@T0;C2H4U
M0M5J72FVOS19NWSJ?H`^,ZQBMMT0<L)SW$;[S"E[`+,`%IG><`7,CF.)!18=
MH1A:4(#Q&%+%$6A#94MY(20?9=QN5W9-W:S5DGJF.=:AQITVQ,^,RSD16/R`
M=6S+Y#I/%[@ZMM/F?G1SWU,.;:*KB4_'N,,4K>H&%$F(Z/0)GV,45CSN+SVX
MW`^2IQQEJ,/O6C71@2;&5%";42R'1TTZ;4IO2FWJNIO.F=OB.G_RB7!U5RQ"
M:O[!H<V_D],\_330UV/STTB<.+O+,YV,>(CY7.(K(B(!S,P$PIY+W:7-6@"2
MA`9(3X3?R?1T-`JLGXQ0DYI>7^5\/KT>,,Y-W_\`(9WX^^-[O'Y1:ZM4A2]2
MGK`I^,_'U7;ZJ:M)E`=,M[VKRLY1?$P3FT!/'C!N[F1(ZN!C$E=/P\7"N%R0
M1DY]?QDTQ&U33KIHB7?4Y>8;A1P7#^-3IDU>70I*.:?+%;/9C(%6LDE)6GIQ
M\;Z/*(;1DW+QH&E+=+/=4U7RCAZ#)'F"",69FUW)5$DX>;CEV8MTX:C-:A?D
M5-\JK5X1+(%Y#^4_I:T?D68/[,."E/CE[.LGI*@>%=D(Y%F/C"?\N[1%GI,W
M<R8@&LD)B+RW8SY*.#)+(S'JTH]V&`VPQH&\:JBU4I4V_-2DZNU7I:WR[J'>
M?R>=`@^F/D2@DD^6M3E(I0UX2J"\Q<ZH<557>*]H-&491)1N-MY&VK)]+-W9
M>4*(Q5'5\9>F=]W>KS]3OKIYY@JI44__`!ZDTFW+6[G>,'Z(:2Z;M\'\:,=Z
M[ZQKIS#K>AW+,@O.Y*[;C7,:()D(/"#,O)M?L1#Q=Y%BDA%!4B*\>?)[.HT_
M**!W3?19@HAJ.;2UZ:7*U0GX_.YSMY99?,K?M2<R=S@NS:6+M[U?0BTI9Q;+
MZ1B\1HZ.<_3Q;PMI'XQ<\:`RJ[/X@!H<Z8$&!0IZ12<'WFXTJH\'"=MC`U5H
M3=,.TK5-Y73$3X]L%@>;NKK\G]S_`#,Q.6SK4K'^3I\'"4"P\B\.8_L08ZI`
MG,%VVSH;'VCV4_F2)NB0_.F3B0KZ_@_2:*ZL=MFVPD*/P[9F<W^J/8XASOY?
M?D!@-0?$5>*USH%HO8E/R2^>V!GM75'XM:->0CI:"5_,%66S2`)KPI89`)*_
M646@.\7U;M63DJIHJ];ZJ^CIHI^M1=.*;NUFUWN6<&?*#V+//DX[<K^(VNQ9
M<D5Q1O9[6C(@W@E:/O4;1Y*KNO1$AGZ4Q<P]U*I".VMDK*%F+$C(B,;<?IG(
MQ86X8,D4_1G32J*7'U.I2Y>',>B6Q.\[[WZP"_$'\<G4@VT]6]Z7U<W(\3M>
M;_L:N5M92`M"7D!<Y8>1E>(JQ$'][8()(>.HX!$/1OX?S1+A@MMLIZ)I2KK4
M62J:5]E*+U\`=)7/=W37R@UY9TQUDL0YTZH"UM3HGR/18-[$86[@;0TX#^OP
M`063D'JA)7=S]QD[PT5T_%^3H]U0\\2\$J22H:WIE^93CYD^].QJ3L^`4IP(
M0$[6)4%'61W;U2S?QN-2;5WS359,8#:P?\,ACLD]%JV`3VE7BSP"F&ES5,`.
MW"%V^C]?\8M%-+3=6&U2NC:SX>5[DC?)!>W2IS@';Y&N&NT2='5]&N;6=UL*
M[;T72EHM+1\E"00T$W-2>R@4C*0Q^('E-A!`:&:+)I/D7";UM^L0V\T"A+5H
MJIEZHF7:.S1"4BN7Y`>>1'Q8K3SN4Q>"W<765(QR>.'G.W/5>+Q^KIY5#Z2'
M:\&>1F%.FKGQ0VLU?HRQ-J+D:.S'1NBY39+KM=PBEZOIC32]WE-*;LBM3Y/N
MOH'\?'3U72J=LI3\H%1=S:?'S7$G5A4"$K3^?VO839S2UEMH&-C",!U8$*K<
MRA_'6W[04&F?8#J[+#7>SYX[<BZ*=2</0Z=;Z)97.;>.2*K\[\Z0K;Y!>LN7
MK7^5JR.78/S[">2V<`=PGX]8)T\\LR43CGR+R2W)(=WAE%2E["E'DRVVD[9@
M27:"%5)<\$11DR#QS4>R%5*TTM4)MZIFJ,.VZ/T358ULNV>*H9Y">K)`>LFQ
M*E'%(EUP1HB*Q22/'DF;>%P-B.^?9(!#18*03&O&NBL*/1T:DANGZF3&MW?Y
MR6HY.U6,/$VMM,^LG'/C&?\`R(R+J+N87>?R22:=T]\=MI1<;+(<WY,YDC[B
M]8:YK9[8AQH_-1F*!S\%<_DM-V#=2/%'CK;Z:JZ/$-MO=,'2I4Q3%"FI<NSG
MJX([A5S_`"WWEP/,/EIBG9L"K=@VA5J="0#AO7GBN9-4JM,U40D[O>!2^V2/
MB%L/9=*(O$'[_P#<8LT+];$G3(>AL&1=.5!(-4*K1&\:I<R]XQ;V/=V3T[WP
M8J3@+L[FWND]1U7?(7>7$].#>>=^:^=Y\UH]'HN`_G2XZQL6<Q$Q+9P_#R8&
M5))#B_K)DY4*J,V3YB,9LM/0I5,U4NE-TJJ\M3IG:2WG=]Q]K<I\N\U\M5%T
M>A=GR+=8WNRI^KKYE%459#/6X)"0$K"L"Q#%6!XZ7K5K':TK5N-A)ERE&R>_
MC0LUE"C)8W[NMH)2DVZFHII4M)OLE+O=E<Y_\HU^ROX?><NKJ[EVM>=)J]#T
M1SET5JK$882=B;%&6DVK.\0+Z*R./F`$>4EF[121L6K(8W?`0\D&>"W+%;33
M?454+6T\0VNT2OG^#]*F#D?DRZW^1RW(-\DO>5"S[Y9]?C]J*BV'-*M$Q7WC
MVK>AO)F_LFB`LSL!KL0>5P8F?NXF2J-"*;-\><NB'DMV'A=FK46BW0G/1_9,
MZTTS2FJ-3;<N6L1&\>FQI5Q?)G\@<;YZ^((]?-]27@Z4]2.^M6?25@`>3X_;
MTL?1RJTP"U+35.@Y#7<YE`9],A[H:]?AXD*%IZMY>O)5F+2/M6#$6W79_8JI
MIU5I+4E$2XW4WE8N="^?S_3O4_,=G3'GSYC[/G9N"6`HY=VM)OCAJJIB8\?'
MJ^?E"58(5Y:57PQH5&G'9R.212=-`SYTP<"OL;)_ZFN5:Z4RXI=Z%C&IOQE-
M]=R@L>ZY^3:-?!M9/RCR?O<E.+$EU7QUQ7T!<<S<UQ\35,GVZVB56$I,T-AH
M%HG,E",*92`3L(D\;6%M?9,J0;(:%1`U\F-::7^)HTPDWN[PF]W['8GJ;IR[
MZW[Q^(*EX9--0]:]2DNJF]ZQSV-Q,C[-T:UH:/32%Z:F"@)Z=C/V:2OG1'W:
M($P&Q'Q7]&5V?,-$VV@YI)TUO=)1XU)'YLZ_^77MN4T!M8L4^4ES9';:ME2`
M%`_CC9<%UQ,'-GMP]L.(R.CB4_KFM`9UNB4@39>7/"0XJT=LF[9<=Z^;O]]'
M:43E+XL=OCM)U=%,I:(IA37J?$O-O"-CJW,_E9Z+Y\^7XY2]]>(,^'7L'Y@@
M$R\T#1']%S3??14(<&X5(C<Y&B&LG)PZ0S2+2:%'2$E-/(L"T),3*3@5^F:,
M2M,Z$Z)7YIJ>]Z:<VYNNICZBZ\^66[^/J6MBAFP&[IM[USTA'K@>/H'!A#YK
M5%-7$69Q<(GJ*/5^`<#G\2"/8:M&Q4:2FTY(O!SE"TX"^'NB1T2JFA50[+2G
MS=KYOYX/TKAM2^@@5I(%AS@]J-8ZFW`ALY9"5R^K5+PDL+9O'9!VT'*O/%MV
M39T_>N4&VR22[MRKILMN.9DL`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP"C?>G$PKMJM(*"8V.>I.WZ4MB(7QS]=L9#CI&4K*V8/NZ\"F'<7++-!TNCC
MMJ_>,C\3?OF3,NENV44<IJLD-O!JFK2\2FH:Y3Z[=RM-:?&O<$V/]!2[Y`^O
MI%U6[OKGPER^K6\!ABE"TC#:L-*O')HJPK\5*Y0R.VB]?/'#X7893Q,M&/UC
MYB,\6:[,?6`NI6TTQ#U7<N>\*UL%;-OALZ>GE5USQQT'\BY:V?C_`*S+0CQ*
MFF//\8AMN6/7U:%!Y6O:DL>YV4O(*.XK&MPX1LN4%QIN5--PS)39,6\0'NA@
MO^HI=2IBI[S*3>6E&?,]?:?P6#>P'W;Y)7H-*OWO65N\HVO#5V-6[E=Z;7YO
MI,]1)H+[^3803]XM;$ALKDC?W9']J-P")#1FX92!!+;U4*?Q-.FTZ=6^9<\6
MAI<F=M;X1AL\A?8\`C-ZL89%^HK@X\L>-C=ZLW-HU?'.2XY%(PPA*NGD_%Z2
M[65CXLCHF6UUCB8+1?Q/848\1]]5!5Q%IA5+.=3;G'4Z>]2<ZE[GY9O+GFF)
MB!Y[/7+!#D!3L(3!4#B$8'RU'0+*B+>,"#D+W>EWD4<&!0Q\F>'+B2#QH7T4
M<>C]6BXPG%2;4PYB<^^YRMD'^SW<EPR+<_G>2%-^;^F^>+$J&Q8WT(X6L:R_
M9.0K=9LK)!DJKHU:@N-;"[)V25<'VX-0/HV<;Z(-]%!&SL4[&_\`4=YNJDTU
MCMMML3$\^'.N)G2_R%TQ;%@:S$?V]U58O5\.DHR&^1^1\\3R4,@O[+?QA\I)
MBRQR00(P%2?>GFJT5TD8MX2CCT6U%DG^CD36YI:_I27=2VY[S!](]\6MF'K9
M@]Q7WUR=L.;!/CEFOQ_S.90&$%:HL&5K2B=OI,POH/,T+(E#R(V`+#*CT'2:
M#4I]QF+1S,$B0YL]\CC8-2B$K:E5>^$[84J_E8CB#?$]U!(;)Y`?]<][->BZ
MCX6GX*RJ3CP_GD)`+8E<JA@[[;`GMKW"I.I28,I@$$F7W]!DP_,GZK7Q])G6
MY;;0DD+K4513#JS>W-E"CIP8YW\1W4M8CKSI3CSY"W//?'_0LPG,N/4^9Y\C
M=E3BI/;1W4VL@#25H.IG'W<?!R+1R[;A4'PA1U"_%?"@MV]D6[XR^#6G#JIE
MJ+S&,2H_8L97_P`3M1U=;'+IZ(G6[BD.;.-K1X\5IF5Q9"0KV4`M4F+)264R
MN5?=F([UR<5;&%I2&UARS$X]D#]5!44T\T8^C+K;3Y=6J?!V]>3T?%S\7D?^
M,,=TE%8=:A"QH/=-NHSZ#B#$=5%&*VB`L2H"C<$)'EI*>]FBX0-JR'ZR/QC&
M_'23+3;[*W_'^#06JO5%HA1WZD;SCXT>GJ\OKH:X^`^Y&O+$?ZTD2<ZNZL9M
MS_&[TCX^UEF'VTS;E7/"TKC*\:DIY+\3\T')-RHLJ:4V=O72C%H$%!@U)I*J
MF8LFG%NMG)_%<_#;"*>3^.YI7UP&]D>(+BMZ\IT:F,9UD,NZ*L*Z8^J-F!XT
M:;R,4A$'BA1?UTUW^WRG\D,T&!5?7#AHJ8=@ZYU6_,DNR34>WW.T>#!Q=E?Q
M?]`VK=4`5O3NJ2V]R54O60SL:NZ5DM6CO;893N+.GY&OZV-WKY+%-RE304J2
M=.!PY.$M2Y$6I]C>.T]D6A=L-ZDE:F'ITMSX-QR^YU"Z%JK>]:!O&D$SFL84
MN.G[,JK22[CO3&D>WL*%FXCJ<V$:OAFQ743L7\?[#O"0_P!?>-_6WCYIZK^H
M3.Z:Y,*S3X.=]X?%X]N'XE8K\82-W-HX]C-6\^UQY=F]=J%FSI6C)77\FV-?
MP[\FPY1'62_L;UGJ/]FJWHCTGXOL\)^-/47(VJXKUQNW$\SO'7@*<D_*-)(C
M:4)L?Y-*PD@:PZGL&O!RT;X?"P0S$I!-(^Z`#)T/-"+R</57T3\>N"@\=INT
M2=$4V>Z[K1%'=)4)HM]#LY_-,],%4SG^SF\BQNC*A"<XO5Z+ZXI,I2\QB'6_
MX[#FSMQ8]7&H\;/2\M4I&U1T0\TGCP64>.1`5T'1`D";98>X59CMF#T7_4<M
MNZ<RN_AMUDLLK\0M<S>%?(U7]W39I84<[\N/:Z6FPN%_MLO1LN:1ED*C1F*$
MWDFD.Y:110\P;R(29\3!IK)ZJ`R0]X,>$-'8FMS2U9TJ.]W[S!=JBN?9I&^2
M(YS)U!9[3IPLA69:HK!LAQ%7L(7M&&D!K^,Z>R4*M+)@]^_/(:Z0#R8U^Y'+
MF1$TGL@4\9NB2C=$9;4RE&Z68.85??$;U1#@U-<ZOODKL)SPM0=A1V:0.JHI
M58ROK^*1>&FE3<.J"7=&Q68LBKN%A%U-&CD@)C`PD5%((C$6@=-H'7#C;K3E
MZ5J:AN95\O3S'6#<[O\`B]Z97OGJZVN.>X!O.$5[C#QMAT/7TQY^"7'XS/Q^
M%K5_O.:PD+N:19Y'2Y*-NG>SD8[;N&WWATN1](*)IAF8,15J$JJ=6G%XM,P[
M/_!BI/\`")7):'\]U@)ME\UK6B.$NC.+-A9R%HFC\L<]`@&3!S;*IAM)1#$,
M5CLC0<RQ"/-PSM!R^70;-2XM-GHKN+_J.]I;J57EM@\7)7PDQKF8GSFJ7NO^
M)`>H.7^F.>+(9*P!Q'REQ$^F[)(3V53QP;VG1Q:.*#F9'>-(B%F\B=.F;9FY
MV.M]D?R=@JKF;1]2:Z0H2P1Y!/A8Z%81OFSFZU.^O+*X9Y2N>'7'6U/-N>(W
M%+5D/\.#Y*10"!3JW6<R>ZO(V`=E%FKYZ/C"+LTPT\22:!EDQ*X0'6KM4Q4U
M#<N+J&TMNEW!,#7XV>XJLZ(ZRNKEKY!Z]IN.=86XE;<E@DKXZ$6P["E6H-L`
M9,T)26N<'LZ319H;?C4;AAJ:VZGFVS;7;3\6P:Z6J4Z6]*C\T?8)?"#0ETWM
M?O1O?Y-CV%9=P.:^'151!E8-)QZK81`(4UB>D7#!(+;"J)7:2NV^\A/.W:C=
MEZ1W^H\4S46(.'XFMPE39+Q;;>9@VF%?%+((?\85Y_&7MT5Z:ALX7M,!35@$
M:Y<JDJCJR>RO28`(.;#*S]=6?O(>3=G$M#Z9Z*)D6)!FT1#BD1:>K@-?UJN+
MJ)OE\XM/B39=7Q^.+=8_'&STM9$!_N"VY5EHN%-H4H3_`(IZ5M!-H7L$1T\E
M;#]E[&=MON.I'?:4^,///TGK%Y[_`-YP151JM^9-=I:?V(<G'Q#0>:?*A#OD
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M$?<OETO\=45NBF^'Z,K:8(T_`^(NE>7[PB`Y2-+3+[Y$.9198(%K;S?:11Y8
M6Y-#'[5#>7.%3*C)5GNX7"$U'6WJ8RJH;;NVJE_=N:+U)\453=N]@16_^KS>
MMKTI6E%DJQJWFY-M,(:SC%@2.7,Y#*K@(6'$+!$&"Q0N&8M8IK'6XD4-T',A
MSIVX?NF.GNX*IJF%9MRWRHLON4TF/P'MQ=9=.T-S=T>THZA+HO\`Y]Z3J:M2
MU7'+02H6R*>:,M)@JU-'K='D)T-LY^*#/'"1?T<Z`H!!0_UV:21546&E^)=-
MJ6DTW,2GX;7.IO+E0]Q5S)Y(1ZH[)@'2L6(`4F49C<0Y?"T0[CQ_4@W75..C
MHRQYJJ;;*#M'##P2HR9IIJKZO/'6VR/B6PRW2\4QXS]D0JX^+^N)G>GR86+<
M\@86=6'R/P_G6&R&J%HGX)<UTUH6KBM=Z%6$Q4/%?O!XD_?M9?&R[2/1M["C
M(MBLT5)NT$7R3GK^R7V&II4QFEMSWC]O$J,_^(?K1&&\`(QSY"PVEP?'>7OE
MI4UQ33F7R=/Y)7EN1>,PJ-1:8QLE=;9@_,5[$A)2-H2/U[NF:%.`/NX<<2!N
M2!B1>>_K'[&M:FKZ;51*3C#FUN?\G3'GRF^N8O#K3C75O5<+Z0(3(>B,A)>(
M<\"J+2@S5<6:8'-7X\7/ICY*]B:[\6Z0W6<BMA^HM9!/\[Q_LHA3#:>%'C/V
M16&#?%+$QWQ+H?%98UI$)?'OX>R*&.[:C\62BS_PJ^LXM:L8DS*(O3TE11VC
M,E<AE%!3B0NDRZ8A5/9XQU?_`$:C6OZ]<;S!I=&_&ITZGT[S5T?VGVV,Z:5X
MTB-BQGGF)0^@`E,(>&+/AS6OY3/K(*LYE*5I*==Q1FV0T%M6K-DV+-FA9J^0
M_`0:%@=2AJFG3JB;SAS"LHN1ZT^$,$C\?M<\C>7V[$7G1-U3&_\`GGKB*5_Z
M!EE26+);1,6&BY%Q?]ZO'3T/ZQ+[1J0B/9FT:'_TH\][HQ)"A/C&)62XCT+K
M^IN+-).GE))<=))X)?%F#M:==JRSIBPPML">X>;^>Z/L:-1^O-X2WCTHI*-&
M1[FSXH[?3"7_`*)\1EI1M-X<(4;;JP0F'&);FY)LA^K]IG4UIBVEMISS'[7Y
M)G^,?AUY\=W),3Y@?VG[<SN-2RP)0M/]XFK"U2N\YE9&3;)+@EI/,%$W#+U_
MZV7=[G''KY739UZDW_,_*U"NK4YB+)1V\CH%@R,`8`P!@#`&`,`8`P!@#`&`
M,`8`P"K?:-^Z<T\UV7:K8G'Q4H:L!<0KEQ*W2#.-?Q3L8X-@-:[2-==1+1",
M-)G(PQ*6O/=]4QD48FRSC9-JP753%2EI><<*[]"F-5?(X;/4]6R`**A>D+E\
M/]#UC/3,'FD6A4%?R+EQDW+GI_\`<MDSC,8(N"`/HO94)#!&93UE_$"-!7^@
MP=Z2+!AITWX5FIS?]KS?9F[Q3Y''LP(PV'C>>9*QLZY!5"2RB8:9L"*(,)9!
MNAJ_Z*M&*'I]*1C4NSKDC&H3RM<9.<`1S&?;L7(^-C(T0E;V1:I,1-/6RF7#
MV:3CS48S>#&N_DTT_2R\D+YYF3X93D.VF/02SJ;P\>[K5./]"WAS78@$"TUV
M>Z6&=B\XH2:F0OVYT'"2Z'M_"29H,66%`B[I\W_8:>N<6Z)KSG_),M:=H/+'
MM*`1)O31P36]N2*^([6%JKR^/N_3*W/9@I'Y2]D,)103+1EG*R0=^]K_`/*(
M&W!*.ME",J0AI;9M'W(D6GB)\<1]\%([W^0*]Z1.?)(QDNT9'0JO4;!C''=A
M^!&^Z4>NRM>+*IZ'+518Z+C\0\PZFFDV,3FKWCK3_P`73AMB1$HKHNVA;,J-
M:5%+W>5TU-2O*'X=8D.X_E($,&W1\4K2)/DS5>@^L83")]Z]9GEV%R\TUE9\
MF.%)E7G@OW4#6*<MK"2Q$'*W\@?JGI0/%C2$8$"I2"+/@5.)Z/?#C?F_E<V2
M-_(;*;%)\W2FM*_$F*-LN2=%!)3+Y#)Q4;F1MESW6[\D=-`(T64'C80BYGX>
M4C&XRQR\<+;#HXT?GF\-'F]5T!-.>5%EU_RL&/BORF:3@JVA4*HUM.K)-R^G
M(W%`\$NR&R6!F&-WP?HN:1@JO:F@9E'O%8[KS-/1TY1CC65AF/JPMU$9)-OS
MMVVHKIC+A7RFG:)MXV^Q-W<9:_8</J665#?12JFTIN[GJE#\9:UY6TU'N$+@
MN2-P,Y*424RCI(J@8$AY)OZ+:HKI"-W(]LN[8J_FN=%!E1NIL^=E)$T>[&M6
MG;:NZ`72'(694E8=%4G0OM^)+PJ+F`Q&S^9:*G;5<E7$>%M5)$BK8LV,/I22
M';!]8^+ET>;1P7)&PLNV!BPH49=+<7VJJ7LK9->B/RS@)W%&9Z)4/*CQ:9_P
M.<U7'QTTCZB9YI?EH1>JHJ+G\C<#VP&M)L!+S2,FY?&=74O8-XX_=.XS))4^
M"FQH\-,9<9F5PIMN_DP;),_E"`5U-)9#I?5S#]9%8_=BKX?$+DA$\E(V:T12
M<PN^4QJ7`8TT=C(4+/@8!*Q\-(&Y-K,WCEL-=22MXJU);>M`T-J>V4TKN+/>
M_![9Y\F#.JR[*O+-I=Y!;IDCBJR$.A9NQ@BT1<0FX(M=\LC<JF%B!P97R*N`
MJ/.MJQN7Q\7%I>[8R\='V,==2H!(VTF;AIWRKX5Y43;Q7@;C'/D7A,F@DWG3
M:LYL.1@E;\^SXN',.!S$DHXO:[K<HG[$U]_KF[C2*2BGSA3R0-U5A$KCQ,.5
M`J;-72:NX:7,6W7DI(+KGY$[']U;+6E7OCB:2&37'`H'6T"+!-H[*)`+[T6Y
M'K'8A+#S1L3CKAHLX:)S$FKL]#^@@IZ9L0JQ1\*B"(:?*W?\NIV^7WW)ODO>
MYZO;4J^I+5H%]5Y^>/HV+=EIK:T)`P\F0E-J2&L&3*G9P60'PJU#+!N#96*5
MA!B15I9RD$ET-1CD#DD_.:P1N$6E.?#I-^.-U*=XAN?.S;?GU#<UV7:]8`8_
M))O%6\<]"B90\<,`BOIJ7@(\^<.UVJ:BWN[$>6=/&B7FOY:SQ!NFMYLALIIL
M(E+2*0B/DCE53B+2E?2M7$V]91JYNT85'+$AYR,E2#C_`'9@UJ6EY#T8*BD+
M>N6W\-:NDT?#S)^5:/CTX![-2D?$B2@V1O!=,V6?IMWA9[OR+@\J]9,.F=[`
M%^PQ6(2"N_V@[)_;9!I-H<3%3EF9<A?0LT0"Q]N]/BW$=-BYC'OM>BD??-V#
MIL^,@3P(V1!J(ZSM&#GAR5\AEVV#$/CRB5].XE&;HNLY"9K:K]B*:"HO:?.%
MK<$=0]-0&RX2F[V\3C_H.?5>$@EFIL5$]@$S@$BU_(80R<Q/<D-.E)UQA3'=
M5)7\&S[<^?(]9=]Q/JH?7\PI::6R3J<UTEQU'_N\<&,QE>R662FOH#5MEZ.Y
M&";:6)&5!M32Z7H2HY$D=SM_`X6[-B&@=P1'B.F(F4IAVW^3MMN?TYZAZ':"
M2E9H7C8T=LHS<7&T0;M[YYHB5<7W78"\[K>5M81EH/&@E.?+9K]TS1:,X)*H
M%M*-XS)F4H$RXX845CR_@0N%%\-PX4KJNS@D*UNO[7YB']35'9EM0F63R%1_
MEI2BKMD<8`05HU.=BS2UJHCK.T@0]ZE#B"M*GZBDUN2H@(:QED1J55JD\#(/
MA3TR8$23AQ:\K.$G;=3,*=]^/[J/L6S.I`O*-55Y:44A4]L&-=,JW]<\.!1N
M8I-Y'QY+:NJJ<"JA$G_#$)9.;>E]JQZSH08D8J9"V=-H/'#0$1=F!AT4$1+:
MM:%WEJ=[)/&^Y-\2Z;L2O*D[S=VAZRMN6\(D)IYI)XX'0BBMOQ\5S9`NE8PW
M*A1VST4`GZ8B>MX3*$0**05^_&M):("`F4D0C(D(O3%M77JUTXW,4K9=Y<XU
M^*Z%O?H"+7!#"U4EI5+JD!P&'P\PZL%<*).Q0#S`]9/V#XH#=.UB4?>B+<D\
MO>J#WH>5.)]'V8@RB1")<)?-Y_B(ZGH*]V3H18`VAU^:B"W11*8LHVE!6]KQ
MGV":A350S^X@$U]LU8$BM]E>BZQFD2>L?83J>'S41^F3%OXR]'2IV$+,VCB^
MRB.;K>(WFQHL0^34A-0$!*">9Y@@6NF'\MV-2<??V'"TUY-`>L",X$P8Y-'[
M31ZR@;R-K09X9F8=KM+UV<6)#WH9<W(M7\39`Z8<3AM/_KF/B^YEW7R3ZZB[
M6=BZ!E98ES'!9A8_609.;1=LO5D8A5B6Y73[R!.5T?T]NFCJU$VA+XH-3]A*
M#^&A!RAHA'98=81'`TXOG'C#OQF_I*N8*8_),-V.7+!F<1(P0M73]9,0Y(RF
M'-K0,"0EUP"K_P!V:TM.F(8VZKRQF<Q3E->V##/;%C#J%*MWLL(P"4F(R!)`
MJ<=?+#B_A_#1'P[Y5#L.CKEG:=2B25DIV'VDOY'XA-T1K)2H.:>I)_0\=1"*
MF`[E216Y)]XLX!@8OM]GC<G)1,W)S,NKMF?!1_473Q,13YM)OP7/N6VZ3Z?+
M5.XY8F,936=0&RC%MG9J&=BM&9TY"X3Q_>U\!Q;3[JCHZC9A600".[+[*)).
M4?$W`YYIJDLX3P92F5V]TB.A'R#GB1P!7+GG4X'N>R-:))U!`W]D1A4+)XQ?
M\*Z)L2-EIA-AHU\V@I"*P_E2[2,Y"L@LR_1N00)A%R$M5DC;=L+IWVO-MU&W
M_99@KW#/EB4C('0-;%<%BUC1U[;<PM8(.*!&$@A\`9]:=#TA`HG!XX#8FFUL
MV1'P%)&]I"%%D0+0D@!0>"I`;D,I$A78NF<=.V$VV]L_X+XT]ULRM^_[CYU9
M5S(@$SYYW5TN<@3*"U@,<VE+Y-Y1_P"WW;;SU>7:W#7NA&PTMF;=GY!&0_:.
MR_\`2R5RV'J#+4)/G'7GR=B`?D4ZOO/FX>:;U("B:K37BOO2^5I6;7]<F([-
M^<:QBLCKY8:!<-5Q9D7X?E"'WL20]T^[)K-O4W;%N+>-3(M*3\TN\^Q\9Q\E
M"=7D74!LJEEX3<REAQ>%A(@9LL$M"U@\MJV1VVPETDL<("+_`&!`8"B)V.'@
MHN)2E^A-_M(T&I((T2VES,-.Z<KHK[+'C.<7Z&0Z&Z\E#_C"J.@Z?\G];D;3
MN+GV"NVC:O1L_LN-B9]>$<K.>C(["'0Z1"I5)&[=P::1APR'F1QS?[>8#:OF
M3QHHH"5X=XG>UDWGYP5BC/573L]&DX_#K<E3&*$.R:2YMCEPV12-?P6\PI<S
M')B2O*%RVF"0_0:%VBS@?`WL-.RVNX:7.C980=LQ1B.H1Z5G!6DLJ\3"=LI)
MS+Y=IV)3*=(=+QN[->)'%E18Q8DFN^NH=&^F7-<BF+D!64UYXO"_33(M`&A+
MR$&+J&[<_P`GC$:710&1/<%-HO,B\));1@N'E`D*)AXQM*:4\Q?SW+3<H6^4
ME4DO6L91<!^UBE1&(J]0)V+0$^YXLX3%I<R/-&FTR%2BN*R@LX$O)+")FI#[
M&JL$UBYD$T]9/&WKX5][/B-8<1V<J?79J5+^RHG%NX+XI,5)+)ZF.3+Q\&Y^
MOJYY#216FXR)K>:DJ@KDI;:8[BWI.N'$@A$X#*1.,GW+4!<4X)63*(8LWGG@
M6);1R5`FXU";26)2F=FXFI;;=+Q>Q:85WG+V]E/8!8/-9R#M8W=,0HN;21&T
MX1)&P28674["X*[W%,6Z([8XP5CY82(GCMR[!MHC(B*28)Q.@;=^>9B:;6<V
MG'#A_NOL0L$^31W;,I@L,@L>C\8*$K2Y=6(%(_/XA<\:,U;>4RG$6*1Y>4Q5
MK^UA]A`G$+51/I0TU.8JS\),%HU8$@U_5;-PC[[1A3\P8?E2^>M>TJF82\)>
MD9I$]7?-W)\B)+>UA$Y()L^[+IY:KCH>62ZQ$#NNRP>ETE[&#QD?&:U6@\F2
M>!9PZUGVNFHD<(BND_'T#26TRWOLG$+KU<[6)V-?(K'HG=,5IHS&8A(E31N/
M0E_):^MZ(RHAK*Y!3"EP,)$VK\.F4)AJJ+)(^QP+(9S((K-2+U=H985Z0AST
M;*"-&FTWYQM/^<3WDECF7KI_?A",B)54)JH2M@T/!NDJZ9$I8#F&QRL)NXU9
M>H'50;=LE&9Q&7KH+Y(H[YL8$^,Y(&7#2DPZ3/L`0-1ARDXF(O\`/F)YL5GV
M%UU*0`N=Q:96I9#G>3]*HVM&)AQ[(:\I"L:YK8=>2,9F$&Z)?0.$Q";&A<IA
ME;B4!(>76DI*MC9P<N&8>).I%'!6DI7"4.9;=LK_`!'H[+0KY&I2*JX4XN.I
M`T,LSRI>5K(07EMTUM#X')`G2[>R1H$Z=D[G7SR*'6LAIV;)&J\A\?LH]XH1
MBS:&IRY-Z55`B.F[C$M8EVZ>*AN#R-OE3;EX2?G\9YTF4ACM?47,KNM)PA.H
MH/6CB$)M:^J1>1&--2J#-W+S)VQJ$-MHT\60C8Y:.%VIR0*QMTUV"N0TX4Y:
MBVS2<^3P2(P^0"3CYX7AMB<WFH:SB5U$>?)K(V-KP$^Q&6=OS/YUG&FH75_Y
M%VY2,E*H>`FAZ4'"$2:1>;'FP?\`(,1X>:EPT'3O.TK.-6GW].MC4J^^3X59
M)A6`Q:J!TBM<Y(*;!5N#A]P1J6UQ+?XTQ7H"<C'!*W1@'4**\A<3YAN`K.E8
MP'GHE/8.'8PDS.'9M)-N&G>;7GFT;=943!F#_P`EX:)VB-JB54G+(_*@RM4C
M+<`NI5'2DJA!ZW#^X02TAX&,IGFMFB8R-W'3V8&&QN,*,X`:&O@0R12Q$W#`
MP:;3W[6SVZ<LPEW?(L>!TA!YI3]9(/9W:E,3VY(FRFIQ)N!"B:VZ`YQI&1BS
M*HY!1PZ*$$^@FQP&JVU\9(;Q]=)^FOJOHCN*J+N7AI>:;7L;A!>VYQ)Y%,X!
M"*8EERSF!2J[2UA#$)3`H8M%H'!K_GE-@`T,6()#A<\DY8A`Y8E$!I=Q$6Y`
M+$G#Z8S,(9*"VQ5_/I8D>&.MXGOWXDAF\_D]7"M;]@T!C@`1-X;7'0D@@$M%
M6'";3^WR*@)."C!IC946C"9&/PU\>\-^'8S'_9C*)`@-:.A\_!023HK1]$%3
MCNEAK/'WQTG)9/KWJ\]S!8,-+*#',CK@9S!V1>4YB`EN,UDDF?T'I0SZ,CP)
M8GNB@-<JM)Q*&GB:SENQ=N7K/=^KHFS3WT$2GS2\Y,8W[CF+F>.J-UYU(Z=$
MH3]U&-*]WM",^Q+:)LJE`W(ZG2UDZ"-T44T`<D$1+>/)1AR_]L%ZBP2<JPSQ
MS/&PNFT[<^,8G]BM=(_*TW)Q6A`%@0<K(Y\<K7FLO=I48[%B38.8="-1>[-"
M(UV)8E-)8VAC0J.E=E[LS8)H`C#_`%4AWD[,,B(-DV^?<:<]W'ANW:)V]8+Q
M\U];,ND9C;L*%US(H>3H`\K75PKG2@MRS`7(V*E-75>@-V/FRLJ9HPUO'+$T
MFC=)@#<QNP88Q;:JR?69`H<(TU$[J5V^>Q<#!!@#`&`,`8`P!@#`&`:-,*VA
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M3UV_E,-936Q+'W2.''<H6.$)&6GMLV-+Y-.ER6TZEL@EA,G)Y&7<_IMT`E^5
M_GD0357![J!=0I=`EI^(?A8T4OPS!(-&A=GAF;(G?\H;'S[U^#DET36IXVY9
MM]'Z<A6J*JJT4LZ5D=Y_,/?NZ:C%V+JM$<>GA[MEA[(Y%YSMZ#736ME5B,ET
M(Z&F(FP;>!$R\F\2E,T`QNOXD%D;9XU-MR46)"@-6P)J/4A[P!JT<Q](JCIH
M6?%'SX1-J'.,>O[OS,`<XCYMDIR;&S<,D+U*PM;%5D\4_BE;#:N52]N1,O!K
M,E0:LF<W;P"+3::Q:02$8;FT7C@>5*J2.2E4"Z!F2GR)()?MLIMB^3YROAOE
MZ:OC#^05JX5WD1LE()"S&SRR`(<^2.U1[1\F],@0,O&A"3&859XWB<V%.QZH
MN:MQP@C*F9<R&%$68*IK#]%S/OC@_P!A?$7.,%F(JPQ46F)>=A7T"(CI=.KF
MNFQSJ+BKXW;40@&N[R?6#)/SV<8C=Z6J,8CU]%&"VLM<.WS9V0'!G8X)<1MV
M2S''9$V6?#:XF0`5_%%N/4CL-FL&LH>Z*''D>8!YA7<J%2R%''!!F2%Z[:B)
M0+%OM6)!PJ)(J):,2;)\S75:JB?/.Q'S:FN=K%<3B0CA("8;22]`%F3M\)EQ
M<LR<7I1;"(UF-7))CCZK`<7@K>J(S%3L-22:"/N,:=(2<`Y+.C>[P67Y*%V<
M_N_,TZ*<.<SPE$<@(ADD781Y_6C^)CY);5O2T5`FM-S)G8-:QZOATJG9=C`H
M7$Y8-&DVL)B:`B).VPH0$*AWT?#"13()?S[\^)`,YY&XLNJ!.CU?3L.W(=*M
MNB%J`G`N]IU.:N<VATU3MRHV?.J?K).U=*LE9.41"66O8\E#0\8FW-(MY7,_
MQ,G8]P?'BRYOM$VO":4-Q/"-MC?+W$O[+F"C66;''5.RL5K8EP(]-6@ZL>H)
MM3L"+"4PK^Y?;6=S^GVL%KZQ)2B\KY.8@``:)6-*O"X/<=.)`J9"7Y],STB_
M\="*GD/^)N6U^G:ZEU5$M4U;LJWJR434=V/*`];NU8G-REDU0"NHP-N-A'+"
ME(^?S$Y.(>_MQQ(Y.0D4M)GVCU\Z.JN7`36MGROI\+6\+6P25&*/^.J?UM8M
MO0N40&95.[?6)+9=:\5Z3E4@@\"?K6B-Z/GAZ,SX1:#L)3JL5MH&SMU)["2T
M0_AU)47)\'O'?';[9<)JLO2%QIXO:W4^4LYW^/JM(=&K=GDK%Q*NRK^(&MIU
M,>H+*'P6YBRTV)6]`B5E%35J:1WH`DYF9HE*8FI8.\V</$'R@L5JM&_=!7DM
MY=??^1-7Q8VM:W@30QBW/-D<K2P5(+386_SC-6%GS"06>ZN$@3">PZ0323S\
MLY&W&(EOW,%&JW4=KBHN<&3)JX@8&*"FK(LP^P)*(4ETU:&HV^WR2&(@Q^,N
MYJ_)"H=9O/ES5W#9S,I1*=QW0K"T0S&<]0A9Q4TJ5GI/VPS_`(_<W`/M::Q%
MD&F#MVP,DY/OI'A^II`8JT%^I7AJ>G'[06FK>FZGYV&2HL!>R-DB<^T.)7,;
M5MJP[,-*,(ZSV%Q]@\F]OS&6FF(`$U<+IC!&AAL):NR),EXVV+&2KU\,S/R/
M8C24\&<FS2'4A!)%4;9Y'^;JSE=.4CLUE]@")#7]:3BFB'/\LB8R9!I6/F+U
MD;J8FXC3MR9/$B7CM$;*D7J4Q#"#[$74Y;F[N][S._7Y#-HMRAN8K1(5W#;:
MBT-)DVL0LB"UK$WQYW'G3Z$R2.!1MC1L#'Q!D1N>"H!A$7).FFK,@C%R8"*2
ML;X(/@`)=D";6/G'W\)ZFA*_']S*]!G0IH1;<F<R`C79-U-95TWTS)+7&JU+
M)%YA6S6+7(8MYW:T+%Q"4NG4@&B(A,@@U8R[>%2+5\0>O'*X:GTWV47L[1!F
MQ','*U(N8O.W@S847C]JB98'L6U[ALB;R@I;L]CR_/,/=2.P+:GLDD4ZDQ(%
M8"M45P+EYL_N+5E^D?@K%@2+HI+!+?EA+;+QVEF6G/&G.UA$9<<.PHLPDLVG
M;.SC,LAUAV5`):VGS2NP]2*R>-2:#R^/FH<^-5H`#0J7(1-Z&'SB/CT1\S9G
MT?5/%`EKV]9]S(\[<F47RM7QVIZ5BCN/UI("[DT[AIN1R&<CDWA`&+CQ731]
M-R4A.NFA4>'9^/694N1;^^^;HMM&[+\MHF#;=W\\B)6?$G%D.?#H.7CNY7::
M0.<517]<VC=MI6`)#UX4$M%9Y#*,@5D6)(1E>"4@#`<F21J81'G`.-#!(UNL
M.CX@6S9A+^^%Z^/)*\(Y'HB`2`1,`T:DA6;!)4[FC2=3JSK1LF<.)`[K\E5?
MBYB7V!,I+(9`P80`P3C@4&=($08-)^[(AQK(PX6([A+^>9`TFX:YLMROJ385
M$3UC<.JO3GV&1F25]8,\).'%1<J2&2[P6N(Y.(]8C$T$*QLP5-M-;"'G',V:
MDT5M#1(LX9I)-A9<WS=WY:)"(\`\JE!3(([@$@\':`S\8DJ32V+?8*VG&Y7+
MS<_E("\GC&>-WE\")+-9/*9(>8W"XFR)8A+9AJ^U69S"4-2XFIS,WMLK1B.,
M+'!AY[RGQ>%*R68VDD@-1>-)U/W;*>WM8[&#1%D3G<1G=G36'0X[8J$,K=F0
MGJ<1+3<_#0\>:^OR^C(HY3:RTHT,BR]NUEX+^#.&."N9#.YA7>+3H2K());L
ME,K16\KTAZ[_`-ON2MIK<4657BUD"%DZXG\T;[S(S5Z&Z->)2TB;DHR-,#1\
MT]?B:G[;+;'D2%=E>\Z&Q5>:7AI$Q`0!('4*K;]P3!S!!NDHMV#2>B4XB#V9
MGH^W*FYE#[!D,'CL?^KUZL\-(*QQHE(6HIXU!3MW\K_8C:P:,XY?^3<U,G@"
M,$:CKZGDYK,6-SRNOY-3$#HIG;,DJ>1/9@#G((W5:,<!VA<*RTSU)`'TIATD
MDXF7&)!%4]V#<)?>[ZRW$]]O0AV;T'\;=+06`RJ>3&*U-7!=CL$CTB/]3V)"
MXO<0.0S:6WLG'9J;?6RQ:W]'G,NF\ZG[$-/GDX&-ALLF6K-!")2&1,7POU.?
MVQMQ;;C8QUAH?&G6KEBN0Z2IKGVP[;A\GED<L5/JU&!6-/H7==AL9\6G+"1D
M[1'D;)$&Y=&_QP&2'599'XL@V?1F&)M(BX,QA^"U/9N-HG'3L65Z'J7EB\'=
M>QF_'H-V0GT?MRIZY";6U)*[)69&K<K5^PMROP;2(3**OK#'R"NA2YTF#2U-
M>BD8VQFXU(:3C3`VP$3:QT>$XAV=\7]XW(TO0)P-M;#8'<UGU[75]S0W`I.`
M\\Z+,4[<7WP,%E%;P0I#',=L2)S".J&`<NET%3TC6XUI/&9LM&RJ,@\649^"
MK5#A.-[2MG?RGP-_M<;QS0E/U;%;TF-:T_4$'L"O'M9O+;MSV#CM[-KLOM9<
M']\FLREXTI,9<@6B;R8OFQTZ=)2S84:)R=(VAL8W5$NVXN[S"YL_<T4A3O"7
M51M><`97&9S(+>3B-E-Y91/2DYB928*<\$'T.`67&#5%VC&W&Q2OG<]T@IZ>
MQAP@4W:OXM"9<8>L`T4$#A9J5N)4-*T]UT^Z)(1XIYM2KTY6N\&-/@\DFXZS
M3,I,6=:YRX'EE!68\8"L7^/9J</[P;SV/"!0T)'9BVL)&1``#)N!#D60=/QC
M@DO/AM$<1B.D&]4_SM5=&[2QW!1TH=GYZL*5F\SL2QK&M^?RO0`@]:Q]B<GM
MKRJ9R]X%CS<F32CT>],Z@0.A,GX'&LON+W\\&V_B7HB$6GQU<DM0QR+JP*7%
MH48@$_JT?7\BNZ]))7<"@-HQDA"IS&ZA@9VR"$4IAL8AQ8G$FKJJA,/(QR+O
MG4<BSP($6W8>BZGZIX4MKEQ?QF7=W)CD_,5%S1]+2$I@+4TYG4_C5H2WQX:D
MWK4W.(A`QU91\NZ8)FDV&B#.#"6`!8(W;(@"22.SPH+>DG#EZL)+YZ>LD;0[
M@OF"#F(_(14-EY,]%&U;,(V7F=TW=/WP433Q8H;J\&/4F]BR#5N!A)(V7<AP
MFNGVS\90EZ]:N]B#WUP#J;]=DLYQR:1)^->'V;2%5X217@30#6M6<VCX=&.B
M[<K':<5@`%&@-25/9(J*6C'75RC?0XJ4B(PPLQ.8%3(Q.9#$G#]@0E+9X++]
MWA>+Q8W8KPCS:]D#J5CH>;!F/)6A8@,2)LBTQU:QNRF,'2KH=/`]/"YP/J]D
M<0A[=N!<[M(JV2?C?UJ#K3?<L76?":GSTZQWR>+D;F*D^6@X.KXG)UIG<4#H
MFDH1-R\CL*8R^5MX``:2:/PAT&B$XG,V>5'6$IE48L=]%(A%]Q4,V*")`-%Z
MO]XIO]O!MN[PV_/>^[Q),U;0*DMZ9_A_5V@,Q2YUM.QB:$<E;^2AB+>6R"1K
M3MLUE*9LD05W<2,M)$'GK8S^<)>[.6#/9A^A1;M@<S?)%,TY2Y2,R.NQT@%*
M1V>CXY7T9JET`M^Q8#8;0#SP(LUI$48(4C,Z!RGQ>'1J]+/%2(L&<;%#,:GQ
M(7-7Q82HP0;!+OZV35_#I^QD(_P[R_%XC,H*'K9RG&;!A)>NIDR?3^S#+P]#
MSUDV3;Q<6Z-&9D0.)+/K%MZQ9(J7:DFYKQ61[CDR.@<8&'C@E^71=%]D;/-.
M3>>[$3FZ,UKAG(F]D6(YM><-'QV5?HI%/'E#LN9'9AZR1.HM-&SJC1S2".`#
M9%".+()['5!.TH77-JA+YZ>L^]R/F?`O,K/PNYUCUCNY$81K%%2=EN@>@#5D
MB_X,J3K:L5HQ8I>SGTSB#F*-[-L`8@XBQH.J5!S"0`#^Q8*4=L%0U/WV6^=K
MXW/<-X2YB"DX\4"PB2!MP'L55=#Q5LV^P`SI_"9:2GD8-V['6T\3!W1)!LT,
ME90K)K883*0%C#]R[-DB6V_T\"7\C?CCP,-Y\>?)W_XH\4@4J72E4.GM?*-'
M-T7>Y'Q:%67.8I9LPCE:C5K&W'U4P>S^#Q25#-JW;19U&B05EK&7`=FG^EP-
M3YXV5XM?FSW,H:X+Y</MMVA""2+QN]5L#]S)L;9N$9[8`VU9>O/K#C-I*#IZ
MU5M*&2R7NWYDG"[!WD<5_$4-#VPAN).FF!`)?SI;P[F,5^//DQUN_P#']?R<
MFP>B[/!-0)*Y;M?1:-@;G+:'K/!0J*.+%WCD'$2XTDW)/F$2%AD&SAF-U&ZL
MFXD4BR#4^>'A;8)KMKG>G+TV\WM2'>2G;6N[.JCSWT_*`OT@%R)19"R`'TCI
MH3Y])(E"XSKZ4^GWD1]L\V!$1FSQ_P"NA)CW\C6IUR;1=B2$K,3T:D(^:F92
M(F3J;PJR[.KF:-I`&@RE:-W(:5P"8QL]'FCN!JJQDT)`OQHB0,=O%C;%^_21
M=IBR_GF::%X-Y=C6T%TC4$D$;&5['ZQBX>-@;7MX3$302EWGW"J6UAQ)C.T8
MY:B\$=^)J@B-E#)623T0:-G3QRU9,T$`U-S?,[+?/:>ADA?&%'0]%EO6`J2U
M8805K9(K)(9/["8'I>'KF[]+[U&3XEM*]W5@/);,GTR1F<GFZL@E4G#618P@
MZ8)"YM)V)4-3[YSU46\(CB%P6OP08`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`I?\A-<&[6Y!MV&QT',9*872AAQL`@!B1!9@50B=@Q24DVH%Q%2P4Z[(^B0[
MY1J*'OM7)9=--@@@Y<+HH;C5+BI/Y@YNN.?NMX'!IM-^9M[WC5Q65=/R5K#0
M4ML2<.H$.C<WBW1<LYMDCZL)U*%JWCQ8I:C.I3@J;DP#24.3LB=(2H^J&,EF
M>1?=^[$IQ.(I[[3?.)+C\`1ZZ0Z5T>S^2W&<@KUM7"4$&W%"+DB9,9+FH:3:
MV8L%==$]#]`7&8:/OSX4R*>.'D<K1$^')%*U]D:)Z0$TK\S/N*HMB;X:\,)+
MGKS!SFI?G;J+D"O?C8;0JCIE/ZLKNO->BYU5(GQ']VT;TW'?C8Z"K:Q:Q1&+
MK^;:`>C;?L4`1&(M]MF<3NI>RWA=WHPL((B*&I3U2U+M/*UTN>ZCI;L2!&N1
M>G:*BEDP"R:U$],0[J?FF0M[R"4.4+UK('_2L8EY*PI583F43$R8#,K`NT=;
M5G>"C?OH6,O954E50TGL('&ONK(24XV:=F[VM"B,4QB]F\GU,!N@2A5Y/EJ_
MZ&NN"P^Y>$91I9EJ\VQ"M>LY"/J>ZYQ)9M!'\=KB,U\K:<$JF.FTI%'Y#O6$
M73:FII*VP$S.OUY5T#%48E*54K-Z=KWF&XO?BR-ZL:L^AK]LNXRE7TY(*EK?
MK"=\J0^4>W+&-Q#9Y"N9&%KVC;]E61"HZ?3D`X5?OCFH^2T1!ET$G)Z+"")5
M9B/C@P*25$32B;M2_.(7A=\3R>2J*ZZ'YRF=(D;5IV36M7?&6_5=)0[RHXJ2
M/-DH3>:5$V3SK:U;0IR]+2PP`I:$`[#XX,MP2$BL&.MW2A=(0]B1B1EM@E.8
MLWI=^5*:V5_S3TC)O=7@+-M7E/Y3#FE%V?31_HXK<9VN>>)W%7`*8!BDCXXJ
MV!.=D-4-%(D7)6K98&1S=92$FC0OPK*54Y0Z&V4I.@8J/#[,.$Z;IPE+6/S-
M][)I76W$%>(M7O63R1,Y?#=>M9@N-H>A*V-3>\JYK^D)W`B<=ZOY[D)2N*B:
MU5%:G>36!R6LOXRE[9+R^)2!80-AD1&B)JHVE<H!N:5M=+MNU\I\S%XW]I,+
M:U.]4674<CB!&.=>G)[O6=J$.NF!JPK7UKZ:V"#N:M)96"'-;'6:HQS79T+"
MS(C"!G/+<*%TK;;>%VFU\F[R.`4P32>T2HCB'G=;3._28V60P_Y%GEB76_K6
M97B)L=V[ZK7JP26B-K.:OWJDE25E,N36).<69T;[SN'-L9.XIE<BH#H9Q?XV
MW@Q[6RDG,!*SZ8&`^G&WTWWFVJ(4O?>(WE)$P"N>E;ENRBOM0#OB+T=%2EL.
M3DBMZ\[VB4\92`W349#+M0,Q)3MMT/%(TYD39ND12VFK:%2N9C2CV&-W43<E
M%Y",S"?Y9MB.OA_E&KTU6/;;Z#5S:EBG.E$[T`2WXTF*P(Q9M@,84I'BM2\W
M@>RG,JJ@5)6E=R1OL>*6^ZGK@[&B3D))!)`_&MQ)MML0<"U1+2B/J]W%_*#1
MQ=8]6RR-T>'=1KJ,L>$Z\<G.T6ET2>:2:,%^GH!W_P`36&4EE'LY?(2L6;PJ
M+0&)]0RR2$:%9AJA3@RU=L$F?W$,Q#`!5"G&*HC,.BI7[MI7O/C..)-NN8U!
M8(1(E>J(N?;0B$`?D#)SFV9A'@<TM`_U+S(,.`^.S4RG;*,`9%-Z\<]'@*IW
MYG?1`8L!ET#@S5TPN!>N6L="W2)>FUXAQ,*;6F>'M)X6,_OU$<?5HJ?]`H-K
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MV)-JCCC-_P!&UJ'$Q.M-::`LXA9LZ>"I,XZ'M,[:GMSJPCI6J:42D;B*$8<1
MG#_I`%/(6>A"VB%6/GDL_<00@--TWWS..$E%F^;KVN7IH:47K4%NWG8G0+'H
MQW01+T@ERP+D4@)S-Y%8G(+W4CTG"VI'O-D"2UAR642:(RFDW4S?R>01WF[T
M;7XWV.2Z)V<RE@RX:49WVVVXBZ>TJ<1&J?)_0$^M:=A34&AEM2ER:X3[II(<
M^KXO+]P@BQY[(.8)+`ADC!"RZ<7;_N6-PFTMQ1*2!'88A+8]#$R"JLF!USL/
M%I<+_M2_!3/V]=I-!O"INL87-I+#(%*^C].71O0"9I4BK)NI;XL'<`8Y@@NH
MQ(6=KR_H!U"9K1"[$IKN6%Q:SWX\!."(A<C&?8*W+;AWSY\8367$Q;\J4SO*
MC'2Y/5O\[V)T!Q1R-3=[!9E9\@>6-SHI>JAP6PB\X2`CMUOW1)Y.C%9K-VD9
MET=05;/BAR.3P^X$REK]\$GU'J2#K0$TG4U:SB/\*W=8R592I'NN5S"XZ-FL
M3;E',\N'F"'2?HN6#5GU9V[0'-D5EMD+S>4C8V0$/D35UNQ5;4Q:L'8;BTM)
M),[/V`;^1(<.=+A],3W<;IN%'NT^W4S(6L+XJ2-U)`9W#NBHF<Y/D%\U-4?4
M?(T4CUD:#J=G2-2SFJX+_`*QH7;#B;U(^AWK.FSDB;#'TP@<PYO9:;/@0Z=I
M2G4)3F(NDX?-TW*B\WVF;IFT4&]MRC[!]E-P<DV24;3OC*LZX9Q"B:3$[QI\
M6BG1?7<@3!2B+#Y._@%8RR85W85?2V:Q4K+_`&(QZ3S(X%^^^C!:SA,&I_J5
MF\OHNE\$((<7=PGJVKE@(#P&(3'B'FZH(S18F;IGS2CB]1,B@O2$K#UG*0)T
M<'4AH].OJ3Y@<2@D/+CB`>/6@&:H;@RY5D\%U*_^YN7TPMNK<=IDEV>26R:\
MJ'M&-R7AV_+TD791Z4V,"81F"L))H>@EI\_QN/`X?:)#=SOI#Y'19$$A5LCA
MDF_0DU(V(8GJN;S8PY_:WHF]/U):;9Q#VMOF<3,LLU;=.WK+HE\7XV!34VA,
MZLM$6<L.YB,"=2!<&P1X,Z8KXI-95"IM['2C3>7S"5A8TLTD:`XT).S%EJ08
M($6ZK;01-?5*RK*>JP5QM+@>=1BP93(XC,;]E<Q)<N=T64\M6NIH=I(@9ZJL
MJ6<ZDJ\%MF=+%(0V39?IH!MM&:_)*&8T<4CBQB<(2T_LY++BJJ>(FFT393N^
MY&TR0[Q.W,E)`0/I6-E]9#;0&9B&I>[G\5=P9YQ?:(JO)6(?HV'&N:0K`W?2
M==$8_$:XIZ3VY#9EKJ4F]EQ]7[LT.BK3&VW>=5]ILIRX:VF#?)+S'TBW:N-`
M$[[0]<1^BOC?7CKI/IN^G2[JV9CU-<BW;Q0DD[L1=D?.-JA?Q7]PAS;1]%X1
M%U0K:#@@"`L.B-?,_/(DJ,*9JM"Q"T^L]R..A8+V>'B\_JRO676:C2/N>O5^
M?IJPLSI>=F2)=V5B#^EXF1,P:W8#+'[[39P=<P&R>E[A*5'&PR3X`M%Y*XT:
MCVPJTVQ_3/W=UCF/3>1I8([,)1V[UHRPZZT[`,MKC=0"1#Y<;%<V#*N*4>0\
MJI)G#Y-(1]$_O9K(/0(0>$"#XQ<PZ_$W$IEYP?4'[B?EQ)5L:;3SUO$_:+9/
M;2BW4M5RZ#3PTOU78U"C+H(,RT35K6^V\G08FN=):*V>?M"\>@[YZ"F,#]M?
MR'LEG4R<#(E$YS^LEL8:_LET0E[(''28Y7.[4)6GYF)*=J+LV.RZN9DZ`]#"
MKML"IOC\7L:42^:6#((DJ2@$0O<!;@&R=]969AWI$#*B5?O9<*V;*/"J10G(
M6/I+PW)'SX65#Q$U193>(VGSP;7Z.OQM5M9@AL.^0-$T84I8;U',K%LCHJ1"
M`%GCZYN=U/BL4A-93-A?$KCSNQM88+E"/,EA5ISR05/5F1#F5(/$+%"/!+3_
M`$[Q$*5:-HQS?,W:+-?'/!>B`LTEDQZ%C\^9R,IR'RK6[J16%^K6.EY/5O1/
MR%K$A!,D0E,W(E#8."SFL"9$@1F<Q?/V,H#$WDOD[H@L:>!4U"C]53A;2J.V
M\[+LBK<7Y\ZM&5)-_1VO1T*DE7\SA)!1T1A5EV!!XZZO[;JWJZ6F/N4,BTG$
MQN=%'T$7JO4X`F8TY'344-"F1@6_2_1^,IOTMYWG[!M3M#=[7B$NZWZ\&%LJ
ML.Q3$G,2"O@/3:G5L7C_`,@R!">2.02DG1[!2;E'Z/.'M'L9?,&]0A2A*M4`
MH^ODJ\1C.HD@SU97P0&S/WQXI2ITQ>(^G"XS/CF<_P!-CU.81WPO64B&4-+>
MFW<S=V7Z0K,C-&5M51'@,&8TJ49W<,,N.J+MZ3LLXZF#]V$CU&+V0U9#8=T=
MX.LB&L"50";`<DW;Y[B:9NE&^'+FV$HC>-K3,1VLI>PHW+A#J+`!5CB5JW$U
M\%+-K0;&_98@M(:ZC$T&,3YB1$"ILW*QX.0#6\S<F2+PTG)?'_A5T\<*?KG0
MYOY!-&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`,-(SXR*1X]*32CI(-&@Q0^658C21EZF,#L5R+]1F'#-'Y@JZT
M:ME=FXT4P>DGRWFC5BT<NE4D=P*:^_(%2**^P1['+J'S_:P(M6C.JG51RG:R
M2$GG5=3ZTX5XVCC1%UJD,D<0K"<.O"C]ZR:1US'R#69;QK9JYV1%TO\`F5''
MNX]B/K)^2NI1-?LY54X.<605=MJ@(E&^M>S9F#KQG;=O^5&'86J2]$:+0F2;
M'!$T8^@7:"SP.0C7KB4:!`)$66?BJAS#MGC93\],,S78_=*W+!XU%VE7')<Y
M&\O7#TAY)]="2D;;:53,*TB^T5>-Q`U\1<+%DIZNZ5<L=]WC)ZA'!38626E"
M:PX*:9WW2\TWVV-NW[\H]/5P,W"V_I836<E(`XIY6J92WM=$L%@48M(D45BC
MENCJE%VU?36(2+:2JO\`05LXDH:):+[3M\A%MA-+Z8F9MQ[V]<7,'TUVH"J[
MG^D+[K*450K![SL&K8X!LFW3!>(UJ"AUF@S!YA,Y"Z]U&EAJ:;4>T1^W$M1K
MML[??HR*35VBHWU%2EM7MLL\6*[1;Y`KKLI.!QNJX[SQ.RMA=7(<\PN\HU+Y
MX?YLL"/Z<HV[TL=E4,.,@:!8J7BA.JGE9'V(,A*8VU-NOS]9/L2;EX\"3^WI
M(A)WFV5%U>(?SP-O+]96'8ADOQW):.ITYT@3M*25-,HU*I&5E7."];!J;AEW
MO[==_KX:C)Y,`)12Q(9$]*N>Q]D4_B,3?!WDEUB`KV</0A9EQ9]<QSWOX]"7
M^43T"F4')DQE;\J&#_-QJ8PFLC'*1^N)I"U(](XU'9,3\KA(5YH7I9_+GB_L
M7EU>&G#%5R:B_A;8K(8R^"%U!'/6^9^7[D`TA\EBQT7+)A>'M-`HU$*E]M"R
M8/6YV?/.AN=3&T@B`)K6ELT#.(I'K7D;E^M*2#)I/XI"Q8K8_#2P1:,([FH\
MX=C3IO"G,2XAVRGCU?<LE&?D!HF12M.&N0]S1,SI+IA7)+]X4Q/@[$-9L)JX
MW>!2MWKW00[1=3)Y3,?)68%&A?2R!..ZM&R+SR1$&`-R)I?3P:Q,3TOS!&%D
M_(W%PC9BR@T&E:<T9S(6&F,(MF,R"O)`#BDLH;H2XH%,&[%R@KNJTE3ZAC`#
M1BY4;EQ.S<V@>%B2C)!HL"I_A]92?E/Q'S@/673=^@YA-.?*<JD]'JG9P`7*
M8W-YV>CLLM>R9#3M<W1+8561-(,K&82-CH>RP,7`3&>KDF<DFJ1AB4%Q&,BT
M9<5"$G#GIYQ+]_\`-IRF?;U+UW,'T0G#&S(QZU3L-%C)R];25K#I&>JFLY#;
M\^B\6.[-O=)`5`U_$96:U?CD%8L76C9D0"D1,RR4'X)I;6W:;WM[M(D"E.E*
MYOAX?%1)K-@)Z/1V$39S'+"A$@@9]W`+,TD&U>3T<+D#1JY<1F7J1*5,V"N^
MJ)1@4C9H.?%ARK!5EX#4?.,G*6FOES/SF+-I-)O]VYUJ9YBO;H=^(KZ86(7D
MU)ITO#6TM69VY''475W,B'?KKP.2]@Y165M226G@F+&V*Q$@"&G3Q.4KQ><1
M\\B]T[^02F(4PFZK<7/I(XB:5I`@I=A"),SKZP+:J"`R>PII3<2L!R+4$.9H
M+$0R5-W'NZ6PG[M&9/'6+\E*8V8`-1E)VZQW2;B8^<X:/ZA'R!TE)]X`,-M9
MI%3<J;TX*E*[V('5X=65E7I'HQ(:XJV:S+5DF.&2R4H3.(ZB4MTOTNG[R@^A
MMP%>32-M"(0_?R67Z&AR_P"22O6S*G#=>0"VIC'K9LR`QT`24J6PF>M@5U8\
M5LHQ%;"I[?[-XVF34T5@K%%J@\7%*L(T=934^W$1`@*/NQ52WNM]UMS?K]E+
ML;BZ^2#FMJP:$_=K4<,$HBC.YB[:5%.ET:LBB5G3FFI&4M'?03](CM"K+KB8
M1B6C7/YY8?N%(%VC`@`'DBK(32^GGG?YL:_>WR,U76=<7C)HD-DA\]7$+Z-=
M5\3D40E0"J+8M#F>*S,_9%8Q:PMAWZ`B:C+J!RQH6U;^)IOTHA-EXLY/:P^0
M[#152VZ4]VNZ3Z>,^*)(,][\WQDI)D91()1&HI&2%P`=K2,P.6-JMD$LY_"R
MR071#(G,4Q:S60RJOA4`GZY(6P1W]++P*<#XNL>)1*0-!X:7[;WAQ#\91[89
MV]3$OGP^KWC"SJ_GA"1A8GY'K.K630==H?DU=6!;,:8O'A9KJ,T^_0"L)F<8
M.4GJS31R'<1M\NSE2+@&@(Z6K^-FGT]SU27J<0I"^5+'KD;^Y(5U!:]>0X$3
M-($03E.%6%#IA+Q$Q9#UT=77N[YC'1SL:U?I-_%QQ71PKJEO^%/`2ST3?D1[
M&ODCYKE4<828?Y:S5I)XC7<VK-B7J*<"C5Q@K3E8J!PU6JA3P6FZE2SZ:G0T
M?<I_A9)CDBC"5/548*Z1E.XNE_9W5N_!J,1^2JK'`&2E)[&+"`EQ$^OX;Y#@
M-=30[,H]6%`RUA%)98T^CB0S[A'D!KTHP;.!C?1^3D#W=QI`1TL;,7J[<'2^
M>/-[+DL7".O:.L:U5:4ALA(F[):Z%B1&/-0)/WT7#Q\=B<H&6.0?_D?;D:XF
M8R=1-*`S#1TJ+F94F\#`E'92,3!I'A(<3%BS>"#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(^M
MFNAMOU99-3F3,EC@BSH%+Z^*2&&%?L4O!#IE'R$>>F(L:_(=>"9$-;D5'@8C
MLU=:,R*+==1LXT3V1W!.&GQ<I33?QLU135@QRR0TM/;F8Y.X/8;4!'X13=9P
M%,W!*>Z&I0>U80NKJXB`P>+)1GHR4%C&NNRY9W)@@-]J72'^D!3L:=3<];;O
M=/=OA>IY%/C7@K-B4"1.Z;DAD9F3Z*D+0CX?RMGC>Q7,$NB5W=$E7[\[7Y4K
M'E&IN8$HL;4BCT/O(H2R"BGWNA$?L7<@JHV5N_$<]":.C^/HETD?'GI!.9Q$
MORJ@M:D3@V*>17=E)83;!FN9*1\>[R&-G'P\N`DE6Q<H"(!7@[3;7TFP,MBK
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MO*]=5='X]`O:Z1K-I'&HF/A3HY%C8`UK-$PU=%$1%X]YF;S/I8DNF>6(]5`>
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MY'Q.%4E6,6:[UW7'2%8BE!<4K:KXP(;+%0W34Q+2)X]3)$B4C$`7:;YH,2=A
MW`:G\GE/=]/<DE7@$4+&R6+5QT->]30&RXS"HW<<-@KFN$-;!7AE<1>HMI8.
ME1>OBLTK2:R^MH7%HA,)!6\@CBBS(&/-1A"*S5-25JOGSR&KHLM^=^S4\ID-
M6G\5L%/%[,LF'3:0JV,76Z&F$*8G@E7IZN)G>-"VU27[<G5JIUPYN625S%1M
MKE-(#'7\V79P8>U%#$&Y<4##,&(*IJT6LM]FGB8FW%[\EO.;^;'M-.2$VF]F
M3*V[6DM9U-5QF42Y*'M$Q$+J-.6O8S%@C.%1.'C5TT9%84X.%Y(2'N#TC?F=
M/UCAN+%A!`L1N>BS"Y>?9%8&WQ9P]]5D:I6=='7Y8-8UW5MJU;4\3+L:-!-J
MZ:VU3<YH0Q*6A:'T['I1)Y,$K.QI@$CODQ/G8\DN85+&`!DLT%/1PNK-E?.>
M9C/*3\.Y*+[X^J_+/WHPK9MI/:FVGUMVV%IGQ6#MHO';4O"+6#&+!EK&0H0O
M2=/6SI:UK&F`>,F9,2`B)Q+GQGQJZ8BHL'CPD]%M>^T1O&QHD5^+NH(W8,9L
M5Y,STH-CB-/R*7.I%75"/3TZEM'0R(P"%&U9OM4_[ZA3-[&*^@;.61JO9'&`
M!I>*MW;-D'5D$W_=0NIQ'?=X;F+MK=]>I(<"X/"0K>DV#R];NF$/YN*P=2CH
M%("$*;Q>&1RO8G-(5&P#]N`A@=Y,'R4;F*85U,Y0[(S!<7%8XAH61=.9>^E8
M:NBO,YO/C\]OYT^/FJM(U>\7\E]@_HN@(!/:\E*_KN.?JA`FPK\Z`Z%*O(_M
M^W/RDB+.5]$RP./W(I$6VD>#1U)RV<DD21(D&IN.D>B2^R-5GGQK5S8T>E]?
MR2V;<5J<P[Z4/PFM&V]?H":MF_5D;M&+6E,(T=\@VTL,.&0N[+82@@68')``
MBJ<],--AQ1@.B36,@JFH:2E1S?3$)WC93O;)X[3^.B)S2)S^-^36:3&&+$.F
MK*JNAY4<C\5KB*W7TU$K<!38_O8$4@#NUV@AP\N^TEH]HX*R=.OU;!-D@X4Q
M['X(+C`*KHMKQ>%'6-EU?-V5JD7"?3MO0&\A-M2(B7E?0UE<Q"=9@>M*&I6#
M2]:4>N\(2>P0YFIJ1K:*.I681+2R,@(/&XVQT+-9#Z0D\R'-9$?#Q\74DU&T
M[6E[7;LK9;^YU7GE%PZ=-:8'[[/HV+HNR(G9,,%1O4>S'^/(9')#%PH!VW<,
M76ND=2&2)QIZU'_H76FS1EJ@[11T525&4XGJFO,K$O\`'76'D0H>-B;`LL&7
MYLIBLZ@J69LEX@X/!5*EEM>S.(SE^U)1-Z`+R'<C7(T:?'.A'[8,QXU(A>X1
MOL]:NV(NIRW:[;?C/[D<RCXJ*JF&R)J16A.)#8;I[<:TFL67P'GN=%S;*[Y2
M+F4G0'`)I3AZ&0\G&#HO56N3\4CHPE&F;Q^.)[21DOHBD&M^%K)O;QZEB:]X
MQ@U:79O?T=FUB[3X@Q?Q&0^/BHI:/R&HVP$0%KRGG8!,,BP8PVH70)K)J\<B
M-&$E'R@[8Q8@<)>VE/43@:G&FT??GQW\.$7"P9&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`*Q]B]2PWC#G:?=%SP&=DD?@ZD4
M'^`H\L%8OB9R<S*/P&+M7)J2DPL9C0;>22<5]^E$B+,`\>#>/BSM17QKHU<#
M5-.II+?[*2%"?R,U1&A7&J4TA%CQ6Q.U)@"B4&JAPVBQF5PQL5>IBGLZG1"/
M28K%FM<CBSV/CVDI#G2VLB5EL8^PLGN[YXD.#2W/3/QW(2`_,914I'O-H]3]
M\$9-(BE2M^?H9LQJUD9Z;`7?:5AT_74TK)^]M)&.1V-$)=5<W=E_;=-5P9`1
M0<QD1`1JB78ME`T/E6F<VB[3MGM)T.YYO2%=,4G6]\5XF9;1"S8VVD0H?(V2
M(V1AE-EEV16/R%@U=D&;4]'C#,@#,HL2)%AH2'N?&)!\T_)=K"-0VGL3-@@P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!
M7?JZCS/1W/UDTQ'K%+569FX74>QF0L0!D2;;=%VW>*B3\<DPXH&D,1DK=NK'
M9<%<-4UW\<)DDAKX83]9D6HJ<-.).;<,^#WG:)`:`4:V3=@NP:6FL-F9*40N
MRYO7\5E2$4MFR;K1A`NJH3)H]7<&AHN;VQ,DH.VC@!(A"8Z\U%CWKA58@\>C
M6MWQ?HGTS$['WC/PSPZ'M&KH!T+8"4QK-]2B'+DI?0^%O$J%AE!VW:%OP>'/
M06B#9G:2+PK;\OCDJ,2%<81+15,"S8^AR0Q<J0#6WE)S,]6X7AA?,='>>N:H
M'SWSG7/-0[U:<PV`1=``Y>S9D*(NI<_5?KG3D@/#DV:8;]8=DKT@>69M6*0]
MBX=>(,D$D&Z/FHRW+;Y-LI%HU'P9V/8-F[)@.LBZAX]BT13;,V(]A<T^:,6+
M-LCKHBU9LVJ*+9HV0TT1;MTDT4=-$]-=?`?V7LB7,$&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`>5R^9,O$]GCMJTU6<-F:6SEPDAXJ[>K:MV;5/
MU7?3S=P[7WT0;(:_55=;;5)+7??;S7T#T^>^>_S\]\]\^OOGU\]^O\]??==O
M/Y?W^>^>^>^?W>^>^>_S\P#_`'`&`,`8`P!@#`&`,`8`P!@$5TY_PD7_`.:E
MZ_\`6ZPL%>?!>R)4P08`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`@6_
M^H*`Y;C#66WW:<7KD:4=>#8XP*.5WLKF9C;9/5,!`H.%;DIE/9$OLJGJA'X<
M!-F5OQ^>ILMM?K[X*DWA2?F;[_/]K=E7I7$TY*XHZ=YK``9?SQY/+OLF0-Z6
MEW0L<6M3?>JHR&K9]#[%'P290&0IGI5%[>G;5O+Z:`F'FL_CT;#2L='CKY)T
MITTIZFFX<)7A\S:9M93-S],'+0Z!B.?*K&5G6LSI^&,(SHU&UK8P,R`L")/4
M7KS20#ILV/N'Q4G*U)'X6>R"5N"IY.;E73J9M)+)F1YN?)#F\N7/4G[!!@#`
M&`,`8`P!@'\**)I)[JJ[Z)I)Z;****;>:)IIZ>>[;[[[[>^:Z:::^>[;;;>^
M>:^>>^^^^>>8!_NNVN^NN^FVN^F^OFVNVOOFVNVNWGUUVUV\^OFVNWGOGOGO
MGOOGOGOU\P#^L`8!%=.?\)%_^:EZ_P#6ZPL%>?!>R)4P08`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`*_\`0?4W/_+$:8RB][.C\#;&G?@R*@U_7AF;SLUM
M[IJE'J[KZ/-2TWL"1+[JI:I`H<`-%-OS/-_6NJ7FRFHJ3JPI^W=X7B4Y_B-\
M@777]334$UX`HY]]/I<?0,;$S?JZ4C=__P!)KSG'5\YA%0^K_E;Z-CE['I#)
M6B3E%=Y2R"VGX=18IIR]3Z.R\=_"W5D]T!P?S[S])W5GL1,BMF_R[7UK).EK
MYD3JUKW.([^*:JLFTU/I^I0F/;Z*>I:0NM1<*A#9'1)-K&T?$_,$=3=L+A61
M<O!!@#`&`,`8`P!@#`&`<W_EOBSV9?'ST&`8[6VGNL+B)%RK2\-WL64)L`,^
MBY]_X?@#211<U,JM<-1BK.X8_&R2LC>U<XEG@@68<Z>#7(U1^9?=QZ^W4Y"1
MN,6(6@OQDEQ7,'3$`ORN[$IM0(QB<5ZA)5+(.?P?54O$R5J.G<UG,A'<HZR&
MJ56]WV7#^B8:D9DU(F(ESK'CB?@=DV@XU;ZKIIK=I/5IE66;VM:;OK$`>G;K
MCY2RQSVK>G;/H@OT11-E]ES62<S="5=<AX,1ZAMDU:M+B(`&F]FJ=$5D!!/H
M%.BA;GEO*A.T#3\&[%)`/*_8`@U*MA/2TKIK\JO+C2\YOXY_0;\>@"[XYP/S
MA'[3T.AK?'5H/;NV5JI&2<I""_NKY6'AIVV=D6TA]DPB!;@!)MH4(Z&F)AJN
MW,;[OF[O38<ZHU./G/J6.HW5_K!'FI15HL2ULR[_`!\JP06;,E'7EUV#^?NT
M;N'#M=%OLI^+U))9RX4TT]\UW64V\]V]$>?!>R)?P08`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P"%+WZ-HWF.%[V#?5G16LHMLZT'#W4A?>^$I$86^GC6/0^.,
MDWDDFDG?;;:Z#XQ$Q)D^0WV\T9#E]OY8*DW9*2D'EK]X]@_U//\``U.%J'??
MT?+]Z-B#:1=,R\;O_P#IU3<P/''@.M$7/Y6_C"4=#%%SB3=T@[6I!7\/GU&H
MIIR]3X6/[OV7B6"Y\X4H/GJ2OK-8#I+;%_G6GZ.5=+WO(G%I7O(6^WBFJ@]&
M:&TM487&]M%/4TX/6HJ%05JCHDFUC2/B?GN".INV%PK+^?&67(P9*V]`=?\`
M,W+;0<M?%RPR`$CFVJ<9A[EZN:L:9+[[[)IM(-6,:;F;"F[U1379/1G%(R8<
M^J>?A_*^N"JEU84^WB\(_P"9Q\\EXOK@^3^_+""1RXJO#G0=-?:XE;47-UC.
M46+"F8&.;%B<%*.=3,>:R%-KJ<#M#K08;W$$&3@J)&/%E62(]?X:6A2D\WL]
MWOZ'[</]FE=.7GQ"<_.'CE=TOO,;W\V7<K*+K;>:W1-M=?-E%=MM_?-=?/-=
M?/=O?IKYYYY_+S!Y_P`7\]7A[([TX.8P!@#`&`,`8`P!@#`&`,`BNG/^$B__
M`#4O7_K=86"O/@O9$J8(,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`:58ED5]44-/6
M+:<WBE<P*+LMR$BF4V/#(S&@K+3WS7U<D9,.6C!KKOOMJDEXJOKNNMNF@CJH
MLIIIL$3979SF_P!ZCJ+L/_PO@^MTZLIQ_P#U2_;_`$[#CHP"5&J_T-RG.'.+
MY6.3^V5%$%='8.<64YK"L5MTOU0[R>L/?&RPU"7YK_[4UZNZ77+)NHC@:FZ>
MFFEU30E,.DNFUVJC=_TIT$4:S:QF"3GSW9X)K8:DP'0>E(ENHHMJA$ZBBT.%
M^M=]42GW9?79VH#J;MA<+'CSW<LNP\>-![1R_?NF[%BR;K.WCUXNDV:-&K=/
M99PY<N%MM$4&Z"6FZJRRN^B:2>NV^^VNNOOO@R<YY+\F%2R$\5K_`)#@UB]V
MV:*>*"B3'G)B+>T_$B^OOFOC:QNF940`T/$OR=_S-7PQE-)),FOY"VJ40=+:
MZH[C6EY?TKKE]EE^QA?X(_(3TC_7]!]%1[C^N7W]-2E.*OQ2&U7+!7^NT'3+
MK6SHXD\8/$_ZML_]IJH:_?)^ZKZBYTKKLF\V":5A3UJ^R3]V^Q9'G[B;EWF%
MT0-T_48`1.COFWLIMJ2+E;`NJ9K*Z:Z.%YE<D]?R2RY-LX]\]4V0+2=RR2W4
M4\:M6Z6WY?@CJ;R[+"PEV2L6/>1J.D7&[L@`"OG2GFGBCEX*8N7"GB>FJ>GF
MZRZ&ZF_FFFNNFGXMO?PZ:ZZ^?3SSSS!#(,V+(<WT:#V;5BU3]V]T;,VZ35OI
M[OM[OO[HBAIHGK[OOM[OM[YKY[MM[[M[]????<`]6`,`8`P!@#`&`,`8`P!@
M#`(KIS_A(O\`\U+U_P"MUA8*\^"]D2I@@P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`?Y[
M[YYY[[[[YYYYY[[[[[[]/////Y^^^^^_R\\\\_M]P#FM-N_7UD2P]3?Q_5NW
MZQM("06`3.T5#:T8Y#I$NG[XDZ2LR\FC$JC,),'W436=U33`Z<SC;U)=D>VA
MGGU(I#6F+U?2NWU/LONX7<]U<_'X/D4S!7AV_8:_8U[`GFIF),I0"2`<W4@3
M]\]]TTHGGOQZ6C`<D/\`/4D$+,G[J>6R\V:(O-9@,U4]'HAJA0K+?E]W]E"Z
M%S[<NBHZ#A).R+LLJ$53`P_GGZ^5SV2"HP$26VTWW19)/"SELF[)._R]DV`M
MG^H(D%_PMV+5POOHGL,Q-E=E#?\`?2Z-Z._[CP?R\8>Q%Y_1;]4=?M931%'>
MMM_Z:)F`U6N-TZ(N5LNEIOLQ42B580XE^)!1O8NC=7Q;!K2E^9WX5WY_E7FW
MT/2R^-YC;CIM(^^;RG_:AC1PB_3JPTGY5/(X%V@IJLW3$\T0@C]AF23/;\Q)
M)Y>LCN(HIIM^9^J0W_EJ&J/RK3US5Y[>"1T:C,7C4+`BHK#HZ#B<7!-$QX2-
MQD2P`@0[!'Z_E,A0<6W:CQ[1+Z^_EMFC=%'3Z^_AT\^N#)G,`8`P!@#`&`,`
M8`P!@#`&`5)[IZ#G7+'*]K7Q6]8N;;EL#8@'#.)HHR%RR9CS$K!1\]-Y`SB`
M:0RU]$ZW!%2,_EC&,!'YMW'8V209^,O=]R3(6E)M)N%\]\(I:P^2:UO8CPW9
MBE74/+*FZDF-;U=+[%KN^)`>"BK"L*R3%<ND(&X<U6U!IC8)J,9R"4LK6DE?
MF7LA+_P7B2,BLT<FS+BZ5-2O:7A87-_:2$X=\RMB3A.*@A/.T)93GHA;GLWR
M8W(VT>VBYJ`]#W7<E0!RUXDFU9;E(+(HBSI8Q.30.&BITT*M9"(C8TLB_9/R
M6PTZ(F^)FW"3YC>,K=G5+ECIP%T9RU5G3!H:QK%C.HO]TD84S(6CH7$)`-,O
MHM)!'DH=MPS8F,8R@608"32[$5N69_HG>XYBNZ]9I##4-HD*C"#`M!'A,4^9
MDQK^S+O=L"`]RB\8O6B]UV"H@Z:.VVZB#ENLGMJHDLBINFIIMYMIM[K[Y[@/
M[+V1,&"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`JQTKV+2_+B,<%S=\?EEHSY1=I5-!U:
M!<SZ\[9)-_-O5FL%KT3O]P<#VGNO_C,N-K`X-&4_?'$GDX9M[XMZ*DW/"RWA
M=WUVY*G><W]0=O\`OA;N$VO0W/+WWQ4?PO2<V<;FI@-]_P#-H=97_&51Y&7)
M.TME/"E.TZ[`5SKILDQDLOLIMHKIL-2J?RW?ZGM_Q7W=^$BXD_M3E?ABH`6T
MWDM6<YU!&&[>-0J.-FXN+"?=T_IXQB-=P4`TU(2$TXV4\\'Q2%@B9I^LI[XS
M&N%E/?Q#*3;M=E3M;U[HZR_J.7JA;\BTV^_H:=)=>Q-^\MD^/5^FOI6HN1F1
M,.8&:[I_]X%'^@I7!M_=5$7"U7%VWU34%A++E\+'C5^T]T2?4?QVT;!9L,N:
MV2,VZSZ+&^^KLKWZ9,-+`D46=J;:++:U/"D1PJJJ0&ZN?%-VC.IX-%'6J"GY
M)`D4W\V<;@ZGA?2N%]]WXE]L&1@#`&`,`8`P!@#`&`,`8`P!@#`(1Z+H.%=-
MT[,*6GSN3C(_+F[+W4W"I,8A\MCQ@.2:&@$@C\A!.V1!D1#F1[)]JCLJH.)H
MI+"3+(B'?/V#D5-IRMO$JR'^+KE8.PJL2FVM9R$K$@#D#Z-.;EL=6)VS,(Y<
M)?H4--;IB^\@V"V)*&5YGS5GZDBS779R=?ZCR&KV-#Q0)B+K=\>2M*B%Q:W3
M8QXWXHN/@@B6BP@*QQ#D^<K\Y%9&QMB<Z2FE_*IL*7VI6X.C#BI95S648A\^
ML";GQH`)_P"'N?W.2%%TB0/5D,:!J=O'97FSGP27A:Y=FFZA@-!U9!*9JX-M
M'Z_K>.#XM%A2KY\5=(#1Z?X?%B!8HX=E"Y5^OLL0+%R3IR1*DW3L@^<+.G*J
MFPRW+E[GFIS_`(2+_P#-2]?^MUA8*\^"]D2I@@P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#0K2
M>S<;7$V)UN]@H^=C(V5)1=W9VQ1*O$RP]JH\0UF3L([9E1D>6\1V0)F6*BRX
M5NIN6\8%-6>PUV'?!P`YA^37NCY,);:-<<=P2D:=AU9V-)X?</3-B%P=LL*O
M'N1XII%H_3$+@<^<#+RF^A%E-#8JR2S@13$D#(@'>C?;S9R+>#HZ::4FVW,-
M);\R]N-VG)TZ@M,<E_'3#)U?MK66TTFLC0;;77U[TG,AI&U+%>:?UC$,0EY3
M1@W%A=5D=6\+J"NA@.)#MDF["*P_]?OMNX&9=4)+M2L+YR[\LC7_`'B.QNPO
M^X\<UJIS52+_`/H;=@=40<FC+Y&,4_L*<^<I$U@<K+)NFRB+P).;[=5]&]T]
M_';."31E^'14(5.;OA/'=X\I[IDWT1P'1=+S+6XI!M+>A.DUVWK<ETMT.<UL
MBV=-%?Q>N&$*6=M&D4J*-;;;J:(Q&H8Q!XZFV_`BLP<[:?G;`ZF^$N$H7\XR
MY9=W!D8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"*Z<_X2+_\U+U_ZW6%
M@KSX+V1*F"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@%=^D>I:<Y4AS"6VP>>IO9(53C5=5[$Q#V
M7VI;<U=:^?;H)55>A='$AFLK(J;IZZ,AC;UH-0WV*'GX@*W>$FXJ3>//9=WL
M?G^^7)7KF5?'CT5U[U$)$5U6$":5HO6/QY-I5*5`$G8S&XZ\@JQWM.S*DF4&
ME$]D6@>5/B@JFJOG(.L(>9:AU9,;L]^R7\2'2A+6J5F\U+L_RRH\6IX@X3?%
MI\J?6%T]WU'4M`<U\'UC95L/K3""3K".]`5[%@D=<U<N==1PN.BUS'1AZN8.
MA68V3PVN2<4)M1YID^'1$O`WLK)2EF.M=%*I;;J:4<<]NN?<_:]3_P`?\2#3
MP/?G4,\.]B]-B=MG(&R;2%CF,`J5PK[KZJSYUHYANY@5.,]/$TD_)`U2D%GD
MM=-MI!8ACU;?7P>=U6A?2N%OW>_MT.@F#(P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8!IU@6%!*HA<BL:SIC&J_@,1'*%Y1,9@981Z-@!J6^B>SPJ8*+MF+-'
M995)NEZLMKZNY61;(^*+K))[A$V5V1VSZAYI(+U6T9]"4BX>WFR2)4JPTM2#
M^$+<8+[^)I.JT8;'-7DX1V5]_)_'&D"7GB_GJ.WT5U]T\%AWL[9MCOP>%7K;
ME1%O9#M;IKGQ)K3:_C6WG*ES5QHA53G8RK'-6]D*[23Q.#K[2%!<#JC)]A:G
MIE%47YKZ^3W0\#2[6=\6=^W)-X0V%DP83(XV7%R"/'AK$R"/!"#0J&-!R;9)
MZ-*B2C!5PQ(C2#-9%VQ?,UUFKMLJDN@JHDIKOZ(1_3G_``D7_P":EZ_];K"P
M5Y\%[(E3!!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8!S]Z`[3+"[$>\O<B0@?T1UO^B9N)"$6)N!E,
M<Y"#&GOHV==.6$.1=>11ENAXH3`5>!T(6Q8*+?5&/@AXIUM)V0TE:79>KZ);
M^RW*S[MJ.X0G0JT>@YG-^X/DRND,[$PP/$XLTD-Q&PNV^^[V`\UTVT?^QSG7
MGP*X_.VD,I+EP,?5\27,6Q9LA->MO?!;U644TKR_[/=\>B1C[F^/;H#Y-:TD
MT<^0FXYA056R[42XC'(_)4N`IL(=J,.C)$.)WC<DFB$@2O.>(+#6J&X$;%0U
M0Q1ZEZ2CXN32%F'FK(%4J6M*E\U+?HD[+U]B)^,?]G&XHX;Z7K'J>J;4ZBD4
M_JAQ)W,>#6#,:I*0][O*X3)((0\,L8[3,6,KZ(B)0_<L_&1X?ZF11:*K;.&V
MBS1<6K\6JI.EJF'Q.SGD_0%@YC`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M*&?)I34EOSBFY*TAU;/;8E+]*'R&/P\-8'\,93L:@TZC4V%2&$RQ467'Z3:'
MD8^UE<5`FVZ`"6F0[6+&R`\:8<NTAJEQ4G,=8G*BZXYB\8N<IHORIVR;UX>@
MEO\`(T-D,)A+^&SOH&X(&3YB@-T2+6L>G97;7,M13IP.5B2+".U*U>`KAO=6
MJ(ZMK9-KOY&`A?K!@8EAF4SP\;&M5/U0WT3EJ],-^.%+LLWQJ@+X_NQXF<V-
M1&CC3"K*NZ"HJ^R?/\ZZ&JJV3/0%D0SH>U)]8TKJ2P'8>"C(I%B41FP63C8Q
M;2%:IF)V);^NHT"(#UI,<HU+HFTU*34*$H<3QM._8[/<'T'85!<04/1$^*^1
MBPX=!M6A]2(.PQM*($"IXG)?VJ#?&`Y4"2:1)J52B"#O[.X&.&HS\X8DFW]:
M*IC-3FIOYW^Y/-&-EF<$>-')!X67;69=Z*Q,AHP3?/U$[KL'7=V[3%,1@W1P
MOMYZHKJP'LFGF^WOB#5%/\*>HC^R]D3!@@P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`/&0(,!#!\5*OF8P
M6,9N2!(D0<HLF`]@S1W</'SYXYW3;M&;1NFHNY<KJ)HH(I[JJ[ZZ:[;>`<FY
M#T3<7>.YR,\>R]W1''X;8DTM3Y`W[5HT,3P:)]63D\=XQ&R)#86\9-TV[L>8
MZBE+1:!1S=-^XK,7-RC!,X,&X5.;U;4_^V__`%SS&\64E)7\MAJG.7Q!0D!6
ME!CS9?\`B;\B%BB'TRBLDEKIULWF4CI,?)7/[E["N@J12<[F[JFIC:H&)-EY
M^=)+"]01C*0-;UN]HIQ"Z_I4824]CHSS/QU3G+C>1%(>WD$TM>P%4'MM=`VD
M94F]XVV50\U\2=3:=OTDW7HME[KYJ"AD?;@H)%F_T:QB,"&_N^FXRZF^VR5D
MNR^^7NRU6"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(KIS
M_A(O_P`U+U_ZW6%@KSX+V1*F"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`0K?W0]/\`,-<D+3NN9,8?%&;I
MF)8>;HNR<@E4E*;^H@X9!XL)0>R&:S:1.O/T@")QD:3.%G'XM6C+?1-91,5)
MMPKLXW]"SQY<`F,V=\C;274_S9+#J+;F[XNH0@M+^E>NI0WV2?1W3H:*0YVY
M)S-ZXW_1E4N9XNZ]K>&?G,B%_P`R+ICW@P0-I;4WJ6:\)+%I]W?@LE'>4+G[
M+T!GNYQ(VI>;@V@W:M_CEK@TV6B"@H1XC['G/6\UC7K4=:A%CJW:JM:,AN[:
MC(S^C8LS2EG.$-GB`DJG\MW^K_U6W?/;!U9%"A8(8."!!K`,&$,6@P2(%,VX
M\8+&L$$VK$>.8-$T6K)BS;))-VC1LDDW;H)IHHIZ)Z:Z^#![\`8`P!@#`&`,
M`8`P!@#`&`,`J/UEUQ'>4A<%(EH=()XK*#!HC(Q\:<LD'<!IBO@BDGN>\SB;
MSS;9U#ZIC_HU4LR8Z[$BAF1QH&R_+6+>.$!4I^9>R\2VJ2J:R::R*FBR*VFB
MJ2J6^JB:J:FOF^BB>^GONN^F^OOFVF^OONNVOOGOGOOGOGN"']X`P!@#`&`,
M`8`P!@#`&`,`BNG/^$B__-2]?^MUA8*\^"]D2I@@P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"D72_:@&FI2)H
MNI865Z-ZZF@OTI".>(.0:LW8H(HIXVUL>ZIDY3<`Z5J%BZW3T=S.5Z^O3*OX
MQ<'C\M.>>C-1I4S=N%SZPEN_CR<K8FXM"PN@BAB".83WE\B436?QR47J7;&A
MGQQ_&8D62TU.P.JF22RSV9VLV;;H#C(B-/"M]3GUO[[9LTJ&)J;`41JT+--/
M2-5?5])\%M+.K?-7$\,HR2F+EGLLD/1'5LU&Z#I_TO9[=AM+7`W93URI":SC
MC'7]M4M4S1WNHH+K>OVS`=MKX@ZDS^4G$MC2HPW-L);+[\OJ74P08`P!@#`&
M`,`8!'E@6[4]3L?"EIV?7E:#/4]E?"-@36-PUCZEI]?QJ>.Y$3&M_4]/I[^+
M?\S\.OT]^OOF!#>%)',[ZNH6`4X%OYW-U9K4LF<C6D5EU+Q29W\C+5C&SM,7
MM%1M(QZP#$B:/%6+I+0F)'NQ::B?T</4?Q:>["PYC#ZPO>#1*.[)"W[-OVG&
M>>.OH6%]#/S&EEW3SK,Z3@*WZ)1KHB,0VLWR-3)4H4U<[+#$M(=ZV51:N=G#
MMMMXCJL*Z8WI[)S[6]33)_=?R!:364QBH>%ZS+1<6;?C(Y9UP=A!X`(DHMNO
MNDRDR$/KZF[CE3)B_2\U<IBRWVLNCIM^4Y106U]UP$J8O4YX5,^[1,4Y9=?2
M&EX:C7,BYWJCH)WL`5L1]+(K8MZ5*&2V%OOW2P@K09*:#E9QRD:W&^Q\W(E`
MS=08@^\)1SQTZ;^M!%$WF.EG]S6*)JKL.(S)U(^A.NH3=4;7`/A[>O('S&(I
M0&P..7HUPTD&AYU:=I2UWL-:M7X](:N7T9.M"F[ESILX:-?=`;IV375N?LD1
M_-^%)!84RE4ID'=W>PX5))"8-,:^@5N5[6,,B`XF_</&D6C"U?5!')OJ$"-U
MDQ@U<Y-#A[=HV14(&GKSU5TH+JA1II[PVWZ^T%>CE8RB-='EB]C\H]5])PRE
MJ\K:G.:9H$LZI9.B;A?E;$$[AEMEDK(Z5K68SF5VC(YRZA=C@;)C9\!(]::K
M^>;IOCWK`HQ%V_-2INU#YMBEJVT<P7+X<%6?&N:H)"K7ADL@YFOG4IK^)BYZ
M7B1J<O*CALI,`:8+S1Y"99.`.TP>U8RB6LLV0E)==W(T"A%=?79[XEH,O+W[
M8ZQBTX+;8(,`8`P!@#`&`,`I%\B]L7527'MM6+SPXB;:W@Z<2;1926NXJAKX
MV+S:.BI5M%&$W/QB)R2QT8<\D#FM8B=.-&,IG"(('N@5V>Z!R`U2DZDGC^+>
M$YZ'.>&=Q=36"PX84J>Y:VM:96R9$Q:P:7=<W2F$6E)&]==`&ZTZ]L>VF[FP
M'P[G2&T'"@ZH0>=8^'!LYOMFH&`#WX.51N*LQ=*^J5"6\VEJ:4K7G_QOU(`K
MOY2^RIZK5\.6-U2*.]=;\ERJN)@TK!ZNWYD`=%=)=$U#(81(@3F;;-K*-@HO
M20E.)F#;Z-*N)V;.^%AK\8U'BD1IT)7O],IWM5"3MQ=^47F6=J.(.BY/T%QA
M270ECBFZ4OF,-V<RYM!@1IX.)'`L@*1(B;BT=;;G#28:0NP^TA%CM'!95@+(
MI)[OWB3;9ZH.;4-I>I-M&O4B,$>/T4G:"3RS+O<IHOV3L:^2T6NNP=]='8]^
MBW>LG&OGOGBK9T@BX1W\]T53TWU]U\!Y\%[(E_!!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!YWCQH/:.G[]TW8L&
M+==X]>O%TFS1FT;);+.73IRMMHBW;MT=-U5UU=]$DDM-E%-M==???`.)W1WR
M3KV!%9*YYELJ*4IS7'RV\6L;Y&[#"[2&%.CNSE8=O6_$-9J(+$>J;G(OD'0P
M3(1`TM5H@FV42$I6<:\\C:8Z*F/S)M[4+/>K]*]>RN:%S3Q59EQQ4N'2#6SQ
MKR58!3R26;M*Y2^6^27O4LNG[XZF74]R).%)%1L-D2"FS?\`AO%225G>@G+V
M.[$:A`*ZPW41U1Q4UB/RT]E$/OC>^3MQ5]5UO2<#C=75'!XS7->0\>F+C4/B
M`AH$!"&>GNV^VK9BR333V7<K[JNW[U;\UZ1?+N'[]PY>.%UU!B9N[LW[`&`,
M`8!XR)!@('OBI5XU'#!C-R0(D'RZ;5DP8,D=W+QX[<K;:(MVK5NDHNX75WU3
M22TW4WVUUU]]\`Y)<9_*Q6'0-JEJ7L2=TX)LFPG(BR.;X57)M[))&5HF>-)6
M1A(2V&+(C)-H7>$;"PER?M$(;_:0\"A-X**2%HD'R>Y$:=+2E3&&WSTZ<%G+
MBZ#ZN"V(<KCGWAF36J@$3%:J7+:%X5;2-'D')80Q*_@C[IBM:=Q'M`NS[88;
M4TIH>V2+CB#)F\=(ZMGSD$J8EU1T2;?V7J2&ZC/4MB<^-`1ZQH'S?T:55T4-
MS.F1"=VPR)MT)4LX\91-O<47BVD@=D(8FU'."LDB#5N.D+IX0;!'S%HW:NA+
M)XE=;3Y8\S1Z6X_D%83T?9TZ["[`Z#E;)D3;;BK1L:)A*M55+LU&;IQ_!VH(
M!6->K;-=5=E@VQ8,7<AG&J3AF[\<I:K8*W*B*5V5_-MOU-G=\+\8D[+D]RF^
M5J`DELS(IJ9DED2JJ(7*YJ2):-T&NKG]QR,.4*,_H@V03_*8.6J']5KMZE^/
M^EZ)JJB)<<2X+.C1@T*P:"@X]B)%L$=&S$:-:-V+!DW3\^B:#1FU32;MD=//
MY:)(IZ::^?V:^8(>[`&`,`8`P!@#`&`,`8`P!@#`&`,`CFW*BK2^:XEE1W#"
MH_8=;S@;Z*D\1DX]`F))MM5T7C539!?3;\A^-(-FA4.2;>HD`Y=DQ*C7+4@S
M;.$A4VG*<,KQY\=G"OW6L#RG)M$+':7$1T%51M>N8XJ6@8R*2!_+0#>./]V7
MKD=LPEA4K*M5T5/%UY(5)G7*BQ0@[=+!JJNI</-W?:YM'^Y!Q[^WK3BFO,U)
MIQR[9`/E=LAT:\C:#*>R4.:=24,<D*2+#3]62"25\0D@5UYZFJ'D1$D=&^M2
MI%Z[7"79R[8N[;6\"PD2B46@,7CL(A$="1"&Q$*-CD6BL;&,PL?CH`,T28"0
MH40/1;L1HL:R01:,F31!)NV;I)I))ZZ:^>>"&F4Y_P`)%_\`FI>O_6ZPL%>?
M!>R)4P08`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`*P]*]?4GRL,`_Q&,EC$\G+I875=)UT%=SN[[@/I:>[?8JUK4)^:
M=/K:[?@U(F5DV$4CB:J;V4R`&._$\U%5+<QME[+N_G0X467:W1GR#V*6J8G`
M&%K?8"J38CPW74_6;\K4T[3WT5'EOE$ZXBB+L=:,M'*_^*J\6T%]_9[+#TAD
MT1E*.F\A:#I"IAS$_P!4?4_^%+PNKCH]CK+SG\?\<KV61F\>AI6WZ-Z1C(E,
M1"9(^BX^(4WSP#_3)--81RG1P]5W%J=C;)@@V$[R37<W9\B9-O/)%-G3-?P6
MW&'5:%9;\O\`Y/?VX1T0P9&`,`^:JJ2"2BRRB:***>ZJJJN^J:222>ONZBBB
MF_OFNB>FOGNV^^WOFNNOGOOOOGGGON`41??)-R@]L=G454R^1]*6.I(A<>.1
M_F"#2B]AL#V(/D&3LK94\@@\E6M>#`'B_P"K.ZRZ9"2K9LDMJU%O7FGC38:T
MN):A=;>2=WX&Z=`1WN&92\7&N<[*Y\I&KG$=;+2BTIO`IA<5R-Y-N2)ZO!4)
MKC4]`ZU'C4A*(99M*Y7*94HH_?$VJL#\0&M7A(1:=Y;X4)>+N_"%WXBFY.0[
M?FO%UD\XDKI(].SBS9%&7DRDG2"T5@`B50I6<PHE9%:CUJ1J/0=7,=.P4%)0
M$2>CJ\F!2+&9#X6<JF/4$O6XJ:U)QI727'F[^:-*K#F&[(A<'.LFBW-G$_+$
M!IU[8(F3(<[VC,#3J3U?8,*68&Z[;P%/DRDXYZB_L..5+.OO3F5H*C7E=M?P
ML2>CURU5!M0_JJ;<948WG4^7YG4G!D8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`173G_"1?_FI>O_6ZPL%>?!>R)4P08`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#EQTA\P?$?*5UG:$NBS1$3
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M)'JPI^!Q6M:]BK/5C'X?#`K$"!&(?7W=39%BP112W=.EO=W3]\OXJ^(O55GK
M]PY=KK+;CG,W=V2#@#`*H7]W#RQS,18QNV[?`#[",ZZ_MNGXHV+V/=TL553]
M4;HQ6F:\'R>RSWZG^CHFY81A5@GLHGLY=H);?F>"JEO"LLO"7=NQ][>,]33R
MOJY(\FI5-`"D[:,C$KDG3L9LC8Y6<:,!&I%EXTI:.^Q@H?L%JX>>LRL3E\\K
M]K'GK-9$DN0735&^`HWGPCWO[,^O/M!616+>;$+LZ;L[J*66(@);'O)S'J]A
MM91MH)3+H_:JRJN#1H:PB8DH@851/??3TU/']&8S[U(7_K!#W4&T\*//UDGJ
M%P:%5O&QD-KR'Q:!Q`(AXV#12&1\3%XV);>?V-Q@,&T8C&"/G]R35JEIY_\`
MJX(;3@#`&`,`8`P!@#`&`,`8`P!@'+[I/Y'RU'W[(^?X'S':-]R6'0*$6%+'
M->M)D;5"`IP[E+9@]=B(+65BO&S%#]K.M$E"*@XI('V[@=$PQ]P+)?IQI4RI
MF)M?I'+7/[EO^5^@@G4]"0"^8Z&<`!$\1D.S<2Y?HE?6RL:EIZ'OMVY-!!IH
M0'NW\?=/!;S9FQ6<C7#19RQ9.-U6J(C4."P6"#`&`,`8`P!@#`(:O^_*QYCJ
M>3W3<!IX#@T4V"M7:PL(8DQPH9DYX9%8K&XY&X\R(FS\CE$H-"(^#$C62Z[L
MD1;Z[_DM_%G"0J3;A9(H"=V\MG7G-H5"S$QTNZT6,H4=7Y^.2F/6-(]HV%DY
MN2+&($9"LI5#1\>1AY\<6+R\6%$-SK1`'J^5)D1K9V+I=[8R]MM\;FF:?)3R
M$L#G\E:S.QGH.NYVTJ]^39\Z='+LIE8Y"P2=5L8-3;K6I_T]\29W/PQ..I"Z
M65GB^JS)=\KXF*T]?X&EVZWRK+-[V\8+95;:$"NNNH7;5721G+Z\L*/#95$)
M(Q2>-D"P0JAJX:./69%LR)CW.NNWJ+T649,BHMZDX'DV31\V<-TAG%F8BG/^
M$B__`#4O7_K=86"O/@O9$J8(,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`0E>725!<SQ?697];]?U)'EM_4![N;20<&=''OGNOF
MHN,B%EOO,I,K;;Z:-@D='E"SI3?5-LR5WV\U]%2;<)2^AQJOWYKB+F1M:NY-
MI8Z\FT@1_'&3MZ0JQ=)Q)6RVNJK,O5_%-=BR'5L_%D6RJ2PN36:"YSJY?\W1
M=Q9:+'55QJ-*A9;MTV[MQ3Q9-OH?BP^2+C_Y-+K[4NRT[`Y,[$L.63-S!2A*
M8><S//-2R.M8PIF)UT9T0C858!=!H9J/$Z1H'/)D5BVC'6.3.3&YN+D9%P/3
M150J4M5*\>O^Z'Z>A^WC_9XN4@G/7QM4A(99S_\`P<Z0G'\5OXQD9C7;N%7$
M71'7C9#*&L)CM(Q;"7H"FT.91MQ'P[S5N*\'JMC#%G[N35>NAY_Q7-;O*41#
ME87W.[.#F1C;-U4_0L2=SR[;1K^I(6R_%XXE%C2X%#@GBNNGN_C9(@>?,6[E
MZIYY]&[%MNJ\<J>Z)-T%5=]--@2;PI[$3L^CG-R\\D+LXWBX^]2)%UL-KP-/
MR$RH&,2Y=M)6H`L:4DLQKDD=;Q,8RW(R)B>%0HVREPX9JG%EW^I-B\]%B'#M
MS$/[_<TNCJQ[<6G[.S^H>D*_]&-QQ-JSYIYUK!J&J1DY(-_TS9_*K6LS]RW!
M8901I[LY8N@FM0@E'_NJSR).&^GC3!6Z<)/NW?R4+W+!02AZ3J^43F<5U4M<
MPB;6<>)2BQIE&(<!#2R=R`N[V?$2TMD;%BB9D#MR[V]7VW*/7/FFWT\2U3UU
MUU\$EXEPB6,$&`,`8`P!@#`&`,`8`P!@&G$+#@8H',9*_F49;@*\8E"4[+>F
MQZC*'L@@U4R7<219)PIJ&U&B452+SQ_^1N@STV<;Z^)_TL`H!87S`?'?!*W"
MV0-Z2@]L:RMPJUA5>4D_0M"Y)NLWD#J,.O8O4T<66G#]HU+L'R3@FJ(;"TV[
M19[^M]9_EK;C2HJG$1ENR7=O!X]>[NB[4:M=^6OCDZ0EK9[HW]UF_416'<<0
M!GJ]_+\0=J"IV[E-Z$FK77?=R\^UT@MJH@CYXP<.MG"/OH:4LU+_`*_5_'J:
MB_IWY>[@GX1G974G-O,M%N0[G>6C^0H28EEYZ$U?U^B(,-8G1\)F$-49Z:^#
MME9DRKN*%=?'#U)E&6J[%L2?!-*6&WU<+R33]3F:1X@LGBSOFS^@)VRE7:\<
MEXJKIQSE;?2,4Z:Z.F59V#!_)$.,1)KK0%<VKZ%G0O=8.6A)@[!X:`5'E6S"
MMG#0L(D8MJ-:E52DOI:F8A)SW:]^^QVR^-ZJ[5J'DN(`;K8_8K)ED^O>Y)!$
M-7?CW2`ZWO>MC7*+@?ZCQ5QKLYB8F<L1!-)-PX0;%VY!JU76:HHJ[C-33=L6
M7>$E/C$EZL&1@#`&`,`8`P!@%0.]*$E73G)MOTC"F=8E))-0PU,<'N&.OI'`
M3*@8^*/^BR28LB**@"CG[7_^%9L*=;$8)*]`LO:,WZH7QDX%I<-.]N,_.F^"
MK%3?'[9L6K[X]64\LL+,;&Y+OB4VO.96;7D\F.$J]-5UT]$83248G$H<FYO)
M`=0)WZ%C,6,3LXX<DH]$GQ1?QD1*Z#TQ75^;_<H\9I;?%XO!5H5\1]Y1N8O+
M-A<KYGKB1P*SJ4LZMZZK:-6E&J?M^9U);]BSQ[9-]#"AV4&8]84JA5ANX&F0
MBJTU<!-V?A)8T>&^C(^%&M2LG+LTYB;I67BIOZ-LZM\C<T;\X<FU+S=()0XE
M)&#Q79C)Y3&G1V&ZE)*8.$);)74>7%E6\@"A_P!PF""(='4MX^U"Z-FSU93;
M=QKN,-RV_D$H48Q1&01X/;;O%$&5F7>U14($'Y9]NFC==@IZ;.R95R\)/W'N
MNOGJKM^[<NU]_JHNLHIMMMZ#^R]D3!@@P!@#`&`,`>^_3^?O\O//Y^^^_P!V
M`0!/.L.6:KV5TL_I6@*XW0V]U7TGER5U$-D=M??IMJKK(9&.]3VU]_E[YOYY
M[Y[_`"]P5)O";[)LK>5^6WXPP[CUJZ[VY4<+:_7_`/(UTPB0I>_3^WS5<`6)
M(;^_^KS17;WW^[ZX+IJ_35Y,^3#Y<_C"(J_D)=X\O-%/?I]/#%N10!K[Y[_9
MMXH<?CD_4_?[E/-_P>^?S\V^F!HJ_35Y/]C18G\CCF]+,L^'\HI<4W/%(!-A
M$&"2LYWFUBARQGK^M:_L!Z=A\0@7/-T,R$58NYVI#4"[27O5'LCBLD:JLF"S
M'=MJ#IA*=2W_`"XNUNT7QY^MEM?="TE>C(*O&F=T5%6ULM(ZZ>IDG(!M8T-"
MS!`*Y(HMVB3]<4D8T8K/4FK9-THALOHW1U4\3U$:AM<."7<$&`,`8`P!@#`&
M`,`8`P!@#`&`,`>^^>>>^^^_3SS^?OOO\O////[???<`IG;?R(</4<4_;EC]
M05"/F6RVS=&NHY*&]@VDZ<:_7ZH,:KKS656(06]]U]TU291APINIYZGIKLIY
M^'!I4U/"<<[>>#GG>?SHUA7CM(%7]"V&]D#[?5,,MTC((]R<U,ZN-?\`N3F/
M5;-=)/UU,4W/GNJ^B$*Y;D"ZC=1#9/Z[.$_,%5#>_E?UM2O&I%<=KC^9OM7Z
MMJZB,OI*OBGU;_=8;#4.1X?L.=>_B:OU+QZNBMG]629KOYM^>H[K;AVG73A@
MDEX-E+!=]JZ2?/G^"Q13U\=3\%2U3YU/L3'2'P>?ER?VS.F>@3YF=$]-=SZ=
M#.IK')N8_'^/1X,E?8MNRZTNQY&,(I*+^%&,`L^C8L_W<;Z)PI@R219:`Z^%
MYI?^*BG-\-]3L50O+W//+\>=1CG^GH)58PDM^K.+Q8&W;GI20_%OML6F4J<^
M.91-#2FV^^RIJ5F#!9;W;WU5YO@PVWEM]_L47^27Y%Q'%1NJX^QGM-Q@UN.-
MW?9(.T3;-F<F=(5^:CX`[6-0!]CX4D4O.TWTF=>53HT:R!KMO`)?J0".4M-%
M41::9YXMR^>BW+<TAU?$NGZ]FU@\_P`/LHX'"C_5J_,VM6]D4+$+@=O0C@H`
M>00Y8\+8&R<)).M&P]U.6$1)#6FKKQZQ:F$M4TUQ&FG#]TX\GGH[D-PNOOD@
ML68Q67W??5&\\P4%(@IY_1?,L!=6F=EXL<1;DG,1GG0EXCV*?VDL@AZ&.?PZ
MHV$&O63IYZ&ES!SXW?ZB_3LF^KMZ+]W^]CY#ROS?+[D']"2^D*TE]UA@0Z-@
M;)E<3%263QL.*=OGS%",/3;=_K&7&CDB[W6(@4QQ)YINF@\=N$&S9)$27$3;
M@GW!!@#`&`,`8`P#4YW.8C64,E%ASX^PBT*A8,E))1(2F^Z;$0%$ME';]ZO^
M7HJNK^4@EM^4W;(KNW2WJ;9H@NY521W!7LLL@VL.K8-94U85X^A=P5-,)''R
M4M@0>Z:X+UZM8\6#*,=#16'J/MW*"A`)H5%NCT(/*`;'`#R#8D:AK!A^<Y2%
MCYU^>'4L(I)8XB=;198^%2DSUDN29QQ0JQT.NQS7;31R_;"-E_""[)OLIIJN
MZ2;[H);;Z>**:^[>>>B$8P+H6G[3EEN02N)DUF4PHHLUC]I`P[`M^;%Y"]V-
M:-P*C]ZP9B")?U6/E4'+,41?*#UD$M"7Z/\`6,_5Q8:CK@U"/7I85BT2>M6N
M.<+/%SQ#<@VB-)W^N%HV5R9PR>-6Z+HD1T7L!O$`Q)LNL^8NRK!<K^4UW1=@
MFKG?1+`B\2NZN0]TUTK(Z<IFLY/,[YXXXWL8FXB9:UF71LI<V#$Q`14*[5F\
M3JYRRFU#EYM*&LC]9"HM)G(]LP),&[UXXA7ZUTU'-Q4I;2557$6[3G;_`"5G
MEG<[BY;6KJ;<>QWOSH6(0]L81>P"GZ&@%3\RVP;)MG+1B_GG1'6T0K=PZ"@4
M77CMMI3D_49JNT1SY=N5UUW0<!IA.=*[N6O"F<]5Y9/\!T=\D=C71-+\8J43
MQ28L>/#(H53D-N=!]R2R/1D2@$22:Q"GWTMH_DJK#I!:/L'Q(Q&(S.W3@@N4
M=D"1A0H3_7BS3$7?@J?-PV_&.F+Y>N/AGYX!)2G:V[(NZZOX@R0E-['B#24!
M^;Z7G$V,JJ*E9+)Z6Y+`4=#9F_>[*J>+N+,TL`@YT453?$7FBFVN!K=HA1C=
MKLW,>$'0ZF.:^>><P_V"@Z/JBFQ.Z.B+AK6L!C$-]?ZZ>^;?F%'((8R=%G&^
M^OBBSLFN[=.%?JLNLHK[[OZ,MMY<DV8(,`8`P!@#`&`,`8`P!@#`&`,`8`P"
M*Z<_X2+_`/-2]?\`K=86"O/@O9$J8(,`8!3Z\>^N0N=SZ<*LR[XMK9KGZZCZ
M;@J)FUKN*J_A^J2(VFZO&2^RG/J^_NJ22_D8U:>J;?UCE/753;0:5-3NE;G"
M\W"]2$/.M.TKB_JN9^`97$`;OW\II:?<EB!.>`27\_Q>D&U.P=C<-\$$?$O=
M?4ATKB-8NUU-_P`I5PSV25_"$4K-7A2F_5PO>/0^GG-'R`VI_77C\@2%3"7G
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MN4&L"2'OU\]1?LV[Q+WSW^WSU-PFII_/^_\`H_SP#B9?O$50"+JF0F6`OC6,
MC^Q;B1-U3!^G.5O9K/\`65`Z.K>'2"&PB0BK$C22K'S2L'$T;*CA09PS-R]9
MAZNX+D6*I(;53BVJRO%46EOCY$DH5'\15>T54U71&C^CNIN?;)@E<PF*22?4
MM<<I\@M@2R+1H:((S(WSO<SVYJ,02D!=F[,+AF,+0W:I$7`Y`KYYYJY\!UMM
MRDY;RK^:AF];E_E`YT_%N:C]._(97+/Z[*$81ZPY9ZE;,_/ZY17>'R`B>YYL
MP@W2T41UT&R^BO'ZNR/K<5KOMLEX)]+YI[W7[KR9-5#=\<X7[+%:M'2(_5=]
ML6NSLSS=?D7*TY?`Q%/Q399TT@<P39J3(,BFGZKM*ZY?S.'*I;)JMI"OIOKM
MZ#I:4Q;E77FBYV#(P!@#`&`,`8!!W1G0]8\KU)(KNN$LL$KZ)N`FD@(M4V[I
MXR9%S3$4Y)H#%'39X71`M';F1EQH1,E(E@(<JH""&R:+86Z%2;<(I11_S*_'
MK?TAD,?AG0$+%:1+6R7$GDLWD\/AL*"#X#9A"MPI!>7'9*U"O4K80%O;$K)L
M(<DB#ZM4TY'*F<27>#QKP:=%2RLQCJOMA]3;B/RU?'UH]<BH;T*/NTPW4];^
M".:H+9_3;YPZ_P#S&K?^`4*L5MLJKM[KKIONY3;^>[>;*+Z)_7?P315Q'>*?
M>"&K+^7N*P9KZLTY+Z:%I[I_J&Y[HEW0'%4.U:_3\7ZM^1ZTNZIY8R0_!_6>
M>)P9VXVT\V\\;^K>:([BJB=UX35_XIE-7/S6WG9KA=A1-<\P+.M%=VK5G7\G
MZN^0*6OG7FWNOFB(#CCF/^&*2B?TVU53=W\V9;;:^>)EOPJ?BT%T)9U>*II_
M\JOLC$DK2^9"XVBCYOKT/`HRX_\`RH_#TYQYP-#F:2W\]6K*6].VEW#?;9O^
M'SWWTMK2H<NW_#[YLRTW^FJKY\OOMZCZ%P_%U>VE>O<C"T>!+56`BY;\@/:_
M,-.0B2*^ZB3/4G4G0?5Z3SZM_'Z@H*)M&UN.N2MWBC/;QT^T:\[2=AIYYXX;
M-%F.V^BXJJ7]*;?2FE?:I\6E%A>,>*/C*N%[)H!57:DDZE]C(MJ1G]><[6/"
M.=*,^W+N_&;34E!^%HI1D4/BE'FJ?_ALLDLV5=K>?GDE7NJN^VXE3K5W3$X=
M2;?_`-IA^70L;4MR\@\U.S$;XW^+_J=9^T>D`Y$]3G"C^GTY.\:.U6KIP[MB
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M)[>Z^^+[+)[>IX+JXII7A/\`Y:CW$^>.D`72-RWQ#F/*\Z(6`[AX^#26VP\\
MTL&M:XB4($!6U9!"(-D42;`/9JO8,]=.&3Y!4N9GY3=ZW20;L6C0)4)/5:<1
M$\^187D>H9G0U`PBHYP;C1LC"EY8/!)P]J5;1F+P%S,I`2K:NP>QM50H\$5G
M`7L=K\40?)M7+P;&VBR[;5;91141N6VIOSF=WXLLC@@P!@#`&`/??I_/W^7G
MG\_???[L`BZ17?3<0LJ"4S*;5KV/6[:"!5U7-7F)>!86!.&8(>2*F7\7A[E\
MF?-#A0\.4<OR#%@LR:ZL5]%E]%-/P>BPXF'"R]D8Z.W6!D]PSZEF$/MIH:KD
M2'*')J<J>=QZHB:AMD)(M0T,M8T$8PF=G6S$TS7*CH@6,[!]]'S(FHU(C7[-
MN$6FWG?R^>QKD,G'0,Y@EK.R](#*-L(00EP6GAEAV#'I_'YAJR#^>PV;2Y6K
MG+Y:-1PQ(=_="<<;/WLF9@F_KK\Q`D[\8-`M:\K>/Y.<7R963)HO\:-CE+?Z
M'JN#7O6/[`N23+T6A'=&TG)4W;\9M(;#*[AERO;`<^O#J,6#"$MY4RD@UR:T
M57.@GD3=DHZJ-4).NR<75[Y32EI?-N3BY0'SH\T_)5UWR*$Z$!NN-@?*]G3J
M\`MH6'UAK&*ZL)F)J.514$&GVH]G3D0:3DG+B\;/H,BO[CCKF.L)S7C5)P$L
M`Z,*CH_PW12XBJ4E&F7F;9VGWV1TVO+YQ_A.I:WE;1%2F"7ITEZ!2@FD\I"K
M0,CG:D51<.5FL73Z!ER4*@B,5]>.W2WV_P#BPF%2465=N4D]%=5=QA?A_B-1
M#2S>4IQ,9GP(^_[=$C;O\JUFO!/+H)7_`,W(^B^@#G0M@^)+?R353IOF`1Y"
M]7"&G]-1NXZ1]\V5VT2_#]-%/?0T;14WPE'J[_\`UQ?E'^>]&<G6;Y^=U)\V
MEOV(S5^FJ\`YQ!&..JQ706]_[RRV6J2'%+Y?LW'GOY/X7]^O?Q-=E$]_Q^*?
MBU"&L4)=XJ?K;T)OIB^O@0Y]+^R>JRG/X*;;K:.'%F'*^L*<6L\<:_A\U<$K
M;L&*2:QR"OU\\V]6(2IQMZI_6[;?C]]VR2N5YD:K>9[2H\I@M_[\OOQJ:^?5
M7KVKVW_^9Y)F?OG\OK_/QU'T?=?Y>>_7Z^>?3Z;>>_SU]^E)HJX;[7]C^]/F
M`^,#W;S17N;G1CO[_+S4K8`T/M]?_5[X4_1^Z^_^[;Z>_P#NP-%7Z7Y?.+<[
M&Q,/E9^,LC[YXW[^X_3]V^GT_7="5>+\_G_Z_2<E:>:__P!O??/?/[\#17^F
MK^U_L;T.^1#X_P`O^'[3W/QV3_%]/P_;^FJ5>_B^O]GX?TTV4^OU_N^F!IJ_
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M[-$B8`P!@#`&`,`8`P!@#`&`,`BNG/\`A(O_`,U+U_ZW6%@KSX+V1X[JZ"H[
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MT1::/2+)KZK^<X2TV"&LIKP*Y2[Y.N3XK*Y-`F#J^['G$0D)J*'8Q3W(O5ML
M.6LBCQ)R(,B]"\%IHU%UEV1)HX:;*)GMFRJB?NS==5/WS?T72^GC52O=HG"S
M^B#$#JV!V;#^;ND+O<6!J!59UM6T2A@.S8LVD,=7D*#JP8Y=%@U*VA>HOQ),
M+(6!4IX<!R!TB*>"-5M'/K<1+JEU?\)F#H.]K\MF3EV%F<66MS3#F@%0F&EU
MH6?SW*7QXMJ08-D8_K$J:M&RB8A=5@Y>D_7Q9RW:(ZC=VF_OZETV\W!I+%2?
M9/[I$3RBQ?E`(R60C:\Y5XWC\58'2S*.2RT.Q;4=DY!'VK]P@(//(?!.1B6@
M)Z6'Z-WZP#:5DO!JR^S'<PZ]1]<[BQ3S5_:O*=7K'@3K:K?L!_6T%UI`MS9%
M;?WU$;V8K:L>M"?ULVVV`[^GFT%;Q&3UK)WNJ,G]3U$/I`Y'^N0.F^[T>U(*
MZZ(B*-YC:+=N3\M%X?)35`WICIJ`=]]DT:PNBJ&2W-W/JE&\L7Z(C-'W!!BU
M9](,N@S)DK8ENNT8RG?D-@U9R\`)V.2*3D*;!O?1T8B+<N1,/GM\@ZJAM)TT
MN'=S53=8A65X;\SL_P`_+]L]@4;6G45<?(E#8)6=X1$=8\8B8_BZ#$"4#&R#
M39TK!BTFD]L%DSI>#//7,4+'=@[!`L1#.B"3!LBXT1T&'I3ATW5G=W^9+67H
M7,/*[A,8CWR`PSG>=QOP7^^+-4CM#'74\V9@]AY3]1$K(4?QR*Z%3/OA_P!U
M#H^;,-]?!C=3UE^+ST19?TRN+V*$'D>(Y:U,`?D)^4SE/KJ$>#?_`,)QBVC7
M&-,DZREJ9!B[3GT`L"JW$*LJ)RYLV9J,&A(#*1KMKJ[W7;K:.D6^Z8U]7]-#
MI[:G.;<8Z',V\.O9]S4Q")\??.[7/2U6QM^4W,T2>>\VV;T:VBJ[URL-'UE>
M4PA=FM[/+`F:[5FS#7`9CSTT@.5U4LQ%R_;(L1=,S/X;3YAJGQX\/(ON3^7S
MFJ_JNJZ(4IV_T)35]CXT&D\_"#?CULBZ[H.#T`_@<EM,:N!4O.8;$]")]5`T
MJ8AKY2,ZN%$&00PL'<H^;I^?/L30TW*4;?4DO.;GDJ7Y/-Z;D!TI=-M]N],Q
MMX%]8A04C^.8=RRU$%O'S9Q]_2E$WUJC0CKLR2<C_P!"1W08>>.OU>V^JS?7
M`=,X5*_[ZN;6GB2C]D_+UT5I(9"^K[JQ&+!71DJ]"QNY1?Q)5[N"#N'SAP.#
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MSW\2:R#-<@EIYKYMLJMXHEL'_P`:X?C6_P#\TKY@Y:_,UQ-\DPKB079=]3>;
M2H2"GD#8RJ%;]E7STZ<EILLW=CTBZ]2BZ+IN@82-'E_%"R+\4(/%!/YK8,U-
MK>+^JNQO\.JG5:%,YI5,>,N?0Y3_``6\BS6[OD+@5?RK^*%.AW\$LL@K/!]0
MP:4/QB@F-*ODV['6\:LLNO@+U]^5LU9R1[%U"@UUNBF#>M2;IO\`F#?XE2TV
MAW6[^S3/V^RWX0:_L1OZ-L;Y!/E)FD<^F^FD+<=31R+0)NAO[M[^F9PBOZBB
M$9:(:Z[?EZZ-QJ>WY?\`1]V]\P</]3BFA/G3+]6R5#'PG?'01B4)BX>C_P"'
MI&%KM'>]E5-)#557+,WC83X*4<6#;D"<`)[+/'WOXBCYH].:CU#6^Q%)FBK^
M'S49UU<^#AKP3E%K^>.+*-Y?+%CU7[W$\-G`B$=)$+2Z/Z$NU/80V=HO4&X\
M1;]G3:/@E='#=+W]:`$"WVR/FS7=SLUWW1V$;;X\$E[)$7/?BI^.,Q)BLRDO
M&E#363&RQ$X5*V!"65A*O2A9XJ_(.E$9MZ?:^?J7:ZJNR*:&C?3\7Y::6B6N
MNG@NJI8J:[./8N.0J^M"PB-1\K7<%)@88@U;0\(0B0!Z(BC9BR3&LF\:&N1Z
MC,$@S'(I#VJ0M%JFW9))M4M=$--4_!F3<6C-H/;(LF#5LR9M]/$V[1H@DV;(
M)^?V)HH(ZZ)):>?W:Z:ZZ^?W>8!Z<`8`P!@%=;:ZMH^DY(C#YS()2XE6T?3E
MY&.U[5-MW&8BT-6=O6#>:SP?4$&G3FO(4Z>C"K1G,)TG'HT\7#F4VI178.3\
M:"I-_P`M+WR3?&I)'IE'04NB1P3)HK*`XV0QN1@2#4L#/`C#-$@),ARC%5=D
M1&$F#A!XQ?-%E6SILLDNBINGOKMZ(8Z:SV#5K'W<ML69Q.`Q5ALGH^DTUD0>
M*Q]ELM[[JEJ[,G7C`:VV5]\]\3\6<Z>[^^>^:^>^^8!']E=$T]44BJN*3Z6+
M"3EU&7`&MFS",2^3-CKYIN'T>+O"D5`&Q,9#,O#XE5[(Y6^!QYFV=^.G)1)L
M@Y51%AN7QDI[9WRU<3T[>_M&V':\3`?E1+]SN++VLBF2$(\([NO6C:"L8\)L
MTA<IJ;+[Z**;,`U4/Q+-+5/]::;K.F:+@545-2D_)_M'FR'(%\L!*?R:WFD:
MY6Z)LR%"S"8NBI;S_0?2,Y_>XS38TFXDU@%[II/FVI(5NYUTCCT/'8[;,Y16
M3=&V[^3,O!S1V0%T8NES+5O)M^B-1!V;\KMI4*:K20\I3YC/)8H]\\OXQ=_/
M?%)T`-=$VSY@E&(+7$C^0`W&%AK9#<2X=FEBQE^Q7<J>:,'JB#M$6*$_S6XA
MU8ZO3,^",E,N2OD1Z$KRJZQN]7X_A,:JDA#SL;+3D9TOV%/-)3"PJH0--9&:
M(2ODX'-)GX@X<$"CV1`'PHF>64,JCO7R;-TV$FE.5JOG%.<Q^:/VW,[;=66O
M62:4WZW^9@?1S#P>NTV/P^F.,^;U=A>RGJKD>$EUXQ^\)0R;*+^>[:MA\A64
M4<?3SW\]7WZ;`H=E1+[U/CAKXRG_`*>Y-L?WUO6E\_-=\BBZGUU<;4+9O1\5
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M_66,CD>":>)A@(81IYY]/-!@MBPT\\\_L\\U:()>>>?^[SS!Q,S@#`&`,`_G
M?3137W133533;^6VF^OF^NWG_J]UV\]\]_\`]^8!K;^%0TKY[X4B49)>;?7\
M7C\"*>>;?7^WZ^.&JGU^O]_UP#1B//=!E_Q?=J/J`G^+Z^;?<:TACW\7U_M_
M%^I"J_7Z_P!_U_MP67RR/2G$'%IS\7WKD+EXQ^/Z_C^Z4#5!#\?U_M_%^KB:
MWXOK_?\`7ZX&I\OS9&Y;XO\`XVC?XO2/`?&F^^_U_&LVYIIT>YV]]_OV=#X>
MU<>^_P#O]5^OG]WN"ZZOU5>;_<X2?*'_`+,=7O44_K2P.'2%*\GI"PFD1LRO
M-H<2#P4TR1,ORK2>QYM#&+KW2:(MRKH03%O630:>'L`'X3054:YV(CI1^,Z5
M%4U<.;^OS[?H[Y(YSCG(W,U(<T1,L^D`.EZ\C\';R$FCHV?R%X,:^>EY`Y9I
M*KHL%#AA9^5^W(KKH#M7>K%%=9)OHIL.53U-OER6)P08`P!@#`&`,`8!SG^6
M272N#<"7U)85<VU!2%BTA6K>S-DIF@T8,G%AQ1`Q&R4I@0&1R2MAT_#[OX"Z
MM1N.3:UMK)?)>0)AV8E8HT&J/S*TYMX/GXSGY2MY7U,XG\-=B!+HM8355D]"
MV-2%A5U-"P.>R>VGD2J7L=[I.Y)?X9E'?;<JERO5D4)4TLWAP+25QC</84T*
MS*1O`[T*--+Z[75*:?$NG;;-_(H/7?9W2A@+HG-^I;2'UK))%QU_O]6(ZFC4
M"OQK9-@=7]*PN[*U$S35FSUYS%:0N'5/'3X+9R,]@<6<B9@@J#WF"IPH-0MJ
M5-]*_4M*AY^KIR\3MF?E0Z9ZD%_[/ERS=6UOVQ!;HFM@U.-D%CQ632"M9W-H
M43$VN@#*2)_$UXX]<(V!$!L6E!QILDW'F'3Q-\LPU_$EHF5TF*$G^(U":O9J
MWKP?FB^).Z_E;E%Y%*6X&N*R"DK,P:<20I7AFV0XZ()A5R0#>92\&'MY8]58
M^Q%%'#1%A+",3,G&?I!\[9)[.O?5TAV_$5$)U+=*4KX<*T..DGZ4/X*_,17,
M6%3&FOB4K,AVQH0&KR/MCHOMRG>M[%(#VS)]H38PT-<4D$N*PU($EF#MBRA,
MN%18(R'[#$HJ[_4ZO6HXIT/-;T\*G3[3[3?N9F"W3_M3M=EU)3,>0DKF-[AU
MQ'[2F5O<1M::9J.G3)TX/#8E3+FN[0V/MO&7Z,0L9NTZ(9L'Y5-X%*.UF3T<
M$?@_JCPJGM>WI^Q5>\X_\W%I6:XGDH^+:WY(!-2N0R:55O,OD)Z,F,%_*-D/
M""$=@,1J_K6M('!HV*_->,F8G6%R)EJPW9-6Z+71A_W@5?Z>%7V>A>,MTSZH
MW637A\Z$R&P>O9Y\0?-4AH"KPD<&US1-T4'-[_A\-,Q(&K%XY,&!;>3S.6KR
M,-&79($Q?_<U'6H\H23W56V>+;;@E^'=ZZIG*:3:S[P_ELC5O2OSPT^0F:\=
MY1H"O1$H<Z;B(U%?C7ZQ1#UT.35>*^A8EO3M;""I4=OZNS\4]G1.<O=OLX[=
MN\25W(^D'SY8C7X;B]7]R^_V1[!W7'SHMH,0B$_Z:+Q$N_\`7?O\3#/Q!]Q_
MO0.FYV3VTT'>1GC=C`/4Q^NFVK1=>$O5=]%5-G2[W;Q+=-\^6$?ASCBW^I1'
MO/J>4ITO\E\@C`B,R;YEA=:[BOT/KF1>_%?UC"Y*159-U$-]S1>6<G1UHI^J
M]4]7?IMT&+19QHGOHDDGIKK@11E4-_\`=1Z/K\N?T5O7K>3/F#Z9_P"TV4M`
M=QVROJ*&W'P"KV2?B_J?YNI%D4AU?-27B?Y>OY/WW1UZW^N_B6R/YBOX@^G;
M\)O_`+-O%\3'@;:*B%F65[KZ_P#]KIJ))9Q[_,=%]*2B#W?\7T_HH-VG3</?
M(>_S_EZF/\_#[]//=//K],%E?_X/U_\`4EZ-?&C-;(WV_4_[2Q?%I(O/=?HQ
MAUZE63#;\7U_HMV,4ZS=MM_-_-OY>+)N?I]-?P?3S\?FXSKC_P#G2NZ_='XJ
M/DAH.3\S=L]!4Y*YQ-K1?1>;N-V-I6(X5>R^S`91JV(A9V6?+OB:K_:2,'"3
M]N^V(._'C51%QHX534TWV'IH<TIJ%T6%T/UW<;?[./6%]\/\U63/[IN.MK5G
M-<Q672&*R:J.<IM&8XV+-W+SP2,"RRG]9=YJZ9K#7PTH6FY3;1JKMOL@]T=(
MJ-QPJ_%:JJA)J8E.I3'9QZ%T#O\`LS/,K>P*M-UQ<4JBM>1]Z2WMJ&FZEI)]
M+K('N/&?VI"*V97D-JA:M7@K9%[LJZ6BLX2)?K=//&K#]+]7`S_JN'*E[.7;
MPES/A[1,\6^"2E0%W$%71R?O.;/(>EJ%##>GNKHG<*,_T7'?F*E'<+LZ,UVO
M#U6WW;U)`?'QQILMX.T_4+I[.M_!'^(XV3_XTQ[22O67Q2T@F3MP?:W.QI"+
M@#[KRE'P3Y%^X[4)67%/S#/K)S/XO/IE$PE:RCUHV`Z.Q(DM.P?KPH_T1.?I
MA*3HF(ZWL\Y^FE7\,][,AF<?$WPE:/+,WF%U_%_-8+9WC!ZQ]K^KK1#6ST@@
MDP,(H""M=6-O:"L4)N5=G&T@0"R&0)CW#%%VSD8%[^<J'="ZZDX5=NT+QMZ^
MI!\%H*I.`8Q6!WI'XT:3Z$YWGJ4?2"=%5IP76>W7=$ZF8XZDZ(OL^@JU@<J'
MN48TQ9NA4HN"G":8QJ?8)C"U;,RQH:X)"MNJ8J:=[.KZ7M]+;]'YG7*K[J^-
MA8G2PBF3/,WKZ_6A5W2OE:1*)ZM9M^WT=ES;(01C(#P<R,@]$U=2H$D['&QJ
MS9TW=CT7#1RDD,-57F;<[3W+>#;<J8K8YVF1%G5V2MV*`VLDDU4C9I&GECQJ
M-//!GZ(^=@K8DI)@X-UX:#?I2I`6W8+^%AGY2^WZYK^:,PXF+<[&V"I"`/;D
M4P9P.94$/EQA;0439$=Q9)JJH@Y'D=6:ZVS)\W61517:.?$G"2J2B:B>N^FW
MG@&8P",;BMN)T?7Y>Q9CJ7=#1SL$&&A(V-4-2J6RR7'AL3A4)B05)1+8M*IG
M+30:,QYALNU;+%"C;U\]8,-'3YN*E+CYR_)$75=TD[F-A:U)9M+V5S]912)D
MI]#(]89"MY$/GT.!$0PJ4/(O*JKG4^C>YR$D)+&6LRBQ,B-,CO)$))B$3\><
M;&DP:WE-3$J?NEDL_@@P!@#`,,[D<>8%AH!\=#,CIGQ;8.%=E&+8L6U;)*KN
M/1HY9?1X^\010766]:HJ^))(JJ;_`(=$]_?`-:'VO5I>PSU1"K)@).UXL':R
M&3U@/F,=>V''`#W4;NR.'H4V(J200'=Z&1&S4F0&MV3C4J-V27W\?-?50C?8
MT2#=/4+9XJV35;64$L%C1AF0QNU?(4@5E+Z)22*MG;H_'%Q00>]*DY`/T8NT
MM@@1D3*.'J/HYHU7?[:-MA8=K9Q-I,)KT]&S'/6W1U?UC?ME1Y?;WP+70.G)
M9#[ND/FLS\A2JH^J;B;UC)6"";KQ8_XXDJ(%!>'H;RAJHX%JM5G`1>)7>4UY
MJ41ET7VS&>?(W5,D.CZX`)S@G'-YX+O#HRF.>2M/1(RR;/R9Z1H3N0N$9&8C
M^BRK%S%8BX*N'I9OLV:$O6>_A'P$IF)?9-R58/\`RU5@:NJ'#N>2K7IVC?0)
M3:=[\[T=U;?-N.Y9JD<3%-8.3K&H2M"(1=)WK'%BIV66FR<>ME3B3<<EJV:/
ME1K0X;=GM+2\Y<]H1^0/YG^_/D/ION6=2"N)1U?QI6=QD(+>%=QD^S;4S/9,
MSC];PBHE4I=^QYC)]I-#Q)VLC#H-!)89]'CUI$;-E8,*(S!^L2?/M\_<[_AT
M4.F\5-2LSN_G6$?HE^.3F7Y7Y+\?L3@,^O#GF%0OI*)2*Q#Q&QXA=]GW)%(G
M?8]4TO$8G&(3.N7XW1_C`*<U7:1F+GC/D0D3\N0`DP[E5NR%#E6Z-3:55HPT
ML=TV[ES`_P`2)P]5$:H^\>Y^A;`J"(>ME`%40*&435T%9N6A%P60=J%"]<6?
M<K]\U).W#P>6)7$\-CUU/5&Y37?77;P9U7E4I/F_[I>A-K+XD>$G.S5Q9-6R
MOH<FW]1VW)=0W5=?1WCE1#\/Y6ZH*X+`EL30U3\TUUU;#X\R9ZZZ^:ZMO//Y
M8)KJV<?\4J?:"539[X]^"`NKDP\Y&Y"#ZM/?6K?5*I*3]>-OI[IJW%"V24>=
ME-U?P^IHLAC1TNYW_JD45-_?-<$^JKFI^+(C_P"TXK^=_P!1RWSIUYUPJO\`
MU+"05C19NNZI<N]_Y)Z_QJZ/=TG6+QCY]=%%R4<D4B23;[ZK(IN?KYIZ+IY:
M7=SZ*7\X/]_<_P`KUM?SC]7<@\<`'/\`4^/[4F\\ZQM-HEO_`.6]V@M9-J2K
M,>^23V\_(:^7#+F7CE/W\_=PW]\\W%^A;U5=EI7FY?IY#_<%MFQ?Z[IKY".N
M+125_H.H73!F*<>UHJUV_FNQ\;4*$#W`NU7^NZ:NIB[3"V[;?UNHLIKY^+!-
M26*:5W^I^MO1$LU/\='#=)F/W/`.8*G2FWJFBN]CR^/>6=::RJ?T_"JYM.S5
MY?8;E7WWS7?=1Q)E-U5-=5%/=]]==O`=53RWVPO)6+I>>>>>>>>>>>>>>?3S
MSS^7GGGG]GGGG]WGF#)_N`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@'D(#V!9@]%E&30D,)-'(\B.(-D7C`@P>([MWC)ZS<:*-W31TW440<METU$
M5T5-TE=-M-MM?0/JV;-V3=NS9MT6C1HBDV:M6R2:#=LW03U20;MT$M=4D444
MM=4TDD]=4TT]==--?-?//,`_WU!#;5;3U%+W1Q[MZOIZGI[JM[MIXGMZMK[Y
M]%/=D]==-OQ^;?737S7W^7GGF`5QZHY!YS[8K-M3O3];-;3KAG*!<T:QMU(I
M?%]$).%9%1PPJF4A$@C)O51JR-E6_B'W+](JF\4_/;J[:I>Z"INERG#*9\(_
M%1P'R;+7]Z\^\^,*^M9I(+OKUM+D[`MB2KH0]"U91'D@Z8N8SR0@M?-0T>#L
M?7_@O[GNFT]WW>[+.7:BXU77559N59X68Z+J=7\&!@#`&`,`8`P![Y]?Y>_S
M\]_E[Y[_`'X!H1ZJJOE7X_W16\"DGYGU_,^_0^/&/S/K_;^/[@.<?B^O]_XO
MK]?[\`@V2<&<-S+S?R7<9\I2C\SZ_CVD//%1F=]OK_;[^,A$'&_FW]_FWFWF
MWGO\_/?/?//<%U5<OS9^;[Y#_P#9;XQTIU"!MKDZ>5#R_4$F81P;:=5,:_<#
M1T5=`T4ACZ45-'H>V9QQTXD(E%JN0C!7>*M-)&@_-;2!WX=5:#AUI_&:45)U
M/9S[_/8[81GXB.28'&X]'JVD'656*QP&)!-3%8]P=<PAPN@(8-V"+A8&%N5&
M&(*+:-_%5FP^,,ANNV^R+=B@T\3;:#GK>^E]Z:?V,W[\?5@`/ZZM/DB^0J$N
M4OYM$)%8E+W<'TV\_P#)\>-+UHBQ"S]/7Z>?T53VF^_GU_,4W^OON!JYII]5
M[-'^>\__`"71;^OAWR)5?8'Y'\TA=_\`$L9(^/\`Z?V)O3E%7#1GK7\7_P"\
M69Q[;^_\#?3^7O@33^E^%7[IC]Q?+G$/Z\A5?Q]WHT0_\ZA%;>O_`)X./=?/
M_P""82>J>@`K=3;Z?^0\DWX-/??//SM_/KMX'T<U+P3^Z'^^'V5%/ZRSOBVO
M9RQ3_DY)\_WWR[<R&GO_`.LV$3"RZ0E[Q/\`MV\]2C'BONOGT_(\4]U3]"%^
MI>*J^R8_[3^HP/\`.V.>N\Z20U_DN1G7$?0$E`M=_P"SW5Q**7B%KQC7Z>_V
MJZ&5$/-?ZSU7\OSW?`T/9TO_`+)>[10BPKM^,$Q91BZ^4OD*JK@7J61./N$I
M*2%;2L:LNE^G_+QKTASO<Z5<1F?.%O-UFV\W'?LJWQ?KGW<=8".J.C/<:2JP
MZ74O-KLU,=L="7J7^6+G$)8PR-]>NN:ZIMR4)(Q*.=54G9D'MSE>Y6^V[;=J
M.'7<%<+2>GWQ#<:D^TK>_$(RBAX.;Z`);,_TR+WT-%46EQ_2U%2\-\Y7BD=6
MX91]`QIC8;RN*HJB,,+T=/I':)&`0V*QY*V2,A;//"$EF9&,CV7LR*&6Q5_N
MY/EEW[]]J0<J[O%/7&^^PYRWOC'0U%AR%SD'H%[RY':S8Q*AW_J^RL`A9V60
MMLALZDB<N<;#3D4/!Y0'V6D*6I!382;9>[?51I[[^A55;;BRYG?DJY\BE'U>
MQXZCTA)$%HU#N(3]7]`QIL9M^SH&.?1KG]1KN3AY^?1V1ZRT@2D=>(G8W&2T
MB=R9;]^O8V=*M#3I%;1R+2[Q^I-83ST[^A2SC+L_F#YB.S(%T+13^SH@PXAK
MJ4_<(C/)H<A<KF$ON]!J$$NO*CA\X.0$U7T-!CY@SD<L.;$2Q29%8D,:-&88
M"V?&AJJFJA0X^KA<=?MP=I@U'0\%=,MOEF:LU:9S2,L8H7!E+=LPQ5C0:/T!
M:(.HW3A25.ZMBA[?6.L?U<CC<3%G7NS@ON\(+[FRWKP8FT6\E/G$^I'HBMN>
MJ&:VVD1L(X`:W2;.22=^VET=8QOQ!W(-"&A%&$+V)8I!2K0NB1-UJ-"5JK$@
MX;SQKL)9LMV+/=`);BV,0EZPK^,E.Y9=GQ!U70+_`):G/7-!(U(ZW7^X0J6=
MJEIS8;W9:4)S!31:7F+AD=W/?I(DDG":?[E6\0;ZZ!D-4Q'T'^C45S,.?^-N
M.(2]#09SUY\5-Q0BKJR1A5C=6QNFB44,5)#JMY0ZNOQ$"7A(CT%%"PD_':O-
M!7;\.*V];MBAR3K;K>[^NW#I=Q[LX\"*KO$Y;:77GT5^ANYWHUW:EB1"V('\
M/735H6[`&1`?7UQ757O+5%'H.++I.FY1M%IK=ENC[9BC0FW?/4BC`'$VZKQL
M[<HKM''JZJ&P1$K6DMTM3GR4>9LC,A\F,MDI::POD'@[FZ0'VS9B:FEJWC.K
MELPNS:I-4&:1H54%)0,<0;L6[%D@F.7N)VBEHR:)-G7Y2*7J(?1^JI\6277+
M^QL?^[A\C$Z_IV5\C$<K9J[_`/3`7*?(U?1%5HCM_)1J/F'1,OZ6?[[>Z?7Q
M,CK'Q[I+WWS=-/3?7S;T2:5BF?\`DW_^=(_[+VH)/_\`MSOOMSI-/W^DL,M;
MKBVH_$G*OO\`Y2KJO**+4U7+GS;^>NS=>)*,_4_?4O6WJ7]#`U/94K_JGZN7
MZDS59\?'#-*.="%7\C\]1(YHI^=M*6M4PY]-'"WXOQ?G/)L7%$)8^6_']=_S
M7AE=3\S;93\7X]]MO1-53W?:;7Z%P---$M-$T]-4TT]==$T]-?-----//-==
M--=?/-====?/-===?////////////,$.475UM122V1.(_87,_"-AP3E\E!2>
MEJ=OWZ%JL?%IK.(LWF2+V#(2+ER[!(/<<*T':KR+26@BJ[U';34<FW9(.EAM
M6_JJ3>U*FU_]RXX,34?S`U!==<Q<_4E(]$W_`&.49N=)'`.8ZKE]HP:+&V9!
MX+48;='S,#4-"O!3M=ELZ%%WLT!N70M9N\=A1RN^S3030UEI=VI\KOR3)'_?
MWRH7#_1A="\S\;QU?^K^_P#0ED'.DK3016__`$M.I:*VA=;,WC5+WW;5!QT2
M;;^NO$_%$ET/S-<"*5NV^BA>;OZ(?]G[8ME_U_5?>?6%SI+_`-6]@=2R89QY
M4:[3W^:H_P"R<\-HY:K]BO[LIHLE*+KDZBK?;5!17?S3\>P:DL4TKO\`4_65
MY)$[4QP3QCSV1^_U#S14,3EVRWCE>P%(B/D=G/G'GT^C@G9\KT.6"57\]\_'
M^<2DKI3\SW93\7YF^VWHCJ;RWVV\L%N,$&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`173G_"1?\`YJ7K_P!;K"P5Y\%[(E3!
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`Q9<(%D#)0:>$"S8Y;^2S`NP:$F2O\`
M+WS^L:O4ED-_Y>^^?TD_?Y>^^8!6.8\&<.V'LKO/.-^6)DLM^+W=S)N?JH-.
M_P`6W]N^KPA$W#I-7^?OOBJ:NJGGO\_-O/<%U5+%3\V<H+J_V?KF]A.2%R\:
MBH=3\M>[;.3E$6`C-S/,TU5_,]6V19)P.5Q"V:1).%-]]43E63+V.C=?R_-Z
MV+HI:MO1O_4>*K]?ZEXN9\?-$9-:TXFI-RA'^[.8NL^%B7YJ;-&XXIV]VY.N
M/CSC;;Q-)4;?M87<+95ZF\VT670&WS!ZD=H(IZIHJ/\`?7\S8)J?Y735T=-.
MKR:OX-YL2CV-\:'"UO<-W$7A?5%M1F&S2&M&$'N*7][=1W=0J,J+R$*PK_[\
M`D=WSJ$38$>G#B/QWQAL)/.UG19OL!9JR#07]`IJJ52^E=E32GYQ;DY#?!5\
M-]/1RT+A<=17Q7UF3LM!EFD`IWG2_;NA13:'`Y1'_)?94GD$`)4^=,A6Q0G#
MPC".[K&P[+>0I/Y(R8&%P":0Z?BUMI0H7+2S&-XW[Q;!^F'_`+(OX]UOY%*%
M>R5/W^6Z,SN6^YPV6\_]3EM+[1-MW/GO]_CA)7SW^_SW!QUU<^B_8VZ-?%E\
M;$2W\6#<'\E^NM=OQZOC%#5O)B/BG]OYOA*2QXL_\5]]_GLKXX_,V]]]]VV]
M]]]P-=7ZJO-QY%I8/2%+5EJGK6U05?7NJ/GFJ.L'@$4B>J7GGGT\\3\`B6'F
MGGGG\O/-?IYYY@S,Y)0P!@#`/*^?L1;-R1)/&HX>R14<O'SYPBT9M&Z6ONRJ
M[ETXW30013U\]V455WTTTU\]]VV\\\P"AT[^4'A:$'G,,87Z`MRQ&_\`5^UC
MS@&E73%C^O/=O4TA[B'4,#L(P*>+J^>)::'&XM%/W;7=PL@C[ZKX-::N(7+L
MO-P:9_O;=IVU_4\X?'K,XJ)=_P!2TLOMRT(ESQ'T-O?Y^D-*L@2%WWB^;)Z>
MZ[ZL)!#("[<;;>I;+M-TU/PAII6:O[5/JX7BFS_/]V#O&X/ZWH;O9:K0+S^D
M\K/ABI(]5*::6O\`+1DYNZYW%V6@^\V_EZY)Q%G6#Q;WW?\`2IL/ZO\`+":5
MBF>M3GT4+SD@`=\1$=K.\IA<M7L>>+7+RMO%'3:6]UUS;?7MSQB0`A/@LP1!
M6M.KT2)MD9"JBW*J:-&#!08XV5'#MD!*39KH*ZVU%TN*6J5Y)'3?F6GG]!T7
M7M2%3XV3E8B.(Z%#@4&M&@SXF:/%9$0]#@7)8ZY%"6SPNLT&M'!@@XT9-T/5
MW.ZON_T&6Y<D[X(,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`Y_7=WW'J=[*H7C!K5$PG4TND$-ECV1"Y+7\<&Q.)F3TGC3<V
M,$3&2!#-B[1TA$B92PA4.0=%(?%5PY71L:*'P<?(C2IFEU3"5M\\6QTFW4KM
M#/F0JFQA=A$:_IZ8S)S'KXB_.%<`8[;/-1>4VM9\SLJ65S'&F\2&W([E50`W
M_D+/31(Y=X2OVSZ%L7!,'H9<I>,=Q=#42XM.*K*)XA\6;OTN='N<;XA_3M&U
MI?<#:&AL7LV-H'V(B2-FK.1`76KAP.,QT\W8/"(],U'3;$B$*?;B)$=N^8+[
MCW[UGL@Y5&6H<&8IS_A(O_S4O7_K=86`\^"]D2I@@P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P#Y+H(.D%FSE%)PV<)*(.&ZZ>BR"Z"VGJ:J*R2GFR:J2J>
MVVBB>^NVF^FWNNWGNOOOF`<6^[OC2YP0KQY;E!U-8=,6HTO/EV92LMQDZF\)
MDI6,QWIRH#EBS92E:S\=P&TIM"8./D,_CKH_5<WD323Q@4;%LWQ9@W06&Z:G
M-W-JE>'_`$M)2[I3PT0E"HO\@<@ZLK"4T5T%-[@%5O0/0L=]D7R'<&611;(*
MQG%@<Q/&4'5L"``.>4YK,9II`MRXZ2#H`8WC#"OI!Z>!%E)>P="Q9ITM-1+3
M^FJ<:MG//)?#RY/E)AOOZ:6\0\TV[KK_`#\.49V4:C:BVOG_`.;M$KJY]BB;
M1;;S^?X-9P^1TV]\3_4;Z^?G8,Q3^IKO3]T_L?U_OC]B#OZ)_P"*'IS?W7_S
MBT-OGA^4M-O_`.IMZ0Z1BQ%77W^?T_/%M%/_`%I^?7S'A'SH(7ZEXJK[)C_?
M:ZB<_P!$7\4/9RJFWGT3\+67PL$2]V_L\_-56ZU<?E:?7^W;\&_OGG\_P^X&
ME?KI\J__`%'^\[\A1;^A'?C`=!5-_P#S:EK]GT/&6B?U_L]=*5>-NYUI]/[=
MO&S-W]//K^'W;WZ?4(I_5Z/^/GF?S]T^7>8?TVL0^/*A6R__`)'AF:]$=,F6
M.FW]OKAD(A_,8APNG_/Z:('-D-_?//?5?//?=<#Z/]S\E_['\^\C=L3SZ)W-
M\FMDB1CC^F_CO*G/U(T*UW^O]+]*UE-C#>C;#9-]/??R_P!0-EHY\JG]=O%V
MZONNR82EBE?]FW[0O0]#+XHN,B3QL8N:)V)U=(&RR;C[MUW=5K]&LMUDMO-T
MO4X+94M,U>/33W^ONC</!AS;3SW\O5'Q+5-/0-;VA=DEZJ_J7N@M=5]5X%O%
M:S@D-KN+M/I^EC<%C`2)`6WTU\T\_3AP#$>/1^FNOFOGY;?7Z:^>>?V>>>8,
MS.3<L`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`<Z.MOCW%=;WKSW:TLN&<!(92<JA\R>U*S%P\F!,R6NI7O.8C)8
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MI(HIZ)IZ:^:Z:^:^>>8#SX+V1+^"#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`BNG/^$B__`#4O7_K=86"O/@O9
M$J8(,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`^"+IJX4=)-W*"ZK%?5J]3163549NMFS=YJV=::;;;-U]F;MH[U15\
MT4];.FZ_FOY2R>VP'WP"*Z<_X2+_`/-2]?\`K=86"O/@O9$J8(,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`_&A4-#W
M*'>=4Q!7F#H"6<ZM>WN69QT@]EM33T?T#:];AS2):Q:KL"LH=+9O%.HOVW]]
M`3L].Z>!DB%D1/=R5-*RIA*P@4,.SBUTGI<7MX/^GB'A\7/TA?'I#KKA?`_.
M,-LW[G&+<#5F/9N65D-",E.1<9Z5?.(A')@P\D`LJX.1V"*@8^49.)"B^'DV
M2C=ZX67:+I*CG5&I\=+?+D\1."7%%!;H6A9%:/-'4FFDEV55IZ4)[:+3.8GI
M@X:^:Z7?MYZFQ7.J,D5/??Q*HM]%=]==]]M?!EW]/10;-]IN?_'U8?Y12O\`
MUNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8?Y12O_6[`'VFY_P#'U8?Y12O_`%NP
M!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8?Y12O_6[`'VFY
M_P#'U8?Y12O_`%NP!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`,&6B-UD
MW\8>Z6?7;+6.G'!E5LWJ26>(E]%XW(8_X.?^>7CIYLT24.IEM-=M5//UPMGM
M^#S;751,.3.?:;G_`,?5A_E%*_\`6[`'VFY_\?5A_E%*_P#6[`'VFY_\?5A_
ME%*_];L`?:;G_P`?5A_E%*_];L`?:;G_`,?5A_E%*_\`6[`'VFY_\?5A_E%*
M_P#6[`'VFY_\?5A_E%*_];L`?:;G_P`?5A_E%*_];L`?:;G_`,?5A_E%*_\`
M6[`'VFY_\?5A_E%*_P#6[`'VFY_\?5A_E%*_];L`P4=B%U@6#ABI9]=E-ESD
MH,^.7M22S99).1R4M(4AVGNUXJ>^-`Z1300PU_%YYHQ8MM==$M?/$]`,[]IN
M?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8?Y12O_6[`'VFY_P#'
MU8?Y12O_`%NP!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12O_6[`'VFY_\`'U8?
MY12O_6[`'VFY_P#'U8?Y12O_`%NP!]IN?_'U8?Y12O\`UNP!]IN?_'U8?Y12
MO_6[`,&6B%UE'\8>Z6?7;'6.G%S*K9M4DLU1+Z+1N0Q_P<_\\O'7S9HFH=3+
M::[:J>?KA;/;\'FVNJB8<F<^TW/_`(^K#_**5_ZW8`^TW/\`X^K#_**5_P"M
MV`/M-S_X^K#_`"BE?^MV`/M-S_X^K#_**5_ZW8`^TW/_`(^K#_**5_ZW8`^T
MW/\`X^K#_**5_P"MV`/M-S_X^K#_`"BE?^MV`/M-S_X^K#_**5_ZW8`^TW/_
M`(^K#_**5_ZW8`^TW/\`X^K#_**5_P"MV`/M-S_X^K#_`"BE?^MV`8*/Q"ZP
M;-VT4L^NRGKHY(C.J[RI)9LH@F>.D#28Y+W:\5/?&@K1]J.9:^>^>:M&J.NN
MB?GGFFH&=^TW/_CZL/\`**5_ZW8`^TW/_CZL/\HI7_K=@#[3<_\`CZL/\HI7
M_K=@#[3<_P#CZL/\HI7_`*W8`^TW/_CZL/\`**5_ZW8`^TW/_CZL/\HI7_K=
M@#[3<_\`CZL/\HI7_K=@#[3<_P#CZL/\HI7_`*W8`^TW/_CZL/\`**5_ZW8`
M^TW/_CZL/\HI7_K=@'E5BUIDGX'<W8,,]$BCP\R_9QVN9&")%$1_YN^HWPH[
MM@ZV:MG*VR7KKU8._P!%4$]T?$==E-5D@)9P!@#`&`,`8`P!@#`&`,`P<EDT
M<AD?,RR7GPT6BT<&NS,@DDB)L@P(&(8([N'Q,N6(K-V(X>S0TW6<NW:Z2""6
MNVZBFNOGON`5*<_(?QBS'TJ5<WO'$1G0L<CLQJDAL&E_K,U$)?(1D1BLL/.=
M8YZE7T8D4K,BXP%D%B;Q002D+Q(*T>*DOQMM1=+O;$I^&?8SLC[KY+B5A@:I
MD=UQP5/I).'M<"P2X^2;^:S!C)@<(W&EBR`14)'VKN<R0+!`YL^2&`3LY?:P
MT(3(29%R*1"'F/GR_:^#:J5ZTYTZ*D,XBM+6H!GI^NMV_LI'C6QEELDP>&#\
M>9R$&X,#!K27Q!X?BLE!LYI$%SL3=F`)88W,J/6+A!,&FL_,?NBQ6"#`&`,`
M8`P!@#`(8E'1-'PNU(Y2,IL^)A;7E4+E]C!X.\(^>&?V'`TFBTJEY75/11M'
MH\,3>I>Z%9"X%M".R+],6J]4&$M6@L.&XLLLC"LN[.3;B!*2.N;D#2$6G-8%
M7_OOH.7AB&\DM-%%W6_Y`4_'A9IS'IR-6^\Q::-QZL,-`&[^0,3ZP4:0?M@A
M\<^F3"G?D/XMCM;N;=(=`0]Q7#>SYA3>LJ!-9'*6+^Q*^'EC$Z#!$(R$+OY`
MPAX,"<D$DE`-H0B8:.ABL@?G$`P]V^2%TO$;3X/'N7"%DQIL:.,AG[,J(+L6
MA,44'.47@\D-?MTW3%^Q>-]U&[IF\:JI.&KE!3=%=!315+?;3;7;T9/=@#`&
M`,`8`P!@&*.'0D8#%9')3`N/1X$/=E39TX0:"0P<6P1W<OB10F_6;LA[!FW3
M47=/':Z+=NCINJLIIIKMMX!3PG\C'%(>*5!.2-_1="(WN&<2:L#VHF7.&!J)
M-)$)B3J:E]VL=6WA4%;R<\$!+3><Z1N)IDRPYIN8\5=H:[C6FJ]L6??@DT]U
MMSA%Y0!A,@MN+BI?*KG\Y[C$;=>D?#$BN#P`,D[F'`V.C'=<LH-"F1KDT;8:
M+QL$X=>#3)AB3369IB0WMM/A@V^#7S3MF6#:]5U_84=E\_HQU%F%MQT"Y4?K
M0,E-&90A'!)QZBCZ,2,/604BX7$(/5R0O1%/[NU8[.FFJX--)-JSQU)<P08`
MP!@#`&`,`8!#TMZ!I:"VE7U)2VR(P#MBTQDM.0.!NWOOL@.@H(%<R"6GO6B"
M:O@H"%%,W*[@V:4'"U5D=F+5VN0]U:^BPX;V43XX(EK7O+DBX`!>3UQ=`.3!
M@<LJ:%/G"`67,'&YJ]Y,PA],N1HTM'F!,W%[./DF[6%SD*S(0D\U2(EF,A5$
M""S]D$-;<^F?+=9/":^0;C8%"Y'83B^(N3B$6N,US\3*Q4?*)LHYN.-1K692
M2"1T7#@)TO,"L=BOZ@^>7B3`V,#"QIMT2?-DP)KU@+IJQ&T^')::'R^+V!$H
MO/(0>%RF&36/!9;$I,$=I/PTBC,B'-BX(X)?(^[(O!I46\:OF+I+;U-=LNDK
MI[[KMY@R[6>4;'@#`&`,`8`P!@'B)$AP8<^+EW[(4)%LW)`F3).D&(X<P9H[
MN'CY\]=*)-FC-JW347<N7"J:*".FZJN^NFNVW@%+2_R1\/@X%65H$>AHAK7U
MQ:3)W7<K:#Y42$G0=>2M&#SB8N%AL?=[Q^O8M*G3$09L>2IAX&S5)B5U)%XS
M+#7#H:TU7MC/2?F"4Y=UOS?`I"WB<PMR+@),]O&%\V#03_8AJ4,7A8,?A$KB
MM>@V:;%18X5>1NQX6;?NQ&KT/'QQQ)Q(B(K1F1]9B:6]GB?!3?T9]*VZQYWM
M^TI_2M;V@%E-FUCL:UF,7:,SC51IY&)+O"Y6J'*DA3('+6\0F6FT0F#F(DSK
M>)RK\,<D2HPSOHRV"&KQ\S[77*+$8(,`8`P!@#`&`,`B.6WS3L%M*JJ2EEA1
MT-;=W*RE.K*]7<J+2>8)PJ,%YC*G[(:T1<*M`X2/`B;MX;*?H`_ZE%`2D^4+
MOF#!T+#AN+++XDANO^^>0;382DI`+NCTD8PXY6L?,KM!,K;_`)[NY)[Y5U4D
M(VF_`-%9G%[#L+\<1B,TAR9Z'FS+=XV8G%?T3O9`734LKGT4OR63<Q77?-!R
M$7M98>YX22KSF:22F(7G-F9%1:+U])81%`4UEH<B;T0]'D74?CTE#+D_`*Y5
M-L1<JQ_93]P,2`MJ)#M;-UU7)-</EL>GT2BTZB)),U$YI'0DMC!A%%TW2+1Z
M1C&I@*22;O4&SQ!-\->-G6B+MLW=):J^:+H)*Z[IZB&Q8`P!@#`&`,`8`P!@
M&O2J)QB<`7L8F,<`RV/$-F:KT#)Q`\Z$>+C7[4J,5=BRC=VQ<*#BK%D39;JM
M]]FC]FU>(>Z.&Z2F@'#1I\?G;8*F?CSYK15Y:F]#\RUO5C;HJ*%[0M6"DKGM
M"L)&,-1)GX7#4'+'LCI>!D0@^>#8.1=PCVP)WH-0F>C6,`%!\@'353-;^I-M
MPX5DW_R5WCHN9,9,OBOZ&E9F$DT);4#9.V`5<(]9/21^8^'8C)(G\A)3Y!Y(
M>I1%G!WK"?+R>32Z65F@UEY&M4`(UM%Y*W<D4QV\8P-:O:UX7>G1?&U]_N6$
MX,^/>S.9>B[/N*=FX:QAZ-4>4#1U>02P;!GP<'6WETSRW=':C6?Q2-.:Z:,O
MW*'$!*[9F[3V$./),[4LTD*>`00(2JI-)+F799\,][=N>O>#`P!@#`&`,`8`
MP"BUR<M'))UM1?4M;`ZG:EZSJWIB*SC21I/`)^QI%9D6K$+538V;`Q,VY*QF
M/*PDJ/-NB[A=]'PI-+]N"#&ZSEDF-)V:<WB.E[E,.7.#^K6%@1R9]E-^<I>=
M>7&?NZWI?6T^GDT0LTFRHZQJ)JFL6U<3.F*YC<#IVJHI:!72%P@:^DB2#D1J
M?/$C<J+E#+T5U+^F<0K)1>7>7?K;C!IU@_%W?(Z(O?X(O^?6<D$]0]UV%"(-
M(BLPAU9#J7[)IR9TZ+8[NXK6T@>`YC5K20!CK:)"8FZBYEF,(Q)K+0B)%`ZR
M%5:WG"\TYYP_YV.S%'5KI3-*T_3Z954ZG5%75_6J9Q9'].L9T@L3$Q?0JJW_
M`#%?R%2.HOQVHC^:K^5NM[I^9O\`A_%Z.;NV^24<`8`P!@#`&`,`P,FBT9FH
M(A%YE'04LC19-)(K'9,('G09-)!PB[12("2C=TP>II.FZ#E/1RW4UT7125U\
M\43TV\`X6F_CY[;'\U\6\K1Q3EB8U#3HAQOT[%Y+9]JU\YN]X*G6\OA5>L95
M':#FQG^#+-^DQD4YC>R$6(6$48#8R3<LHBV,-I,.FJENJJZ;_+"32VY5^..\
M199YP+*#D9Y@D!)M5.EWUKW"9ZNM6;N$G;DHYBDSM.W+.D]=0J6:150^]:C5
MIY%P8,03U!`G3&'C]WKALJ/8^[C.K/6F/)))OYN6*H?EM2E.I.N[D##Z_C]?
M=!BZ$_;,8AC#8028R2O&EHK6(<E`IJ"&!$WLMD,_T-Z$F!`L_-/E3!$YZU?*
M^;.P;FFE<3ZQ^Q=#!D8`P!@#`&`,`8!1^\>6R4XZIY=Z9@H:L&QNE$[J2GSP
M^BX#2R=CYC3LG@E=QWV0!XJ;=D`8"2R-Z[>(&76J`$44,/@;`D0=+#W8J=FN
M8*2\T\,]@M+"%3KKO7G`_)370T3NBV)G4]BV))4)C$:NJJ\8E25*1NN992]<
M@:WK&E9?.X#(X,"'&)2])/!DUD4J-O9$<W<$!INF(4PE"E)1+3;E-S-UC%C^
MYWP7UO!J3Z,J'D4CS=732^^RY!:B>^TCEU8+U_S#(*AK:N35>5>6B5)SMO65
MHGDX41BZ<@!Q8F,A4*-.GL8>[259BJ"#4FTZI<4]'-4MW3=U?FYUEHZ$[5I2
M]25SM$X?`_8#6L(A?D(KTP9D,$B&D7C0T(G&8:>D0>/R`U&`>C'4:#+'`0<N
M0&MFSLB-9O%5FZ8R[MO-\O<E+!!@#`&`,`8`P#"R2-1V8@#$5EP`+*HO(1[H
M0?C<C%L3@$X*?);(/1A@.30=#R8YXAONBZ9/6Z[9PEMLFLEOIM[KZ!PIF?QZ
M]JM^7^>.4H+MRQ)ZGC,TO21]-16469:5;JW)#YM>4LM:OJ9$S&+4'.S(FJG:
M)T4K<P9J.`$IFH&;0QD5;Q3<LZ.CIJIEU7FVFR<6SE7XXSF(LI+.!)5.8961
M@RTJ?^.D<^1`5UU))N_2=O70ZL6/4X>T5J^ATIUBBQ],I[2L!JB#JCMD`P`^
M?@HC8L^:L6#%ZV$543:VC3'6(GS;?B;Y5?-O1S3O6;=36F]I(9#OX13VEP&M
M:G[..2:R8R6M*-3:K2$IA-AC',;HXG6\;#%PTN;51-9")NB7R1Q-Y&S`:AHX
M!$"-K3"F9G"M;9IWGJN#I!@R,`8`P!@#`&`,`I7>G+;BR.IN..D(L,KQ@7Y^
MFEDDK$-EFBC"=2V$R+GV[:RAD2$G!T>).20\!.+96/\`V@X4'B1+$C)R@K1P
M7>;,"(TG"J5[J%QE.?)%$:&X=[07MY"R^L4N:"IF2=!UG94^E=26;91_5K4%
M"A[EDE`4%7-<2BCZ\`02"U9<<EK>9-ORI`?,RXU_$*9RDLL;>`V3<5NF(4X<
M2DH;B7ES*4;;"S?B;F<WJWJ^HX+9U?TA`K<ZT_WBJXKZ&01@7KDE%P/+-/4Y
M`ZXLR).`P$8`%1NTJWVL=FQB3>0BV#H'"#6J1$@Q7"M057Y94Q3%_P#DW*\'
M!U(Y:K"84IS;1-/V!)QDSF=7U1!8%(I*%8?;0Y,A%8ZP"[["FNR#57T:VT9I
MLF3IRT9O"#9LD_>LVCMRLV2&7=M]2>L$&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@&)/'P46#D9%)S0F.1\0VW>ECIXDS$!
MQ;-+Z?FNR),@LW9,FR?U\_&NY722T^OGXM_/K@$;Q7H*A)T=9Q>$7=4,QDI'
MQSL/CL5LJ&2$Z_U9-5GSS9F)$&GC]UXT8MG#QSZ@WW\0:MUG"OX$4E-]18?#
M\B7L$/FLLDW2577530003W6666WU32123U]W4554W]UT333TU]WWWW]\UTU\
M]VV]\\\]]P#Y)O&BJNJ"3ILHMNVT>:(IKI;J[M%-O=$W6J>NWN^S93?SW71?
MSSU+;;SW77;WW^6`?W^I;_J/&GYZ/ZOU'USXU_-T_4>M_-_$O5_$?Q?F?D^*
M>^)^J_A_!YO[YI^+\7OGF`?;`/X443134554T222TV4554VUT333TU]VW44W
MV]\UTTTU\]VVVV]\UUU\]]]]\\\P#"MI1&7NWNC.1`G>^OJ7FVK8N/7VU]77
M2:H>>ZI.-_?/5G*R+=+SWSZJ+JI):?51337T#.X`P!@#`/BX<MVB"KEVNBU;
M()[*KN'"NB*"*6GGUW4554VU333U\_GMOOMYKKY_/WWS`/M@#`&`,`8`P!@#
M`&`,`8!X!I089:_KA!%@59?J7S/]8-=MWS7]8,?.!A)K^H:J*I?J1Q)F['OD
M/Q_FM'S5PT<:IKH*IZ@>_`/@X<MF:6SAVX0:H:[)Z[+.%4T$M=E5-$4M=E%=
MM=/-E%5-$D_/=OKNIOIIK]=MO//0/GN_8I^//5'K1/P<GXJ0]W<HZ^,4O4O7
M'BCSW;?S]*GZAYZMYNO^#7\KSU3Z_@\_%@'G?FPPIFD0*%Q@U@NJW10?/W[5
MFS66=^^>-$DG+A5-%15U[[YXW3TW]W6]]\\3\V^N`?UN8$ID-!.Y0=H44U\W
M3&[O6VI!37W393S;1GZKXXVU]TUVW\]U3]\]TUVV^OT\]]P#U?JFWCGQEZY0
M\>;(;.M6GYR?ZG9MHIJENY\0_%^;ZAJKOHELMYI^7JIOKI[MYMMYYZ!Y4RXE
M8FY"HE!RIAFW2=O!*;ULH3:M5_?/$'+EAJKZZ0;K>^^>)+*I:IJ>^^>:;>X!
M_KTL*&J,42),>/6)NM6`U)Z\;-5"#[?SW;1FQT743V=NM]==MM6[?Q1;;SSW
MWS3WSSW`,A@#`&`,`^*+ENX_-\;N$5_6ZV[9?\E5-7\EPGYKZHW5_!MM^6LG
MYMK[NEO^%37S;7W;7SSWS`/M@#`&`,`8`P!@#`&`8TP9#QT6_.2`L-!!1;91
MX3,&'S48+'-$O/JJZ?D'JJ#1HV2\_FHNX632T\_GMMYY@'Q`2$!*P["0Q<X'
MD@`HC^H&'`!)D8#D6_X]D_SV!,<LX9/$?S--]/S6ZZFGX]-M?Q?BU]\\`S&`
M>$@3&B4=7)0@Q&M]E-4=7!!V@S1V6VUWWU2U5<*)I^J;:)[[:Z>;?B]UTWV\
M\^FOOO@'F7D`%JDS<.C8AL@1\]V'K+DF:*3[7S\'UV9J*+:Z.O//S4_KZA[O
MY_6:?_KZ_4#ZDC`@/HV5+E1HI-XZ18-%"3YLQT=/G'OOC=FVW=*I:KNE_==O
M$6Z7NRROOGOX--OI[@'W?/V(MFX($GC0<P9I;+NWSYPBT9M4=/Y[K.'+C=-%
M!+7S^>RBN^NFO]_OF`?5LY;O&Z#MHNBZ:N44W#9RV5T7;N$%M/%$ED%DMMDU
M454]M=TU$]MM-]-O-M=O?/?/<`^V`>+4D/V<?I-7[+9U^>HV_3:ND/7'ZE%N
MF[6;_D^;_F?GI-54G*B7X?S-&ZB:VVOB>^NWH'\,2PHIL\U&$QY'8<\5'D-6
M+QL[V8OT?-?5F+SQNHIZU>)>;:^JME_P+)^;:^[:>?7S`,A@&-(&1`GU#PJ5
M&C/77N^K;P@^:L_7&R?X/%/$/'*J?JWNGJJ?X_$_Q>Z_F:?B^GX]?J![-'+=
M199LFNBHX;:I;.$-%=-ED-5_-_4-EDM=O=TM5O$]_4O=]=?%/--_=/KYK[]`
M/M@#`&`,`8!\?U+?]1XT_4(_J_4=G/C7\U/]1ZWU4U2V7\1_%^9ZCJKOJGLK
MYK^#Q3;73W;\7OGF`?;`/%J2';_B_`_9;_@561W_``ND-OP+-U=T%TMOHI[^
M%5!=-1%9/WZ;IJI[I[^:[Z[>>`<[U^?/DF466W1^1ZKT$=U5-TD/]PR.*_DI
M;;^^II?F[=">;*?EZ^^:?F;>>;;_`$_%[YY[[DORO)_N:FG]/JREOR'\J?)5
M,>(^EHO_`+XT:OOPW5YEEM34'X;$AY=8VNZK7;:,@"0NZY$0:$7NNOOY*C0&
M35]\3VT\:[^;>^^+\KR_DM-5*J3TX:WZE`*YYZZAFO8W'A:DP<AHDM"I=<A4
MY=9SX70/+\3KT66Y[LN/HJR4@/M+1K/4)2](I0T7'"A@*@--'F!]LN]>,$1S
MI?I/;^34I*J8<I6UM_U+_,].IW,_W>?DK_\`YD=7_P#R$1K_`/Z%Q?E>3_<Q
M-/Z?5FMW'1/9OO(7;\1M#HD#U(6L+DJ]X96D%@W-8ZGSWDX.UC+A@QNS="K,
MG2LD='W+UJ'8A]F++;QXLBHDZWVV]1VM]_:/NRIK52XB*DW>;2<<(Y0GRA\Q
MNK(CE;12Q),TJ7CGF6I:(N@8Q0,V,^Y_-=,`)Q9M8M4"$?DS-:]*"K8[8E?A
MFZ<;/'2,-BL1E(.+DI6['#GPU-+B7=U-NUI2L^U3AOQV-_8QWY1?XW<P7Z^C
MUOEP06G"D+Z"E*4":A>A3W/[CNH:0CT(CXQS$$A.UIM:L_;DLF_CZ&0FPYA4
MT8E#@9'8/:,CT2#/GSYZCZ(:\E-IT;WG.+V>6]]*GB/R:TE3=KP"@!7=:]I(
M]/?)#8P.9[1F-R*+GB25K"Y+S>+T8>T5*GLTB%E0<R[E88FM,(%5R1O:<Q=\
M[,ET(1`8\'TMJ=,10MY_+#WV>;-X?+.W?(\0OJ:R3KZ2=1R&QI!$I/=U@5M5
M=+6'&H<QJI'G[4%%78DJ(COL.:2"1:2A\=EX(F1E<A.,"`1HD$^U([,7+AV,
M.+1PI=YGS.5#CXY_(C3G6#.G>6PM-V/*?EOHTE6TSJFEX%&YX&Y8C?2G)<V\
M/0ATE$UVW\)X-^U)1/!X)VQ?P-D^C;\FZ`.=$'.B@UJ<J:I6AY;:G34O.\<G
MGLN2_,9&GL-A\1(]`$H]%;/ZUB,$GR5?162RB=$(OU0S#\WE+[:#:V7&E*U,
M\][*.VYYTM4$.E`U8^:.SYA*F$4_.%2HWC^FTM1]-TKYGOQ!(]V+?)4(@5MR
M$')>QBLOL/MWI&$0`5`Q->M8W3_/L"7N9WSV5'QP50,XL&112S23J$L=I0\,
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M-J=INYF;KHO"RQ>2Z/QCR7IF1T%)_.I@]DLYH&MJ4B8J?L[=TW)S6`^!8L1&
M2,%'Y%4=,6-%(RF<(2(`R`VG&2\T3?!";]*7R")/XNJW$JB;<>3XRY[IQT1T
M7P9&`,`8`P!@'A)HOG(T@W%ODQA)=B[1'$E6>I!(>^504T:/E&&RS;5\FT<;
M)K[L]G"&KG5/U'U9+S?\>H'/@;S_`/(ZW(L'!+Y%JS)#D'K59^.2X3CC!5^R
M273W=,DWVM_N-F2CI#51#1WJW7V;;*>+>(J^Z?@VE^5Y?R:FG]/JS3OE1D/;
M]=4(:M'BZ=G4I4#9#XW_``DA?,+OH2:3(S,I0%CZ4L'NA$A2.Q837P5^5DQG
M8;#)<JNT&;;),U'/J#9:_/G^&*8F*L<S'R<%%/A0C%T<\OKRXY\9=3G:4]A;
M"[:;OKHCD6V.>&48M(\07B]O0%V'M,H8VDI(\:5BMS,$F$R50.ECEHN/&`/5
M%3S<:_$:<56G#2<VV>%M;P1T<&T!\CK<B/<$_D6K,D-0>M5B`Y+A2.#U2#%)
M=/=VR3?ZW^YV9*.D-5$-'>K=?9MLIXMXBK[I^#:7Y7E_)F:?T^K/\^5^DY%T
M;PC;5)QB.R>4D+!F'/`EZ'ANJWLF]C#;I:GRLT)B5$-%%6JP"'CSI]5_JGO]
MO:C%WVVONK?;S*2EPYXGV9Q?>4%\DAV-=@\SSFFB=I3?HOH7EFB97<I@^;KF
ML[JY0H:HUWEA6G*+1"Q6<[P`C?5>P8%4TQ\'Q:5NPUDVE(APH.[W'>-V[GK_
M`(.DTS2T\)N(F*F[))V<.ZZ(P-E<V]'2?E?E"FNB^=+B)S?C$]TE08:116C8
MQW93,EA/L<A+2DW\DIF<AH#*+-C\GJQ097\7Z'ACBO9774U@DX\-:Q!.<J:-
M'SY_""J2;TNU4/.E];J8OMB'T-.FG*=O2\!=XN>_';-MNL+,XFX"@?)D^AD*
M5E@+EF_:XK^8BY&N#Z?FDD+R.J&58RDA!B<E);6(:,DF,;]&$"\P=LDUB`NI
M+3%5E54ZO]U+:S3O*FS1;*1UG\@'OR.-/D*3H<@9@-9W/!^2_44YO)VEJ2/C
MY%D]K6U9+'>=6];;BCT2.7K.''4(F:>6>P.>PZN@K%*$O1R>A589FG1IF[4X
M4:LJ\SCZ8C+V*_5=45EU9;O%$+-<+W=#.O(;W.\F'3WR,CJR>'XQ9L,F]C6N
MTEK"273#&9V3S:OKKA$C@84(,D2VT2KIPZ09SAE7;2#CR3\693>JT0J)PX6V
M+9Z[2V7B[?I%B8ZWO.;=#\)61WQ75C\P5'7O)`N"QUF>9U794>E%INK9BZLR
MW,#"'-$EGI.0U;)DNA&.X90>$C?Y;.6)DHHV"K"4OZ4E5I<MU=5:.Z5[>ESR
M363_`"9,>DIJ,B+3HIGZPM&5"HS#D8G!)%R2TXW:<M/7T:DS&T7T<=3B0]-:
M=#:,&:3=Y,W4G*&OS&+Z(?PY4V?X"T0ICS<S/&(C_,V-'I\9\JX:54](IG:/
M4DG9(2#XOS<XB<K@U4)1DAY>8@T-[U#G]`M4AC*,>J%,<%5;#V1EBI7)%ZY*
M$'A8H]\>)`]&+6UP[WC\N^_/7I!7CGGH#Y3[=Y_ULJLI5U+8S.5\[QXS:DJE
M%6U&Q=`IJGUK`XZ4<\7IJ0@(#L"6:\C>7,<48D=IF,]FH:#_`'/1*?.]XRX>
M'SY?^;%J5"J:A**K7;M#_-?&J/"22;8G/RQC:JA!RN''7IT*+N7I#^'((K5\
M1C=\VM4##VJ5J%2N:3@ZDL;2I;#V,ZVV&AJ=H\_-*NE,-="#5\'X@=&C5"HB
MT3>+Q.Z69B]]FX<IVIZ?S8%8=[![_>6]6=?6]&I0/N_Y/"=6QZ+0:%,JT)SR
M:<^4Y[S));A^SQ)(<?C4RG8F5Q@E;$J?^ZO=`R(MQ*QR#KZ/@3IB'_LG+=FY
MCBSQZ'3#XLSG7)ZL;(<=5NK6>;)2V+:5]O=L00B=AMM=ZZBZUBL5-O(56K\Y
M&4+`W,*@R+^!C&[5ZY.A(R<E<+%1HQN,U1*CWZV].M\V.HN#(P!@#`&`,`CB
MVXY8TLKV0Q^IK):5#8)#49Y'K$?P<=9#2.[-30YZ3V5A14L#8&ON@9N1":>.
M"K7]`H2T*)>K+,4VZH+JIZ&E3F!7T<C-6#(-T"+@<EBQ6-NK2E#FG`4N1M86
M-'I-Y(*9`7LG&MJ]4DQ#54@B1&/#2H+17QDW0=II^*^BVO;M?!1#Y,Z1M2PY
M1RW9*\)*]-\H4U;B$NZ-XKC<'C<DD5H,_858@.*6.U:2$^,:6<UJV;R&&2Q>
MDWS1=I(/`/L@8IE#8<>*6%I:4[-J$^+J>TJ5/V9B/C6I.R(;='8=S@*S-\J<
M>W7+H40H;D&4UW&J]D(*2Q^!14!8UUK0V,GB3"K&UC2,63\3A'K$67/:(HRN
M2"`S[]+J4%J::I4S4LU3.[A3O;OP="8+!+W!`[58SJ_AD]-RHO(7=5G6M/`X
M@G4X@@T<(QX.]$LI,31L12.NU&[Q4F4<A536K;ULX;M=%]E-1FUK=[Y.=/R0
M<JW=T%2/#5/O%X7>DQCO9=9R&VIY.>>@\]JGT`+I^^Q9.?6)07LH:@'4)1-'
M(^.>`EI8BR1?$1VWA#\WU/ST:IJ2=3NII:4.\RL.#E;7G(KFNO>.1'47Q_V#
M=D-JJR_DZ;WK4$/YP`VO1\>G]M&J,>UK(><*[^T-8M%N?I8/$/2]2[))LW<0
M??N@:2((FQI5UZ-ZK5::HE40Y:=DYE\K'&(L?-?D3H6"5C62/5G(IOJ77_<.
M&U'S_%Y?3CSLR.\QV7Y>]H2H_`)W6L8M.#R$5,CU`2:G:[$7G%Y^$TC1:M-Q
MZL]:#`B&AQ\^?+A-2VJH^J7#TRH5UM9RX:WQ)TAZFIBU+4^+SDZ$VS1]@LK'
MBKGF*06G6M)QR/\`0OM3&X9&_/'^Q^F;B.6I_O05W"S^@\1**X+RZ7RX^BHC
M,$),7-1GU\X&$TJJFKKZHFTSUM#C]MRB48A_R>03FMI%J(A5M<XCJWYQ[5LJ
MLH93=2`X@+LNXP_3M<O^>4Y-3-C[78ZIMU:<&D5BS!WSG%Y6-%"&:3P8*:@(
MZEM&FPU]&J\9I5[VAZKJ)V4Q._5RQTD>^5*!5];U;5D2[$G4C`]$=)(49<H:
M-5V\*F8>#YPI&7TL/G0F-T"9UED;E=Y2RU@<4+I>U=7@SV)E(_8$F?,F,7"+
M"+0VIC"E7_4TX^KB'OFR-`-<Q=NSVS[0ET0@$Z@MG6%;_;LMAUBO1#N)C(W,
M+8^(#GFI*]FVY3?5OI&AZ]\!C,3'%/?R]1DE`/VVNOBPW=/!9I^F<)4IK.*W
M*ZV\R3Z_C*U/T)9)KCWXTNF>7[B!\[<ZU;8MBQ$*$J>93&7ZVG'AD^:"(#[$
MKB'7>>K^-O)E.Y;T($JRQ9[)HZZ>QR`R-U(2K`@+$=W>M57<;VB=\3A*8Y*U
M/.A/E,23%U`_F/7J'0(KF?HZ>5-$(;3]=OC4YL^-]ER.$\Q%[]1D]=K*"JH.
M50YC+&:251.("W071-_+3X\]LKX5%BC-HE)MMXT_5%\S,9O$6.D_R4\9VGV-
MT;P@)80BDRL;C53]EL+-EMZ\\*],TW`3TW#<[M8]MK"UY[6VC*9DG(62J5S(
MW4DU4'N`A!;P<]V\4U3$HJ5*JS,TPDX;B9O#MR5VAO(W6_)=Z[>4;->@)'$Z
MZ)_#S1"YGV/Q@E&K]J&(G)+672\GG.I>-R`RJUKVM3CTPI[&I.'3@7ZU%^Y=
M%7#(<Z:`VFKI7UOL\TI>-NJ9'\6G'RXS<[9@MOYUY6T>GDTYB18NI?"8+();
M4>Y;M3R)7ZG$Y*XHB$04B/`\VE6DA=J!8E*:U;A&29:/2&5.QDD+K!]%L.)P
MVD_I;4J9_-VS&();ED#^3I:RY,$"7OU^Q@#>Z^I*R#/Q\9IY;=S2M=<@Q::T
M+/M##VG':^\CL;H\<\C3V8I;)HF]GI>*Q\>!_6;KZA-'"PG,O.J]IC&W3J:T
MUM;Y;BM[4`Z$0V_Q:_E:U(,M,%-HE&E*%DLDE?#)Z52:1.4@M1`&M?:ANN5P
M$2D[4E;<AFPHZ.+>*B(=6;@2.=A%,.ZZ1G\T<W^G&WB:^4G_`,FG^[K`7$24
M^05V96L*I]>GS5D535<>LP`5>4/83NQ17.0B!U)*YJ5K!GT"TK]K)2S:JY,&
M0&/![&MI&]A+N?F`813+3TXM#?*S?,3][DQL+/\`E#9RRNJ^F\?O=\<FLL^+
MLN<G,/J>+M8%'X$[6;!NZU)"5'MCT;A)I8C_`-ZED2^Z%20--_L4AFFL2&O2
MK,/H_P#/=S/]/S')4:F*Y^1&HJF;[P&$=$*6;"^;+?ATKG,TJN"DKD'%S/R)
MUI(+%&T],9/"D%9@8)\U.K#L>KPBS^01>6S?30RT8'"+`.T;3PYXG/SP+],J
M<3B?]MI4VO9XL3;T!:'R.L8M3:'.`CY"WNHG:;R@/+;:KJK=)!.&0OH6.,1D
M4M6NH-2Q4HU4TIQ*0D8V[M:44^5,PS;3QW"Y1:[EM^EI$J9<Z?6%;9M\YS?A
M22)5O.EZB4[@\)53-F7IGK7MV8"O'`1TG]PB\Z[&O2:0XZU^NO\`6C9)$SX6
M0"7.O]!V+)LW2?ONBVON#-5W_P!:?2E)^I^@_!D8`P!@#`&`,`8`P!@#`&`8
MMF#"CR)<PP#BV):0*,ECQ1F/:-B)M8:ST'CE2[U%'1R248,$DV++=ZJMLU9I
MZ-D/4T=-=/`,I@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#%A0
M86-"V8..!Q8`(.3]1'APH]H*%L$=E-U=DF8]BB@T:I^JJ**>IH(Z:^J;[[^^
M?BVV]]`RF`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#%_8POIKR2^A
MQ?[CU%[`]3_V]I]Z\"[.]7^P?PK^3^N\%[/M-'NP_P`7_2>N]=7/J/YVOF_@
M&4P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`-?VED6TVVTWDL?UWUV]UVUV,CM=M=M
M??IMKMKZY\]\V\]\]\]\]\^OGO\`+W`-&LRWP=>U[-)T+&O[,(1"-&)$UKZO
MB47>3B8J"&2KW]OQ)D=D`$4^D!'5'9N+8NR['QZ[V2:HJ^N%DD]P7EW.?W,'
MS$<H=AVZK4%"-+(EA,4:/MIC)GD<'1V*5U%@]>1:8#YI/GI\X.?1YM*Y9)U:
MBC,1W'N+$<6!$YSX2B(N,10I(DAIT.E2[??ML[7G$1>;'3G]W13_`!/'O_C0
MW_ZG!DTBT[H@]2U):]S&WBAV*TW6\UM&6LXDJ,,'E8Y!(R5E1=`4S6),6:Y5
MR.#NTAC=\1'-7+SU))9ZU2]W73%2EI++<>95VJ/DHY=N0"QE\0D)S6$N.3%>
MRB,S+#AK,!&JK&R621&5!Y+ND:=$1<_@T@B,D'3&/>CEF0AR(>-]3+ERCLCX
M*Z6O./$CU#Y8N<"'*%7]9AXM;I`#;UQ;\_1&J'H6"1&WFMS(E)<-<P&8LYY8
ML6KJ!%6R4).%574PL@,)W&>BO6Q!P0-B![P-+F.D^'SU/H>^4.#B5:U%C>6.
MT95,;#J"R[R>UR%JB$C+!KROJCGPBM9R3FL8FMJQ)V]W:2<\'^P_PZVGS2:A
M20^0PIY(`I$>]=!ILW-,)I3.6U.R?C,&[23Y,^58[(^+0"4CD4C;=X#&!ZE)
M-'`'CN-BHV=\A[*)R.S7#Y^.)P83,I98$,KV-;.Q3MX\GI]M'73-DJW(+,PT
MU?5;\MGZSY0Y-?G7R?4E`IY/`+ZMK\,U34=LQZB[BZACT)C;SGRJ[6D3R-#=
M(K*C+N<,+#=I`2TPC0>8R:*5O)8A$"A5%I(#['=N_P#68:7$RI:;2O+2\([7
ME[&^=3=Y0;E>PH%5Q:HKNMN8S^N[+M9DPJ%A5BR(2"U,1A@N8F3SRSK8J]MI
MLV=SR/\`C)@'W,D'NBCK9-KK^G^FX*F9<I)-*\Y<\)\,R4'^0#F.91!_9#^?
MA:VK`=2%`W^YL6VI3`*^CS6"=(H2I:N/#+(U,M)7$RKG:)NVJNDSC<<$EW[U
MH/AAB5O&AU$,#I:MERZ85[J)]SW[?(!QMY906K=>BJE4-GZ&,=+C#B<^B7L'
M<TP%*>C'4S1FNQG6/.1^VK4T7T59O7**,>C4A.OE68T?^H5#35$P\QC=_/4V
M]_V?R`)A4$LDKU-SP,KVT"[P!6\X(7-7C*)SLX.=>L28>)2!S(4A4@)BGOGK
M,JQ&.G+D8[\];/TFZWGNF"0\0Y65#L:77O?G*5@S&X:[\N"#0BP*.EUKQF<P
M>Q)O`XO+D0]+?D[3RS&<>4E3HK_"P8W45>;3(FU&-6[)D_=DVXY%HKMX+I<)
MQ9Q=)Q?;N;>GVKQTM`Y;::'5?.:]9P(^SBDVL%"Z:Y7A<3E!+1%4;')#)DI'
MN&$'22;A#<<)?/$7[_55/UH@M^+S!-+LH<O%G?L8%UW+S0.G$LBABS(N#B\-
MYZK'ITI=IF5PH?1"]56Y.)]7\,)#K+6D_@QRX?'*[*[_`)FR"(9PR)Q_<69)
M.R*C-J&EQ,;M=95\&QG^SN0(K$8)/Y/U/SK'(+:+$R3K:9G;IKD3%)\-CB7J
MTA(P^0/Y&W$R)B!T\_\`&G@EVZ;BU-DT7RB"JB>FP:7B'*RH=B1`UY4K(B`<
M3'[>K$X4D,NE$``#0\]BQ)^;G<($NCTTA8AFR*K.",KB(-B],R:/,TUBP$2T
M<D2C1JS046U$A\$I8`P!@#`/X44T2TW55WT333TV4444V\TT3TT\]VWWWWV]
M\UUTUU\]VVVV]\\U\\]]]]\\\P#`_NZ*?XGCW_QH;_\`4X!2WOOY"*>^/OG0
MUTA8`PY8L;"2:*QA>,UL_B[V4KN961^VM'2"!LZ(8>M&BO\`6/-MWNBFJ7\T
M]%-OZ.#5-+J<*)ZE*?C<^>7F?Y+KGF%*5I6-MU>:AM8$[2>';54@#`"]%BY7
M$(FJ)8J@)B;=[%UG<Q9O$4U6R3?UDR?;;+ZJZI)J#5?X;H4MJ[BS?[([4?NZ
M*?XGCW_QH;_]3@YD"=4=:U-R'SO8?3EDJ'I!6U8;1763I5TS&2B2>>2Z:1J#
M#_1XM8P*;/-FQ65#G;YO]Q2=>#$W2K)!Z[U;LG(J4N%N1/(?D=YO!0#HZSVK
MN62N%<VQ2GI:8,0X0*.Z6@TOZ&`II4`RFTTCZ2DM-SM*41N.@F136-IO).<'
M#TG.S1;TAH^?/,NEVZSX1F32Y]\I-!1&M.5K'BL/MNX=^QX<;GE+06MAU=-Y
ML0CT3C<?DTR3*I639==Q9M)XLC)A0=[!!LJ+3@I)-G@6,QXZX&D?6H:7]4PM
M+ASRW"_SB#`3CY8J5@!R6-3E']6?LVL:VI.VKKL_6J@(Z,45![Y%$#41(VQ%
M)#/0ER@'01@',J3T8/JPR0AOH<G]V;Z:-%-\%T.,J[:2O=KBT=KW+`O.Z*'9
M=EQSAC=[(U[CE%6>6F-,-!+1S7&J2^IXB-@;J5IE/5T+)-1**2FP!,9\$;I.
M8-'R)W8FEY^D;.A-+TZMICY\^Y$<$^3ZDI_/($!8UM?@6JK=MB0T;3?4$AA,
M;9\^6M:L==R4=O%HH99S<A831(^4A\E$PV32RMXS$9@3$K-(^>?;N&'KL'2U
M-U*4M;K'2'F\-QN?UTO\G%/\LV785>SFI^@I.)IRMJSMRZ+3KV)P0]7-35_:
M\IE\1B\@EGW.RP,^>(IDH-(URR$0@<I<L1[35SJBOLI^5J"I;4IJ[A*\MI)\
M1ONT2S57?/*MLR2V82,MZ$12>TK,+HB\]@,\FT$CLV&":&E9"(SZRMHUY*GI
M1K5K9\-</FDQ*H#&V@C9)\6;B?=MD=!'2U#BSB_?;OT-E8]O\9$XO'9N.ZRY
MN>P^7RMQ`XI)VUVUNJ"DDW:*AD7</!%-))ZS*RAJI(H_^H`L55RB&AP.HJUU
M3)LMU@TOAVN[,QXKO;AP\9'QT'V/RX9/EST<BXH**ORK")0G))AZKK$P(]BS
ME*SEZ6DJB*J()@V34<E%T]D&2:RWGX,#35G2XSA[9-L;]<\J.R-J!VW2M"KE
M:,9D"-TCDK=@.[RIAXE[N,+/[';^'_S88R%$TE19-U(=1Z`\FFH.>*(O=-D/
M`AVL[XL[]N3R(]C\CKBZP-H]0<^JA[L*NP=/%-+BK[UA:)H>30"$!$`=?N#\
MF6$V!QTU!OF`/=ZZ9FW;0.Y22).D&J@:7>SMFSMO?BUSRVQV7RW2E>3.SY_>
ME9#HO!1MM/C'C&9QXL;=O*+6]8VS&H^`'DERTAF4%->MXS(XD(:NSXF4OA\<
M?L6Y=\V:*`J6W"3FWKCS--"_(!R<0C<RGAZZ:R@%90]Y5C+^*4\M:H0L!D:]
MQ5H!M:$Z`S3:P"*K9<A%S[?=%A*64:)E/6CTK'61N+^,Y"\%TN8AS>R3FSCC
MG@WF0]A\NQT^M"U+\J`K8^U>O;2#U8#LN"D;*E4(9Q-[.4CD4AWDA2+'&)2)
MCW4@$/&J7K$@&2W+I._M2:SU,335F'&)BTXR253-IQR]*>JB[8>V+LXE<5:P
M6TXLTD#9JR/-8Y8,7%RT(V-LV+XFQ:%T!A=JD2;,R1!J@\U62;OG:.NCA01V
ML25@#`&`?!RZ;,T%'3QP@T;(^>;*N'*J:""6OOOFOFRBJNVJ>GGNWOFOGNVW
MGGU]\\_M]\P#"_NZ*?XGCW_QH;_]3@%(>^ODIYF^.JD=+ONTV5D#$G)&4.B,
M)K9,/(YO,90_9/R6@\4Q>F@XIFS9#!;\D6,FBXT8Q;-]4-5W!5\*&$!JFEU.
M%_"[FN_'E\IO+7R3U7(++I0H>B;R%GF\;G=>VB@$CTTBI)\TV?"G*R0TX;"E
M`9QLB[4#%Q)=VFXV8/VKQ%@09.F2(54.AP]\-8.@'[NBG^)X]_\`&AO_`-3@
MR5VZ<ZVAG,46J^1OX-9-POKCN`%1U?Q"E6L&-24W.I#&9G+&27YDXGE?QAL-
M2%P0YJ[>.)+HJB[_`$:.K535951`5*9NE"EMSCP3>Y5=M\LU3&M:Y%0GG?K"
MPK'L&9=&U^YIV)0JJO;&@4LY6>0MI;XF9(R"Z`$1<;C/W]'5Q"\%ETV;&DEW
M";57]6W]:[#6AWNH47O#G&T^<1O!G7'RI4@>$U^_HRJ.C^H"DWIA/H`G$:*K
MR//I96M6[R(Y#O"MC#;$G-<MQDB4F43F<29UZ!?2.P2AZ&29J*C#Y(?XX6$T
MN\M*'%]WTA/E7Q#)VO\`[5J[G6B:^ON7QRQR0BUI!6T1KZ#M(\+AUAF9=:S;
M]9%(R:&6_(*S`5X6T;:.O3VEFR6&(1YTR<BBB[<S^G'+OGSYZD2EQ\])GPD\
M4<[WYG5@<(FMN3X3RL3GJYQH&K7JP_#J3LO9U'I9^RB/K8#(9.H/DHC<\HQT
M$RZ$&I5"Y"/+ABP"1DAI1FY5#2]OJC=2U=3\GA\&SONX^+AD'&6:1ZVYK8UR
M;EA2!AYX[N^M6\/*34&GHN:BH^2*R740[/AVRB;PH*0=[O![%5)\[219JIK[
M!I>(<YB&0\9^3#FJ-V)+Z^DRLTC^L#L*Z:]EDW(APFT%$+4)S-".L9_*U2;"
M2O2RT/1JF>"OM;]L#6)O9"R*L%`[4>BS+/A=+MU2:6]VTO8RE1_(-6-B")5*
MK#K"\^58%&ZYCMO-+.ZFBD5K6KI)64J?^#0LH86(+G,LB4<>+N56/JT%L4M"
M+*:MR;%RO#=$-G"C<'3LFJGCZ9=_*_=2NI*#GM_C%F+@QMYUIS6T$6<F@K7!
M)U>%:-V4\2<GWD414B#A:2Z)R)/:4#B,<VW%;.M4SP]^(4]T?LW+=(2'P_)F
MG]3=N0_EB;TY6Y.IKGMZ;7>'M601$#3[*KU5606FT8,XFA`^^M*U*M%,TTDK
M!!;#4&#XF[>_ED//TZ/K=+QP*J93<I)1F=YC"?!XJX^0OF6QH>-L?:9LJ[K0
MASG673R\_MJ10"O`8*NK6DTLB$<2E#`[-4I3&R21V'D6*Y0Q'6D%+.7#1C$9
MG)B29-D.!TM;2Y=-KW4?OW,[[W[QSO9%6U>SZ'J@F=N6H;$O6O"XN=Q5]#)!
M6%7N$499)6DQ0,;`%V[9%*2$VVC5XXW7"U_9!C;\H=!)&Y8AIJAN'9I.V[^>
MJY-E==L<<,:X`W$]ZMYR9U-*)$XB,;LQW=5<MX&=E3/Q7=[&Q,K6D>@-^=8)
MH+KOQ39\H^8MT%W#M!%!%1342',0Y65#E&L0+O3EF>VM:U(IVU"XE:E2SN00
M<C")Q,X-'Y-+T8M5L'N`].X"`]E+HW(JZ&PZ=-5W<H4'#TV[B/RW=9JF-!JD
M5@TN$XL_W:]T;4,[4X[-0V=V*&ZKYS+P"K]@:=D3<7=5<$(E`]Y/K^*,Z2Z0
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M5K*<"8?)'K)9N*DCV(;-`"4C3#NE$WVHAP79M7BJ.B3O95MZJ@J"KJF]537&
MIKU*`<O_`.S>\J<W6RK."JE>=`P8T:/(3"M[^H6!6`S*0YQ7D691;>*$7RFB
M-;V``MP7+9F5.Q,2A#Y-")LI7RL!&J1:+20:-/\`%J:BZZIM;[[NULYO.QTX
M_P"RB^,G_P!@+D+_`.7^L_\`[<P9UU_JJ_N?[GO+?'#R:!ICHVJ^>Z,I/F@U
MT91MBT?(I_5E0Q$&5:B)Y%#4<1>$6D?2C3B1L03LOJ:3`KF1[=\Y:)I>O&>^
MVCI$-54IMMPT[MO!1N3?"!$G\AOK:&="22OZZZ>JJG*HN:O!$'_4)N!,5L"-
M3"^WE>FO)VQ3@2O2XR.KBY6U\"'T(](99-IIK[(GL@V&M1K_`%':4FTVT_"W
M]KNNT&_//B6+1J.7C":IZ67<UY<MO5[>)"LNH:A%]904Y-0<,*0:SQ=M,9S-
M@1*RX9:PU&`&M6`XE!)1!Y=78@T+EY1H]=!]!-=TVL*%#TM;J,XOYFL5G\2]
MQT)I4Y&@>R(S`91`Z7Z)I(V[-\Q[S**I1CHR\0%Y%FE-0S6^XVSJ$'7I:-"H
M[6L8*/[-%!`2'Y1#PMMM[I@.N9E9:>>%%[7G>(N8*4?!164FB1J*?[R%U`$8
MOS?1/.'-SB,/GH%O4`>@$=)?$Y9.0PV2-Q%U'WG0&B5X/T'C6$#FY)@&CPI!
MA]I;'?05?*3EMOK.>UK;GTO3XFNCIX&M6"5IV^%B='WK;2=_7=1DCYX9EA]E
M6<9(U](;,"-K*966WDU?UA8LN@6LD3#"`AR70Q<\:&CIB7#/%1^XJJIWINE"
M<X7:+M>3+(=W?'!MV;;M-VUI*Z!;J5/6MLUMM!^C^31/5L$+HVH;KHTI*Q<?
M,VQ6;6,S"->U]JP#F?-3*FK&0%D?-$-5=]5AFFK2FKWBZJTM1/1SD@X/\.I&
M(,822B?4A<E854QGAAO6LJM"L/+`$^33B93H-,::L6/(6/&7DUB4Z&]!F!K2
M("9'#"U>^Q>-D0TU+/V3=5J+KZ6;JF.*M.+.'].;S)K)_P"$_<W"GL-3Z9W8
M:32E+DKJTBC6HUQZQ:<VKU/MV*TFU<-`%K`DJPB4<M_?T:I6R:LGW*5OYM&6
MDS!R!PM,\#7>8FZ:OLE$.U[;\WAX-L#?$M8$.\`3"`]-0\%<I`;TQ&;:ELQH
M657I!YG&>HCM5FY@ZC<%OOHRRI`'G@'VGHBW%2FQK&M\)(?-S/DYA<E9E%&"
M8:E>SCZ8NDUI3W2ZO"71FU3?XE&$O0EZ25Y^BEI;:G=]FN7FM5L5G&F_;?.Q
MOG]00XU9382W=;5L@49R?Q^B@Q0EWVEL!3%1)#\@BT#7TVI7]KGU/X+_`!1E
M&,Q"VE6U^`HO9$"D7)DOK+]STEY,*X%R#F#GBR><%=9K!&5I1-W+A,WB-G%B
M@U(-*84<KTV*!KB9`8T:*ZN`U<KF8<9:=K.#01WPN-8R+ART2Z,6;3*NH;SQ
MK#2TAJ!@<B?EMT/U9>O62TODL&93X"W+5K+9;>YR,LJB$F(ZZA$>!@U0MB.B
M#)HLS#7M%I;ZW25GV7&Y5'K3XL^I8K#),'YPU<7;8O1M&]NU7?TR;1RF8G7*
M!_K>TA=N+_MZNK-N.,%:2A`R8;*_DR:"'^@9@RCHMR@[@AR8.`\Q9BTU*5-D
MG2UF;6RE=[WCNE8OER_Q'.H?\@]Y=)3"+%X95`"$@X_3,8+'X47%RZ\9I"JW
MKWH3HB+@XB;-O(F,ED"H2GHL%;S38/+WKM]8Q)]&@OAM=8L(VM"67OV4PL7S
MU5D=AL&!@#`&`8*4Q>-S>,R*%S("'E40EX(O%Y5&)".:%P$CC9\>X%'`)L2_
M278E!!<8[=#R0YX@LU>LW"S9PDHBKOIZ!1O_`+*+XR?_`&`N0O\`Y?ZS_P#M
MS!K77^JK^Y_N4W[O^!CC'J3GHQ4E"5!SKR'8A&21<RRNF!\Z0Y[(1@T(0_5E
M`:*$??P0EZV/M_\`N3K;20HI:I_S5;.M?ZO!JG\2JERVZEPZG_)3/XZO]F,I
MKD"XI=8G1]A51VW##]:$X6'K*QN:A+`-&Y.]E,2.-9VT5DMA6*RV)L!0`O'T
MDT0[1UZUDCO;0FDEJLU=C5?XSJ4).F\RJO3".RG_`&47QD_^P%R%_P#+_6?_
M`-N8.>NO]57]S_<_VP?CBYR=<]SCGWGVN*JY<"6#85*6%)GU65/&A;(P0IFW
M8%:+-,P``+1-(LN5;0G>+H/W9#W8*@85(I-WWC;<:\#4YEMO.][KER4S&_")
M"PAF?QR/=$V#%.>I]U97?3FU0Q$0\CDIB+.I(A)=*SJ&$6RQFWZN.0>"6V;$
M6;$]V<0_5@1<+B<#&:-DAODEV&M>[2;AJ>^6URU;QD]AOX>S[:EF?/L/Z)@\
MKIV/6I=\SA]8=5<Q`>GX0*B%W;"#JP4JB;LV&RHA8U;V%[.9G75L@99$EVJ%
M@F8Y(HG($FS4K@FM3,.;7IJ=+MX;[^YX-?AUL$=$[!J&/]GD$:1O'FWF[F&^
MADFI!.77+-8)S]$I'"W;B*V\\MQD$A!*P`<ND#!\J_JN9[QUDY9HBE5G+!-[
MN+KQ:ZJ=2O9-M/$;1RC>R_Q"#"-LENC&G2]FBN@->LH3TK##K9J5VJ:+QVND
M!=?Q&I']-?OE-A)&S/G-L:HU]-]Y0)-/FDG+R5,>S25VC*@FNT0HTQUYS?>^
M/W-0"_%'?$+FG-\;C79@\[QSS'T0%O"O>6Y51;%J:T2&SR9342/-7H%GGWHT
M0KAW.2:D#W1A`0>72$QT7.VYO0<F5T#4H?T_4U#<].(W[]N"W<U^-_GZV^P)
MEUG>,0@MS.C%7TE7T(@<]@+$VPKPM3\LL^6*R]D2)%GX\TXE#J?B=/1;R+MM
M`JT.9O4WY%1_XF/$U-4Z4VKMV>927V?F0++_`(I7IO>0$HKT:]@4G+V1\BME
M#Y0'JD6]*!BO?`M4:BFGX0F:C5ZK4/X6&^CYRA^.<)#FZ*:$*52;.6HNI6M*
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M\^?/6Y%7"2BUF[_[72\)1EM.\.,FRVW\0\RO.516P;,Z;`$9@3`S*%7HQB5+
MS&J*XGL%EMVB[K\$0F#U#T5`5P9D81';@UI#=LCZ/]DVR[26RD:5EH(,1:@J
MXV[7O,1=QZ+2?2:?$#(YV6M\>9Z='H5G.T?DB_9,584=LG*X:^^2=FZ7L%W(
MYLXMQP/FB-<21VH1A;,?"H5L]$>JB#;MP\40-M!=>+76G?\`2[;&:6^*^S6\
MV:WB!Z>@['H`78E:V*'-%^;GDAIU!_%>+4.,)D-*5,ZO9`P7:2B-^OIK&7/E
MDCWD+,+("'>\N&ZD%"0BJ41%H:S?*>8Z+:_E&+E/Q)6#,KB@]CR3KU8O&X#O
M#B`.&J4TZ`M&9<#R?)>73V@B,P*XH51,<"R#:4EK*:_9Z(1F((D[]@S6;+P%
MD,"L@U9A9_\`95=WB,]<G4WG.H]>?^>Z)H?4_P"RS6DZ:K"H]93L+\![276M
MX0#AOA_T+X1+^!_3/@;[CZ+\+%/!_KG])X1>_D_J51AW;?),N`,`8!H-GU76
MEV04[6%PP&'VA7,HU8:2."SV/"Y5$SFHHJQ."_"H$TV>#7WVXT,'%F/KANIZ
MT),&;U#U-PV14T!-JZ</E6*>?]E%\9/_`+`7(7_R_P!9_P#VY@UKK_55_<_W
M*:=S_P"S_<$]:TDI7%4U/5?']B#Y`PDD8M^E:=A@XD@X:-7S!R!EP(/Y%5)?
M$";4BHLY"^R`,X0+,A!1H22]8K-7HU3^)52YEU=&VS7^!/\`9Y^&.0*I+Q"Y
MH#6W:%D28]J;.6;=-.Q!RW&-V[35F/CD#B9E:8^Q($AK^>[?^>R$J1-%'2KI
M\]\:-Q0T8%7XE53E-TKA-^O)>O\`[*+XR?\`V`N0O_E_K/\`^W,&==?ZJO[G
M^YA[M^,7F"U:QH6BXW5]15E0M.=*ANB)!2P&H8PM7-E;L(/8T.*Q0K%V3@"&
M&*G5IXW-.9,JP-N$5X\U;_:E]UT7@\%6TVY;;43+E8W\"N4,^*BUJ1TYS;\X
M=80RO6/*)CJP32C2<<O^6/X&ISIM]7I)M7DB5#WM6^TKDU9.84^;"K,)^>/I
M2,+#49)'5B01V6D`UK3F5.K2W>+J;X<3NO)K!A"/PVJ1*!B890_0PZ+[2+G\
M7S[?WMS4HE<L>N5@'M:;7>*LMM'HW9U..H+90:S[-L$X+<-3YZ)?;CC$&1BK
M]$*U=*B:Y<M;RH<19*,.5"2\,EL9KPF5(<34OQ]"+@'ZI4R#JZ/K2*\*ABE_
M0>Y0=<@_L;Z+WC4Y\G'FDMBTSU]U*DVP.5Q8\+.L`Q,7(]?1ZR#\35]3JC+;
MLXB>&4D9?!V+0I^35<IT,S0]E/,O6W/GG@:E$1L#@;CJN[ZWN5P2J:`*6@]]
M@M=5IY7^T4BE5>24MNNS.."*LX9[H;L'HU_J7F+S2\YTIJ]E+<W?H;OT)\0T
MJN1M>0>)=5NZTBE_6W?UBS.*-:TE.XI,/>G.E)\_I@=58'>M7$C9"!(5"]DP
M;62ORM827><OA$ZJ*2:1X,0P15Q%I=,0^U3?'6/"S,K_`-CI$S9.0Z3ZZ7TE
MB,TDE\$YC&Q,`TC;TB`OOA*K.(#X$4?6FY[[.\$#*W<6$..*BBGJCL\E&]QB
M?@?]P$PUNUKJ+]JG5]_F#>'O!77LFIV657./D(>D_=(13E?58M#Z"\KB/Q\3
M4UAQZ:/)-832.7+^_P"56/882.MX'(YC6-H4=Z!"NWA:$C([(?T1%D&JF95/
M,WG*PK1"VE/K*L454^%^]6LJDE0"+OA^M,6=ROTO4MJ7.=J!25R)UYTYUL4O
M6902!QF2WZ3FD8F8H&><Z1JW97([(%:JCD7TECQ^4;M7;076K.+ITM*?TTI+
M;IBQT2[F^.1/L&8\S2]G*Z0:Z<X1JY(NWAO2G+X[K2`3!M;C&KV'W=[%C5IU
MB@-DL53K3108:4<&%EUCCI3\IIZW]_5C--6E-7O&'#MUA\E>!_PRK``%:)@^
MGRSV94W4_*$-KJ03:K4)6!2F_*/1-O=!QH[*HGI80?[]6)-:VE8`*J4>;C[R
M$12*Q[<+8CD@Q9JLA=>;9;F_*BV;[RYOL>:4?"^M,(XZ#%NDM$"%C5MWC!K]
M)B*>^U,Y02[EGT0MLN<J`*VL_P`;U`,KNQH'&U&,8..;50E<-WD,?+DFAX^M
M,6P:[XPZ&K_H4*7%YGITM8RP7XD[$B;:-S:'=.PX;T&QE]_&)3/I=1MA7/7,
MK`=$5-5M-2IL[K:[^H[%E[N8`(K3L(WCDIE5PRT(I^F)QX]"#$-)J1Y$->T.
M+6E39MY249>$2,4^*IF2($RGMW>)D"?6DIZB7?ZU.%9NMTY+P<KQ)^P-T@4J
M!BD&S/Q96T-2PD4)$>*J[PH?#13/\L^F)JM$?TZ<_P"_5U[>II&OQ`JA&5:D
M87T`-#3FF:K^/.'UP1+TLD;A.TZX!;7"Q$S.>0=M9H5S*XY9S&X2>CR&C93%
MS,)(!Q9D//BA%!LHT%U],NIN^U42EQCKG!KRWPM-%X^NFIT:MY,G48(D'!K2
MH!_D/]NHCW0-[UVF*-=>SW82E4J5CC=8?_`[[AO^9"E=O-K$U/?4ON&N\QZ[
M:=,3S&_-X*W]5?&1U1$1!^5T.KO?EW="Q7O.,=!'XW#:>A=9M-^Q051,EQL0
MJBY[S![UE'47531E+:P`EB75-1FC:5DS]=6.]EZ:0Q&>I553O9+2U+?],[I7
MF7LN]BUO+?!=BPGO5S>LTBY")514W.E61&)CGDBA98#:762E71JE+,Z)AH:,
MF"Q^/"!U"U_$:E:>V`SBLD+."<F>HQWT=Z@2=(^?/GFR.I.F-VWX4RVEYMNT
M^YVNP8&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`I?
MU6GTJ!:R>R*IO.IZFKB(T#<NAIO9H1'QBQL]U&GSNN;.)39VP+,(W%Z_,CQZ
MI]H2!G1KX02+$7H]?4,F).BJ-TVY6^W$=>Y1RK^A.B'7)1$V(M>5HV/5_6-)
MUU;JUVQ"MYI,V,1G\OH?9]!85*JU?BH&9922-VBV.C+!D4?>2H''9$]B[Z'!
MY*.$'0SY\^>I84XV>)5U/-]L>HNKK3H*!;3.;`[-VTUD%P=24?Y6C^*U^XCU
M$1*G=M!D=OY%Q^V$9J_=AAXT38,G3GDI/09^/M8,EX$%BD`WNXJ2?DG/+XS'
M*[HLZA=]B0:F^M53\TDMBO>>;\$UE$K(5;5U'I?+X\;B="S)TH5W"USO6NQ2
M)2&V)37#UR,KALDX;0S\IVU;2CP@7U$B]/53%^O6=ISN:0&^0J;M&P^56)3\
M+C5<E`R,]4D0:TRI=[$*H#]`C:%L&;S=N6KJ.#!R,+2D(.TRFK(L['LX0RF2
M+PDF]CS%P?!TK9S%G:+Q*B]Y::_R:X*^3&9%).';><[.!\550J%P=>&Y>6CY
M08VOX0YEM:O%RAV"CJX!ZCX@0A[B8L)?/(^23.N+#"`FY%W7C%.<AIX<Y]/&
M>T+C$D;E?D[M@:'%3P[5<8CK*O8I?4\NNJ$3$\\FJP2!\YBKH@X\(5EE21X0
M[3*OG9IDE-88_EE>R$*&:2H/*W"3HS%P(NE<\0]KN&[3@VZ8?(/>3^%6C$HW
M4D,@5R1&MNBIWM(II.9#&X6,`4Q4].3O4B.:3"I]9*E.';V]8[N*BLXA8L$[
MC$2D$]6*/8\\'C%@5*E2[2N-V^O1WDL;:_6,ZJZ*5>D"B4-F<H,<N6CTY,BL
M_GBM:`MHK1X:J%I@+$.Q,,E*6\GD;^TAZ[554>.C<9&CR)$JK[IL-'NA$IWW
M2Q.9_8^=&=E3.WK.C`$C5(.*US8)KH*-PD[^]BK^?IE*$D(0:Y6F,*=0@4(!
MMY,P+/MOT8^7&G@`D%206])H&]U`0.F$[S$3Q?K/V/%85H6S&KJZJCLSZ`A]
M1U/%.<Z6LR#2EI7(P@[J9H?L.X8Y.I`4<R4H61G<\D`Z%-VL63<BM8D%(^QE
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M)T^'4]_#J%RF`WI&()$@5(2*KT]9!)*ZDD7E)SQ,O9S^0GGCR"Z-="S"7B;,
MC881I1*Y2WO;?;R]<F+I?N^RI>K7"3RM@Y*#D)+0T"EDU/60GO9"A^_`Q5X$
M),HM&:AC$)?,XX4:C&9G9-[&?N(\FX>CQS1R&\9&PTYZ3Z>/7J>3L+O2TJ6>
M]*PJ(P:)A'D#J2W'=461(#,G.,9%:$'Y2D/2Z0Y1M&:\E$$`R$.'!$W'M4V?
M-(/,)%%PNU@@VQB)E&*2XM-,Z;Y:37=I<SY&4LKY$IA4[232:25!#2D1"3ZW
M:5:(@[5(:2[:U::H26W>=+R,42KQ`=%J@+^0:0A6DO5)D3@B//X-/W\9<#Y@
MN%C@D3OQMLW'/IW,>8[<MR&=9UY1TU!5VMI+/T5?27:#3SR2U/7DQ*RJ)O0T
MCL*=+0!A,X5,91%Y0)A-?U6>%-4)A8LL@8WPL.$S$=+&P0HF><Y<<+W>T><^
MVYUO(ZXMPW#!E?QLS#(";Y:C\_+%9R\"3IV]ZOMEU4L0=5]#48D4'GQT8)IM
MR!!8K)0RLH6U/QV/I)%HYML4$BV>?13S8PT6Z>L>8<D\]]&2F("J_)WO.N17
M@B+0.;H2GT7`NBK/J0,P9R`_,:O1;*DM`4[<-9@*#1Q%;9LFZ9Q*<@RR["5B
M18NU,Q.W$]?G!"M:?(7<-A>TM'5J-K*/SOHB!<R6A6^CBY9([A0.*=&5-U/;
M:`Z?'O:D9EFTHC8GD^4"-&L=`&!Y@U-HXBB];L0Y8BY!TI3?$K'#2YWGG8T#
MF7Y(+8L`/249D%;#Y:3*1?G^+V7:;DV_"C']I752(.V&\B"+`JW;5HM"&&\D
M"#W6C>1A)`:0TFI.,Q3WV&CPLO!TY\;=$X[^D=2\'&'6&O7%;DK'4B8NOD4)
M6I#QT;]F;.4G7;X1%8X9.&%O&@T:W3C1UT:4D-4EFVSS6QJ7(0"XD$Q`RPF`
M08(U#^?._#E;%;)IW?94#D]VC`E;!YP!IO>\+`F)*8V.G'2C:`5!*:[`D(]`
MA45J%5L_)OF,Q>D@24M*[+-G0O\`0&)422*(O!`NG%\Z8MS/7IZGFF_<5J[L
M8%)Q`.N8E&)5=,I#QL&SL9F?M>4PFI;+EE8SH5,(":@C;V,I&"@D.L2.1$J=
M7@)<FVAQ=YJ669O2P0N]N,?3*O)M>O?DFE,Q@%;5W7,#<RVPJXIRPFA69VH[
MCT+")V13-MW08`E#0N"R-WX8&!:S9(`4]!?OI8.?*31V@R%Q-4<;#3F7B=LP
MTON5LI?Y$;[>4\$(;P\!;D^9\^M;JFIR>3P57P9=.ON&N%^@)NA$QU<TJ]T:
M*3R5=)F=6K`MZ61`&?N9AB9UB*D?KN-"NE3Q>+)\U+=SL7"J?M:1VC;D#BJ5
M>PT-7EFS*_X/&2#BR':UL#2//.NK60%)+6_[,1&-@TH)^;N0:S"9/%&,6?0V
M0O?U&TX:C@PFFS?$/%K]9^W)%$X^0FVXP]6:BZ"C!G0Y9O540@"J$YGY+8A&
M.1)R:@4\.S-*+TW(58D6E1EN%6C8]KH?#AXU^[I4?/\`G[8:@3P:5SQ.-U//
MS@UE3Y&;%;,+&DD:J5A)([!H5;][RE&?V<-"'`5<56'HPL2A<,:P.J2@DL?=
ML;4?JB=I!(7[9`H%62>30L-+,5`X0G%^%9<MJ;OI_!N<V^1V01TG(8:&I)0Q
M8$*L053\[%:GI"_81.PYY;LMAM2);I1N"G9`:&SRJX">N=FR8!TSNK"74[&E
M&3?^(ODA!AIZVB?+._+C/)@4_D=L4F]B;'RE8U#V,GCCX2XDYZ:RZ0"15P*R
MFYH"$B+KV%U;(=X6T+2>K0KF+[7:A4SZ:CIJJ&8-QL]AQ2&D0T]?3:$YS?.T
MXO",?4/=73\[%TT`:T]3)^13J2513CR7F+=E4;9/[-FO!XSMPO+%H^&IHTF/
MB;&.IE(SJ-8O%GQ"0D!WZ;[2)9NG"@-*]XR\3_5')J0_Y<3IN)DK'$<YN_V,
M-K-C)W&Y&6GF1'28D^'AW;#0*F75KO2&/!6@@N.@RC=E(5IJNV\(V2UB>\:'
M^L'`:>OS5',^GB6`C75E^23HZL::-PBM(8BC:,OBMG)A)L;F#<O'%^9XQ>,(
M6C1(I7D8=I%QSZ3OA$@:*LV"#O>-,B;(C^B.O!`<(49VE6ZQRR-.KN][=KRO
M.AB-;PB$BM8ZMU'4%9RTA-G#V=`[=H3EJQ^B%IQ*JW=0!_'T(4LRKDZT`,E9
M`7=$%G-=ERK+]OSYVE%P5*M?AOLW'GY=R5.L>@;LYXIQ""PC>-R&YD./^D+M
M+6E9,R&!!@AQSK$JY9G";-0957L<E4P)2FTPIP2T?P6'0Q43'CSHT.%-E&PG
M<$D[O&I*.\]>G)JD([NE+4X`@!V&/93*K0LR2P&GWA"3!D%)6?A%XAH#;@Q=
MM'*^`,P`:KZPE(JZ!C=72224Y#8[831R1(.X@J:)!IWG"4^*E>;L00C\CMLN
MZPI:SV,>:-J^C1RGQ]S."LKCQJ[++<RKA=?KLT*C$0%U1&(6_8OV1^-A$CL8
MV@I(C+(_+MQ$9C\;$*CWY72?)=*OSMQ^;3S)+L/^0:[YVZB\/"<]P8?8,O=,
MWHS:46=.8["THR4I><W`S=^KDJ8;S=Z^2]@CR.(NDH6VB\A'F`DQ!R!7\9F*
MA!'2E-[+HIRELVM^?L:)(/D=MB4(4_9]=0"$@:L6FTB82:(R>UX\!G]@O6OQ
M>VIVN(A))U+84A$*\B#B2N8`V]L/V8CR#!"*)28HUV@4K*CV@NE7N_*WY],Y
MGG;H=!^7.@7=]1"1/9,$'0R=PZ;F(/*H3HE/!9D(2&1^'RO5$S'[*@E>R86_
MVCT\BY/=-J,.QQT+-@C@&6G!)YBMJ,M1\7V;+.X(,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"LELW^-B\_3H]E1]IWC(S]=.YP;`P-I
M4R@9I"'9I:(JZR!2UK/KI@]T)O\`]0SV%L=2_P":U_,]>)IHJ>>;BI;RE?K]
MD8.L#/'<&`QNA88WHBK6A6939A#*+\*56(?R&1UW9DDCY@U'(*(-/_#3Q";0
M(H417:MW!\00#_DG68*3@R0@2#G-WR[[]?$_EU:W!J"DUN%[9/(R*LB4WJBQ
M;3=3&FTU#JJ8CQUO6LUFZI'S8FIH!%^.=X<=)K[:B!WBWH[QDT\V3#ZL7YB_
MF;77T@YTVA4R@D4CM?0JKJRLD?4SV.J1^(12MMYA(O(1)@3*-BV_B,;=I28W
M9,61!?DM4')N7E-&K%JX).&N[H+]YO\`/(]1:5<IL"8RMCDDY[9&9HWE56AX
M"6,5PW)RQJ^*)-)O7(R+/'&CH\W=FW2+:51!JP=)N"CE)$N/W=K:Z[!?K;TX
M-0.VAPJO)2]H2:Q.3%IC1Z6L6/6(=EU/*26H$2#@\'TCA>7$"'I2`)/G;>3B
M]1#P@)T<N$#S+QONHD02U"'B]\*]_P!S*NHUQC5+BOX&]`<PULZE<I=2.JX8
MZ%53#G$EFQ8<A$7QVOXZL@.4,RDD(/-HPZ*1QFY+/!QI`*LNHV(IME@N^7R:
M2FM\=*T,DL'15XK5KVG#C:73"()J49O#*KDA1ZXCS.3R4!K[Z$@YPB2]=`VQ
MHHT%OW;W]0-2<J+_`)B.!]767WN8?3H?ARZXBU.S]Y1JE9P,ZLM#I1=#NG$X
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M?/`O>9Z_R:F+LW@B:R*JP`6P>0I;+8.0:QRD0HN64R>D4/*^"Q^[$#58UH_=
M$X^0\"LA6S47$46CG[6T'^HH?I$&WN@?4IRN<^IB*.Z(X9-UB3Z3JV;<\P"+
MV0U@\VM"6)&ZKA)AG(;"':'(V/N\D,*):C;#7W.N6RHN7%%C.IE<DT1W77W7
MV4!IX<],^A+L5.\QE)(S@$(,401F"D>CMG#X3%2%?.Y)O%!*8G]I6$SC8A90
MIM'AJ4A!?MV6(,O1K-,X)^V$$]2;/\\+YOW]RLYCH3D?92[+GLZC"<2F%6U)
M&9!*S%@40)>V],J1M-Q/(U"$P@H0UDMAO!-@/8#-0#>K):TCDX9>LMDIA`@+
M`FQ6>"P[)/+V>_M:U\=2TD(JJAWC,-842IVM`KJ45J`C+4NTKN(BCRE9K@1C
M<-!7KQB,\<^15B";C!2,5_5*@VC)BU8(-?TK5#3427B79\[F<"TE3$:!(Q>.
M5'6`",MFWK)O'0L!B@H$@S].)2;UHB(8B4!Z3;V2((R'U#1OJEZ<12+>Z?KT
M]''@DF9,UI7$BEL<GT@K^$G9W#DW",1FIF*`B<MBJ3OQ3QTE')&]8+F`:;GQ
M57QQH,>-=5O%%/S/-OQ[?4#*IQ&*(@@L72C$>2C4<_;W[>CJ84;H"`_M)PQ=
MQ3[*)U;>,!?[9=#!KF/?H6Z'V5P/8K#?TRC1OLF!JIFEZ=D0#>*2"IZT.Q90
M)%(TI&C,$BY,`I'((Y?/(.`W#O12X[<)#790FZB@K9MZQCSDB^7$(,U7;C90
M)?)XU:'HY<F&-K4S5"QF.Q9:#1\NK7<04)@H2X8OQCB'AG^X?UT+BRXTH3'K
M1]DJ@)58D7[3=IL@[<)J"R^7R9?VJ:W\DH&8HPF.,Y/&5MEPIH<,;C7S53V,
MN(8GZHH/T;>/=&L5=N`#!)_JZ2'#%/TS'1OIII^$0]Z]=U^ZW,J.H+#G.\B:
ME6,@W7C`1;<ZR.JMES;,SLHQV])M3*[)FL5;O?5TB"K1LH[T6W02]T`Q;&GZ
ME%R$Y+AE75T.E<G+CI!)9.QA,::2&0GA'ZG[2;.&FXQ,D6+C/UCO[<2?N7#Q
ME^J<_IEDOSU?Q!+Y-90YKYS:QUW$&M`THVB;\D/,OHNA5<%1CKTP)=OWXHJ[
M")@=1KDD,?%2;P>^6;;NF;LD_<-E4UGCC=067R_,V]E5E8CD=VP^N8&P;J"'
M$?4091"/M4=P+P!'(H[";I(#]--A#J+P^)1MP-VU]9K@(M'`ZJ.PX(,;M1)?
M)#$7Y#J6*WX2Z,::FG\\=,C#$2B2_;>XZ,I'V@H>4T%DF,;834HTT&B$14<#
M3&7RF/P(,Z)!:]$1000<LMQ9<1M\^>]R7)33M1SD%I%YM5E<3",IR%[+DX[*
M81&9`"3EA-X1(DI/H(+#'8_60D"!@L_>FM6_A)V\*$72[E1=ZYW5$E\F46KB
MO7/ICUQ`X8X]D+`P*/\`JT7!J^G!DAU'Z'QQCW=CM]S8'-!(O0PS>_GMR>HT
M?J]37\9M_$P/X.UI7$I&RP-)H!"9$'GR[%S.A1V*@BXV:.1C0:/&N)8Q(,'#
M61KCV`8.R8JF$GBC1H)&MD-DT6+71(),*UI"EF1F'R)G4%7M)!7@/2,P`ZU@
M$40,P:-IHNVR<?AY-(3H]C(--N_?-]!(5=DPU1>NTM6_B;E;7<)?)DHS5-70
MID+'0VMH#$AX,MJ>"L(S#HZ!9!SFL:6AFID6U%#FB`\MK#W"\4U(M-$7GD:7
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M.:2`>0;LB*;9PNWT?-DTG.J"ZR6JOB:F^NP3&#(-H-"F:XMTSA\6:N0A<K(`
MKAM'Q*"X@\>9O1YPV+62::J,"YE@2(L2I)ILD\(LW[UL\661=+Z;@:TE25,H
M2*.R]"HZQ1ED0!LHO$I0E`HJG(HO&AFBR0V.QTWH)\)!`8]-PX39"1KELP::
M+K:(-T]5=_-@E\GTB5,T]`&R;*"516L*9I%B)])I$H+%XVV2.F!GV4N:30#B
MV:6A8H&_\)(DM=?'CX9_W!RLJU_JL"7R>3VB:0].L93[3=5>R89&TX:-D?M>
M1'TZ/B"09['$HJQ+^B/N#2-IQXB0`I@T'"8S0,_>B]6OC%TNAN$ODRD.J6JJ
MZ;B6E?5G7T%:`&QYF":PZ&1R,-PK25/!)&3M1*(0:Q3&MI&0`@WQY!GJBD8>
M!1+HAJX7',]T0DD'`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8!5:>\BU-:W0@2^+2A]=V5^V*M0KZ+16?UK&YC^V3",WWF7[V`')%]Q
M^T$MOZ@=^0.#MG7GZ9)Y]W]_#HUT%EI0K7DK$2^.,NYGC&4C+R5CHYU84]F$
MNWCL7F@"62"/3?JR].FMX"Y=";C:UQ(A#%"\2T`&E+-JNQ"L.72D%B56I7<M
MERGH475:(^0EQT\<,Q\@^/NY))"H)#'G2L/#LX#7@RHAWL&I.75FJ3@P"!D(
M0`('9'6_043LPE)V&I)T^6!>V(C33MJMN+4J?5;=8NN&I9C><_NH])ZG^6G3
MD-XY^/GJIA9,HD%AQI[#T3)`M#(RPC4H#EF52553<>+QAH7E91FV-AY1!1,_
M$%EC":H)XLAHW2(.PB+LI'A]M@G-2V_RW_!B17QIDGS^LID7M[\1Y]`Z89]!
ML=-+:0"V+/X'=]@]*2^=QD="+JK.)M7\\M>W[$(^H6?!+3&QO9Q&BL=$C'0@
MNRD=&JT=XQ:4EQ.$MT>Z`_&M+`%CPZP9OT/Y/%(:1KEZ@/=0:;[:%-JWM!Q9
M3%XFSD]Y2^&P5T5<./6BX6J81`X&'>(MR@*&LDT4QNH:K0ESZIKC^28NCN'=
MKZN5G:C>RG4;'%H)7=:V!#W2EK[#C<7K:RY)9`EP$0KR[*LC?IM^M,9(*?[6
M9%;4!(J:18R-!,U(^4&RH1.%_C?NG]C4"7Q[.T]*B)QFVA0R4TLK,"\7<EJR
MW*QHQ)9+TO%>BFCR4@&<^#NGXD<H`(QE1@T-LR*I4PWG3`T*(ATQ#T6>G'I2
MU]SYU-\>CZOK2@5K2"W@LG+Q.PG-CE0X:I_VD"*F7LK^2*7.6@5JM8<FWC0]
M`A\A&R0K110ZN/1J!OMLLZ6F_JD/!OITS_Q_]?4H1&HGI179G//`T=F2)UTW
MEW.5YR$H;JQJF@81HGFYS72C^,3E&SG#^`IE`51C$FE9>UM,&Z)-V<-:6RR:
M2LC&V`N4ZNZSR_Y_@Z1VOQM9%E27I<6UO"&QZCNMFT9"W%!5:4,F;-]B3&M@
M=53*.0NV/+K%1B/^3:)"'+'8F4IJ2O8_]X>K,/7#Q%B[;")I1:ZQ>V6\1.>I
M#VWQB.DI-)#S2Z]E$VMCR^VZJ3D`>V99M%)E+.M:[["682L$=Z$<UN9A?L]K
MH='I`&KBOJ@-S&.KH/S$HTE8W4^]#5TZ/'$<=;7<&QO?CRDY^WAUNRNZ0Q%Z
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M3*2D'5PISN@!)B/&:M=0Q.,N-D')R838Z[&EB2A(T,8%SI%Z`;O_`+6N8/+I
MK&'8RW/KZMLT6)\<RUH\Z&-SFUHD;E5]TJTIDU(H-33.L]I"N.83,8TMVW!`
MR;%1%C6UL-E+06N9"M:]#(BA"HH0%%"7P\='Q9Q;#G/;'&.I;:"1>0P\>)CC
MH^&+1:/06#Q@(V;QI\+/Z'(ZU*,)(<*FU)24'$!1]EY&/`<>:1P4[C#H6>7?
MR26)2$>UC`CO?ELW[!!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
C`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
